Document:

EX-10.2

 Exhibit 10.2 

ROYALTY AGREEMENT 
 This
ROYALTY AGREEMENT, dated as of March 12, 2014 (as amended, supplemented or otherwise modified from time to time, this “Royalty Agreement”), is made by and between ROYALTY OPPORTUNITIES S.À R.L, a Luxembourg
société à responsabilité limitée (together with its Affiliates, successors, transferees and assignees, “ROS”), and Unilife Medical Solutions, Inc., a Delaware corporation
(“Unilife”). ROS and Unilife are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

W I T N E S S E T H : 
 WHEREAS,
ROS Acquisition Offshore LP, a Cayman Islands exempted limited partnership (the “Lender”), and Unilife have entered into that certain Credit Agreement, dated as of the date hereof (as subsequently amended or otherwise modified, the
“Credit Agreement”); and 
 WHEREAS, the execution and delivery of this Royalty Agreement is a condition precedent to the
making of the Loans pursuant to the Credit Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, and in order to induce the Lender to make the Loans pursuant to the Credit Agreement, the Parties agree as follows: 

ARTICLE I. 
 DEFINITIONS 

SECTION 1.1 Certain Terms. The following terms (whether or not underscored) when used in this Royalty Agreement, including its
preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof): 

“Accountant” has the meaning set forth in Section 2.4. 

“Applicable Amount” has the meaning set forth in the definition of “Purchase Price”. 

“Applicable Period” has the meaning set forth in the definition of “Purchase Price”. 

“Buy-Out Notice” has the meaning set forth in Section 2.6. 

“Buy-Out Option” has the meaning set forth in Section 2.6. 

“Confidential Information” means any and all information or material (whether written or oral, or in electronic or other
form) that, at any time before, on or after the Closing Date, has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party pursuant to this Royalty Agreement or in connection with the transactions
contemplated hereby or any discussions or negotiations with respect thereto, and shall include the existence and terms of this Royalty Agreement. 

  
 - 1 - 

 Exhibit 10.2 

 

 “Contract” means any contract, license, indenture, instrument or agreement.

 “Credit Agreement” has the meaning set forth in the recitals hereto. 

“Default Rate” means the rate of interest applicable to Loans under Section 3.4 of the Credit Agreement. 

“Disclosing Party” means the Party disclosing Confidential Information. 

“Intellectual Property” means Intellectual Property (as defined in the Credit Agreement) that is owned by or licensed to
Holdings, the Borrower or any Subsidiary. 
 “Judgment” means any judgment, injunction, order or decree. 

“Law” means any law, statute, rule, regulation or ordinance of any Governmental Authority that may be in effect from time to
time. 
 “Lender” has the meaning set forth in the recitals hereto. 

“Net Sales” means all milestone payments, development payments, product fee payments, sales payments, distribution payments,
service payments, license payments, and other forms of consideration received (whether or not the associated revenue for such receipts has been recognized, earned or deferred) by Holdings, the Borrower or the Subsidiaries in cash or other property,
related to all products and services of Holdings, the Borrower or the Subsidiaries (including all Products).  

“Party” and “Parties” have the meanings set forth in the preamble hereto. 

“Payments” means the Royalty Payments, the payment of the Purchase Price and any other payments to be made by Unilife to ROS
hereunder. 
 “Purchase Price” means, with respect to either (x) Unilife’s election to exercise its Buy-Out
Option at any time, or (y) ROS’s election to exercise its Put Option upon the occurrence of a Royalty Event of Default, an amount, payable by Unilife to ROS in U.S. Dollars to an account designated in writing by ROS, equal to the
difference between (i) the applicable amount set forth in the table below (the “Applicable Amount”) opposite the applicable period set forth in the table below (the “Applicable Period”), during which such
Buy-Out Option or Put Option, as the case may be, was exercised (or deemed to be exercised), less (ii) the Recovered Amount. The Purchase Price shall not be less than zero. 

 

					
	 Applicable Period
	  	Applicable
Amount	 
	 On or before the 1st anniversary of the Closing Date
	  	$	6,500,000	  
	 After the 1st anniversary of the Closing Date and on or before the 2nd anniversary of the Closing Date
	  	$	10,500,000	  
	 After the 2nd anniversary of the Closing Date and on or before the 3rd anniversary of the Closing Date
	  	$	14,500,000	  
	 After the 3rd anniversary of the Closing Date and on or before the 4th anniversary of the Closing Date
	  	$	18,500,000	  
	 Any time after the 4th anniversary of the Closing Date
	  	$	21,000,000	  

  
 - 2 - 

 Exhibit 10.2 

 

 “Purchase Price Notice” has meaning set forth in Section 2.6.

 “Put Notice” has the meaning set forth in Section 5.2. 

“Put Option” has the meaning set forth in Section 5.2. 

“Receiving Party” means the Party receiving Confidential Information. 

“Recipients” has the meaning set forth in Section 7.1. 

“Recovered Amount” means, as of the time the Purchase Price is paid pursuant to Section 2.6 or
Section 5.2, the aggregate amount of all Royalty Payments received by ROS from Unilife pursuant to Section 2.1. 

“Related Agreement” means any existing or future Contract entered into before or during the Royalty Term by Unilife or any of
its Affiliates relating, directly or indirectly, to any Product or any Intellectual Property. 
 “Related Party” means any
Person (other than Unilife or any of its Affiliates) party to any Related Agreement. 
 “ROS” has the meaning set forth in
the preamble hereto. 
 “Royalty Agreement” has the meaning set forth in the preamble hereto. 

“Royalty Event of Default” has the meaning set forth in Section 5.1. 

“Royalty Payment” has the meaning set forth in Section 2.1(b). 

“Royalty Report” has the meaning set forth in Section 2.1(c). 

  
 - 3 - 

 Exhibit 10.2 

 

 “Royalty Term” means the period commencing on the Closing Date and ending on
the earlier of (i) the tenth anniversary of the Closing Date and (ii) the date of payment of the Purchase Price pursuant to the exercise of the Put Option by ROS or the exercise of the Buy-Out Option by Unilife, as the case may be. 

“Sublicense Agreement” has the meaning set forth in Section 2.5(a). 

“Sublicensee” means any Person (other than Unilife or any of its Affiliates) party to any Sublicense Agreement. 

“Term” has the meaning set forth in Section 6.1. 

“Third Party” means any Person other than Unilife or any of its Affiliates. 

“Unilife” has the meaning set forth in the preamble hereto. 

SECTION 1.2 Credit Agreement Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this
Royalty Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement. In the event that the Credit Agreement terminates (in accordance with its terms or otherwise) prior to the expiration of the Term, terms used
herein and defined in the Credit Agreement (as in effect immediately prior to such termination) shall continue to be used herein without regard to such earlier termination of the Credit Agreement (as if such agreement remained in full force and
effect). 
 ARTICLE II. 
 ROYALTY
PROVISIONS 
 SECTION 2.1 Royalty Payments. 

(a) Unilife shall pay to ROS, in respect of each Fiscal Year (or portion of a Fiscal Year, in the case of the first Fiscal Year
and last Fiscal Year of the Royalty Term) during the Royalty Term, a royalty amount equal to the sum of (i) 2.75% of the aggregate Net Sales during such Fiscal Year (or portion of a Fiscal Year, as the case may be) up to $50,000,000 of such Net
Sales, plus (ii) 1.00% of the aggregate Net Sales during such Fiscal Year (or portion of a Fiscal Year, as the case may be) in excess of $50,000,000 and up to and including $100,000,000, plus (iii) 0.25% of the aggregate Net
Sales during such Fiscal Year (or portion of a Fiscal Year, as the case may be) in excess of $100,000,000. 
 (b) Amounts
payable pursuant to Section 2.1(a) shall be calculated quarterly as of the last day of each Fiscal Quarter during the Royalty Term, and shall be payable by Unilife to ROS within 30 days after the end of each such Fiscal Quarter (each
such payment, a “Royalty Payment”); provided that the Royalty Payments for the Fiscal Quarters ending between the Closing Date and the first anniversary of the Closing Date shall be due and payable on the first anniversary of the
Closing Date. The Royalty Payment relating to the first Fiscal Quarter of the Royalty Term shall be determined based on Net Sales from the Closing Date, and the last Royalty Payment (other than in the case of the Royalty Term ending on the date of
payment of the Purchase Price pursuant to the exercise of the Put Option by ROS or the exercise of the Buy-Out Option 

  
 - 4 - 

 Exhibit 10.2 

 

 
by Unilife) shall be determined based on the Net Sales through the tenth anniversary of the Closing Date. Royalty Payments shall first be determined in the currency of the country in which the
corresponding Net Sales occurred and then converted to its equivalent in U.S. Dollars. The rates of exchange for such payments shall be the average rate for U.S. Dollars, as quoted by JPMorgan Chase in New York City, at the close of business on the
last day of the Fiscal Quarter in which such Net Sales occurred. 
 (c) Together with each Royalty Payment Unilife shall
deliver a written report to ROS showing with respect to each Product (on a product-by-product and partner-by-partner basis) (i) Net Sales for such Product from such partner for the applicable Fiscal Quarter, and (ii) the calculation (in
reasonable detail) of the Royalty Payment owed (including any applicable exchange rates used) and paid for such Fiscal Quarter (each, a “Royalty Report”). Each delivery of a Royalty Report hereunder shall also be deemed to
constitute a representation and warranty by Unilife that such Royalty Report is true, correct and complete in all respects. 

SECTION 2.2 General Provisions as to Payments. All amounts payable to ROS under this Royalty Agreement (including the Payments)
shall be (i) made without set-off or counterclaim of any kind or nature whatsoever, (ii) made in U.S. Dollars and in immediately available funds and (iii) remitted by wire transfer to such bank account as shall have been designated by
ROS in writing from time to time. Any Payments or other amounts due to ROS under this Royalty Agreement that are not made on or before the applicable due date shall bear interest, payable on demand (and compounded monthly), for each day from (and
including) the applicable due date to (but excluding) the date of the payment thereof, at a rate per annum equal to the Default Rate. 

SECTION 2.3 Taxes. The Parties hereby covenant and agree that, with respect to any Taxes payable on any Payments payable to ROS
under this Royalty Agreement, Section 4.3 of the Credit Agreement shall apply and is hereby incorporated herein by reference as if set forth herein in its entirety; provided that references in such Section 4.3 to the
“Borrower” shall be deemed to mean Unilife, references to the “Lender” shall be deemed to mean ROS, and references to the Credit Agreement shall be deemed to mean this Royalty Agreement. 

SECTION 2.4 Records and Audit. Unilife shall keep and maintain at its chief executive office in the United States complete and
accurate records (on a seller-by-seller, product-by-product, partner-by-partner basis) of all sales and Net Sales to arrive at Net Sales for five years after the period to which such records relate. ROS shall have the right once per Fiscal Year
during the Royalty Term and for a period of one year thereafter, at ROS’s expense (except as set forth below), to investigate and audit such records, upon reasonable notice, during regular business hours (and may, if it so chooses, retain an
independent accountant (an “Accountant”) to conduct such investigation and audit). Before Unilife gives an Accountant access to its books and records, such Accountant must enter into a written confidentiality agreement with Unilife
that is reasonably acceptable to ROS and Unilife. Unilife shall, and shall cause its Affiliates to, cooperate fully and completely with such investigation and audit (and the Persons conducting such investigation and audit), and all results of any
investigation and audit under this Section 2.4 (and any associated underlying data and information) shall be made available to both Unilife and ROS. If either (i) ROS and Unilife agree that there is an underpayment, or
(ii) such investigation 

  
 - 5 - 

 Exhibit 10.2 

 

 
and audit by an Accountant reveals an underpayment, Unilife shall remit such underpayment to ROS no later than 30 days after the completion of such investigation and audit. If the underpayment
with respect to any Fiscal Year that is included as a part of such investigation and audit is equal to or greater than five percent (5%) of the amount that was otherwise due under the terms and conditions of this Royalty Agreement with respect
to such Fiscal Year, Unilife shall pay the reasonable and documented fees and expenses incurred by ROS in connection with such investigation and audit. If the audit reveals an overpayment, ROS shall remit such overpayment to Unilife no later than 30
days after the completion of such investigation and audit. 
 SECTION 2.5 Related Agreements; Sublicense Agreements; Access to
Records. 
 (a) Unilife shall, and shall cause its Affiliates to, provide ROS, upon request, with true, correct and
complete copies of (i) each Related Agreement (including all amendments and supplements thereto) and (ii) each Contract (including all amendments and supplements thereto) (1) relating, directly or indirectly, to any Product or any
Intellectual Property or (2) that involves rights relating to any Product or any Intellectual Property that were originally obtained, directly or indirectly, from Unilife (or any Affiliate of Unilife) (a “Sublicense
Agreement”). 
 (b) Unilife shall, shall cause its Affiliates to, and shall use commercially reasonable efforts to
cause each Related Party and Sublicensee to, (i) furnish ROS with any Related Agreement or Sublicense Agreement required to be furnished pursuant to Section 2.5(a), (ii) keep and maintain at its respective chief executive
office complete and accurate records (on a seller-by-seller, product-by-product and partner-by-partner basis) of all sales and Net Sales to arrive at Net Sales effected by such Person for five years after the period to which such records relate, and
(iii) provide ROS with access to such records to verify and audit the Net Sales attributable to Unilife or such Affiliate, Related Party or Sublicensee in accordance with the audit and inspection process described in Section 2.4.

 SECTION 2.6 Buy-Out Option. At any time after the Closing Date, Unilife shall have the right, exercisable in its sole
discretion (the “Buy-Out Option”), to purchase from ROS all (but not less than all) of its rights to the remaining Royalty Payments that will become due pursuant to Section 2.1. The amount payable by Unilife to ROS in
respect of the Buy-Out Option shall be the Purchase Price. If Unilife elects to exercise its Buy-Out Option, it shall so notify ROS in writing (the “Buy-Out Notice”). Delivery of a Buy-Out Notice (and exercise of the Buy-Out Option)
shall be irrevocable. Upon receipt of a Buy-Out Notice, ROS shall promptly (and, in any event, within three Business Days) advise Unilife in writing of the Purchase Price (the “Purchase Price Notice”), which Purchase Price shall be
conclusive absent manifest error. Unilife shall, on the third Business Day following its receipt of the Purchase Price Notice, purchase from ROS, by payment of the Purchase Price, all (but not less than all) of its rights to the remaining Royalty
Payments that will become due pursuant to Section 2.1. The payment of the Purchase Price shall be made by wire transfer of immediately available funds to an account designated by ROS. 

  
 - 6 - 

 Exhibit 10.2 

 

 ARTICLE III. 

REPRESENTATIONS AND WARRANTIES 

Unilife hereby represents and warrants to ROS as of the Closing Date as follows: 

SECTION 3.1 Credit Agreement Representations and Warranties. The representations and warranties of the Borrower contained in
Article VI of the Credit Agreement are true and correct in all material respects, each such representation and warranty set forth in such Article and all other terms of the Credit Agreement to which reference is made therein, together with all
related definitions and ancillary provisions, being hereby incorporated into this Royalty Agreement by this reference as though specifically set forth in this Article. 

SECTION 3.2 Enforceability. Unilife has the power and authority and the legal right to enter into this Royalty Agreement
and perform its obligations hereunder and has taken all necessary action on its part required to authorize the execution and delivery of this Royalty Agreement and the performance of its obligations hereunder. This Royalty Agreement has been duly
executed and delivered on behalf of Unilife, constitutes a legal, valid and binding obligation of Unilife and is enforceable against Unilife in accordance with its terms (except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization or similar Laws affecting creditors’ rights generally and by principles of equity). 
 SECTION 3.3
Compliance with Laws and Related Agreements. None of Holdings, Unilife or any of the Subsidiaries is in violation of, or under investigation with respect to, and none of Holdings, Unilife or any of the Subsidiaries has been threatened to be
charged with the violation, or been given notice of any violation, of any Law or Judgment applicable to such Person. None of Holdings, Unilife or any of the Subsidiaries has breached or defaulted under any provision of any Related Agreement in any
material respect, and, to the knowledge of Unilife, no Related Party has breached or defaulted under any provision of any Related Agreement in any material respect. To the knowledge of Unilife, no event has occurred that, upon notice or passage of
time or both, could reasonably be expected to give rise to any breach or termination of or default under any Related Agreement by any party thereto. 

ARTICLE IV. 
 COVENANTS 

Unilife covenants and agrees with ROS that throughout the Term Unilife will, and Unilife will cause Holdings and each of the Subsidiaries to,
perform or cause to be performed the obligations set forth below. 
 SECTION 4.1 Credit Agreement Covenants. Unilife covenants
and agrees that, throughout the Term, Holdings, Unilife and the Subsidiaries will perform, comply with and be bound by all of the agreements, covenants and obligations contained in Articles VII and VIII of the Credit Agreement as they may
relate to or otherwise affect the execution, delivery or performance of this Royalty Agreement by Unilife, each such agreement, covenant and obligation contained in such Articles of the Credit Agreement, and all other terms of the Credit Agreement
to which reference is made in such Articles, together with all related definitions and ancillary provisions, being hereby incorporated into this Royalty Agreement by reference as 

  
 - 7 - 

 Exhibit 10.2 

 

 
though specifically set forth herein. In the event that the Credit Agreement terminates (in accordance with its terms or otherwise) prior to the expiration of the Term, such agreements, covenants
and obligations so incorporated by reference herein shall continue to be in full force and effect in this Royalty Agreement, without regard to such earlier termination of the Credit Agreement (as if such agreement remained in full force and effect).

 SECTION 4.2 Maintenance of Existence; Licenses; Compliance with Laws and Related Agreements. Holdings, Unilife and each of
the Subsidiaries shall (i) preserve and keep in full force and effect its existence, (ii) preserve and maintain all rights, privileges, Permits and franchises necessary or desirable in the normal conduct of its business, (iii) comply
in all material respects with all Laws and Judgments applicable to it, and (iv) not breach any Related Agreement to which such Person is a party in any respect material to the interests of ROS hereunder. 

SECTION 4.3 Maintenance of Patents. Holdings, Unilife and each of the Subsidiaries shall make commercially reasonable efforts to
prosecute and maintain, at its own expense, each Patent included in the Intellectual Property, unless the failure to prosecute and maintain such Patent could not reasonably be expected to adversely affect the value of the Royalty Payments. 

SECTION 4.4 Enforcement of Intellectual Property 

(a) Unilife shall promptly inform ROS of any suspected infringement by a Third Party of any Intellectual Property that could
reasonably be expected to adversely affect in any material respect the value of the Royalty Payments. Unilife shall provide to ROS a copy of any written notice of any such suspected infringement of Intellectual Property delivered or received by
Unilife or any of its Affiliates as soon as practicable and in any event not less than 10 Business Days following such delivery or receipt. Promptly following any notice of such suspected infringement, Unilife and ROS shall consult with each other
with a view to determining the appropriate course of action to take with respect to such suspected infringement. 
 (b)
Following such consultation described in clause (a) above, Holdings, Unilife and the Subsidiaries shall have the sole right (but not the obligation) to initiate, at its sole expense, an enforcement of the Intellectual Property against
such Third Party infringer. If Holdings, Unilife and the Subsidiaries elect to enforce the Intellectual Property against such Third Party infringer, Unilife shall so notify ROS and keep ROS promptly informed of the status of, and all material
developments in, such enforcement. All sums received (including awards, damages and settlement payments) as a result of any enforcement of the Intellectual Property by Holdings, Unilife and the Subsidiaries under this Section 4.4(b),
after deduction of all reasonable costs and expenses (including attorneys’ fees and expenses) incurred by Holdings, Unilife and the Subsidiaries in connection with such enforcement, shall be treated as Net Sales. 

  
 - 8 - 

 Exhibit 10.2 

 

 SECTION 4.5 Challenges to Intellectual Property. 

(a) Unilife shall promptly inform ROS of any challenge or notice of any potential challenge to the Intellectual Property that
could reasonably be expected to adversely affect in any material respect the value of the Royalty Payments. Unilife shall provide to ROS a copy of any written notice of any such challenge to the Intellectual Property received by Unilife or any of
its Affiliates as soon as practicable and in any event not less than 10 Business Days following such receipt. Promptly following any notice of such challenge to the Intellectual Property, Unilife and ROS shall consult with each other with a view to
determining the appropriate course of action to take with respect to such challenge. 
 (b) Following such consultation
described in clause (a) above, Holdings, Unilife and the Subsidiaries shall have the sole right (but not the obligation) to initiate, at its sole expense, a defense against such challenge to the Intellectual Property. If Holdings,
Unilife and the Subsidiaries elect to bring such a defense, Unilife shall so notify ROS and keep ROS promptly informed of the status of, and all material developments in, such defense. All sums received (including awards, damages and settlement
payments), if any, as a result of any such defense by Holdings, Unilife and the Subsidiaries under this Section 4.5(b), after deduction of all reasonable costs and expenses (including attorneys’ fees and expenses) incurred by
Holdings, Unilife and the Subsidiaries in connection with such defense, shall be treated as Net Sales. 
 SECTION 4.6 Performance of
Related Agreements. Unilife shall not, and shall not permit any of its Affiliates to, (i) breach any Related Agreement in any respect material to the interests of ROS or (ii) fail to use all its reasonable efforts to cure any such
breach by Unilife or any of its Affiliates of any Related Agreement. 
 SECTION 4.7 Related Agreements and Sublicense
Agreements. 
 (a) Promptly, and in any event within 10 Business Days, following Unilife becoming aware of, or coming to
believe in good faith that there has been, a breach of (i) any Related Agreement by a Related Party or (ii) any Sublicense Agreement by a Third Party, in each case that could reasonably be expected to adversely affect in any material
respect the value of the Royalty Payments, Unilife shall provide notice of such breach to ROS. In addition, Unilife shall provide to ROS a copy of any written notice of any such breach or alleged breach of any Related Agreement or any Sublicense
Agreement delivered or received by Unilife or any of its Affiliates as soon as practicable and in any event not less than five days following such delivery or receipt. 

(b) Unilife and ROS shall consult with each other regarding any breach referred to in Section 4.7(a) and as to the
timing, manner and conduct of any enforcement relating thereto. Unilife may (i)(x) enforce compliance (at the sole expense of Unilife) by the applicable Related Party with the relevant provisions of the Related Agreement or (y) use commercially
reasonable efforts to enforce compliance (at the sole expense of Unilife) by the applicable Third Party with the relevant provisions of the Sublicense Agreement and (ii) exercise such rights and remedies relating to such breach as shall be

  
 - 9 - 

 Exhibit 10.2 

 

 
available to Unilife or its Affiliates, whether under such Related Agreement, such Sublicense Agreement or by operation of Law. Unilife shall keep ROS promptly informed of the status of, and all
material developments in, such enforcement. All sums received (including awards, damages and settlement payments) as a result of any such enforcement, after deduction of all reasonable costs and expenses (including attorneys’ fees and expenses)
incurred by Unilife in connection with such enforcement, shall be treated as Net Sales. 
 SECTION 4.8 No Impairments;
Diligence. Unilife shall not, shall cause each of its Affiliates not to, and shall use commercially reasonable efforts to cause any Related Parties and Sublicensees not to, enter into any Contract or arrangement, or take any other action
(including amendments, modifications, supplements, waivers, assignments or terminations of Contracts (or provisions thereof)), that is primarily designed to, directly or indirectly, adversely affect the value of the Royalty Payments in any material
respect. Unilife shall, shall cause each of its Affiliates to, and shall use commercially reasonable efforts to cause any Related Parties and Sublicensees to, use its respective commercially reasonable efforts to make (or have made), market and sell
the Products. 
 ARTICLE V. 

EVENTS OF DEFAULT; REMEDIES 

SECTION 5.1 Events of Default. The occurrence of any of the following events shall constitute a “Royalty Event of
Default” under this Royalty Agreement: 
 (a) Unilife shall default in the payment (i) of any Royalty Payment
when due hereunder or (ii) any other payment when due hereunder, and such default shall continue for a period of five days after such amount was due. 

(b) Any representation or warranty of Unilife contained or incorporated by reference herein, or in any other instrument,
document, certificate, report or statement executed and delivered in connection herewith (including any Royalty Report or any representation or warranty incorporated by reference herein), shall at any time prove to have been incorrect in any
material respect when made. 
 (c) Any Event of Default (as defined under the Credit Agreement) shall have occurred under
Article IX of the Credit Agreement. 
 SECTION 5.2 Put Option. Upon the occurrence of, and during the continuation of, any
Royalty Event of Default, in addition to any other rights and remedies available to ROS under this Royalty Agreement, any other Loan Document or otherwise, ROS shall have the right (at its option) to require Unilife to purchase from ROS all of its
rights to the remaining Royalty Payments that will become due pursuant to Section 2.1 (the “Put Option”). The amount payable by Unilife to ROS in respect of the Put Option shall be the Purchase Price. If ROS elects to
exercise its Put Option, it shall so notify Unilife in writing (the “Put Notice”), which Put Notice shall set forth a calculation of the Purchase Price in reasonable detail. Unilife shall, on the fifth Business Day following its
receipt of such Put Notice, pay the Purchase Price to ROS. The payment of the Purchase Price pursuant to this Section 5.2 shall be made by wire transfer of immediately available funds to an account designated by ROS. 

  
 - 10 - 

 Exhibit 10.2 

 

 SECTION 5.3 Other Rights and Remedies. 

(a) ROS shall have the right to enforce the provisions of this Royalty Agreement or any other Loan Document by legal
proceedings for the specific performance of any covenant or agreement contained herein or for the enforcement of any other appropriate legal or equitable remedy, and ROS may recover its costs and expenses caused by any breach by Unilife of the
provisions of this Royalty Agreement or as a result of, or in connection with, the occurrence of any Royalty Event of Default, including court costs, attorneys’ fees and other costs and expenses incurred in the enforcement of the obligations of
Unilife, or any rights of ROS, under this Royalty Agreement. 
 (b) ROS shall have the right to exercise all rights and
remedies under this Royalty Agreement or any other Loan Document and all other rights and remedies which ROS may have under applicable Law or otherwise. 

ARTICLE VI. 
 TERM 

SECTION 6.1 Term. The term of this Royalty Agreement (the “Term”) shall commence on the Closing Date and shall
expire on the first anniversary of the last day of the Royalty Term. 
 SECTION 6.2 Survival. The expiration of this Royalty
Agreement shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such expiration or termination, and the provisions of Article VII and Sections 6.2, 8.3, 8.4, 8.5,
8.8, 8.9, 8.11 and 8.12 shall survive the expiration of this Royalty Agreement. 
 ARTICLE VII. 

CONFIDENTIALITY 
 SECTION 7.1
Confidential Information. Subject to the provisions of Section 7.2, at all times during the Term and for two years thereafter, the Receiving Party shall keep confidential and shall not publish or otherwise disclose any
Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party’s employees, advisors or consultants’ who have a need to know such information to assist such Party in the performance of such
Party’s obligations or in the exercise of such Party’s rights hereunder and who are subject to reasonable obligations of confidentiality (collectively, “Recipients”). Notwithstanding anything to the contrary set forth
herein, (a) ROS may disclose this Royalty Agreement and the terms and conditions hereof and any information related hereto, including the Royalty Reports, to (i) its Affiliates, (ii) potential and actual assignees of any of ROS’s
rights hereunder (including the right to receive any Payments hereunder) and (iii) potential and actual investors in, or lenders to, ROS (including, in each of the foregoing cases, such Person’s employees, advisors or consultants);
provided that in each case, each such Recipient shall be subject to reasonable obligations of confidentiality; and (b) Unilife may disclose this Royalty Agreement and the terms 

  
 - 11 - 

 Exhibit 10.2 

 

 
and conditions hereof and information related hereto to the extent that this Agreement, such terms, condition or information, as applicable, are publicly available on the U.S. Securities and
Exchange Commission EDGAR website, to potential or actual permitted acquirers or assignees, collaborators and other (sub)licensees, permitted subcontractors, investment bankers, investors, lenders (including, in each of the foregoing cases, such
Person’s employees, advisors or consultants who have a need to receive and review such information); provided that in each case, each such Recipient shall be subject to reasonable obligations of confidentiality. In addition to the
foregoing, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in order to comply with applicable Law (including any securities
law or regulation or the rules of a securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance, provided that the Receiving Party
(x) will only disclose those portions of the Confidential Information that are necessary or required to be so disclosed, and (y) will notify the Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto
sufficiently prior to making such disclosure so as to allow the Disclosing Party time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed. 

SECTION 7.2 Exceptions to Confidentiality. The Receiving Party’s obligations set forth in this Royalty Agreement shall not
extend to any Confidential Information of the Disclosing Party: 
 (a) that is or hereafter becomes part of the public domain
(other than as a result of a disclosure by the Receiving Party or its Recipients in violation of this Royalty Agreement); 

(b) that is received from a Third Party without restriction on disclosure and without, to the knowledge of the Receiving Party,
breach of any agreement between such Third Party and the Disclosing Party; 
 (c) that the Receiving Party can demonstrate by
competent evidence was already in its possession without any limitation on disclosure prior to its receipt from the Disclosing Party; 

(d) that is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or 

(e) that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party. 

SECTION 7.3 Remedies. Each Party agrees that the unauthorized disclosure of any information by the Receiving Party in violation of
this Royalty Agreement will cause severe and irreparable damage to the Disclosing Party. In the event of any violation of this Article VII, the Receiving Party agrees that the Disclosing Party shall be authorized and entitled to obtain
from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, without the necessity of proving irreparable harm or monetary damages, as well as any other relief permitted by applicable Law. 

  
 - 12 - 

 Exhibit 10.2 

 

 SECTION 7.4 Press Releases. No Party shall, and each Party shall instruct its
Affiliates not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Royalty Agreement or the subject matter hereof without the prior consent of the other Party hereto (which consent
shall not be unnecessarily withheld or delayed), except as may be required by applicable Law (in which case the Party required to make the release or statement shall allow the other Party reasonable time to comment on such release or statement in
advance of such issuance). 
 ARTICLE VIII. 

MISCELLANEOUS PROVISIONS 

SECTION 8.1 Loan Document. This Royalty Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless
otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof, which are incorporated herein by reference and deemed to apply to Unilife, ROS and this
Royalty Agreement, as applicable, throughout the Term (whether or not, and without regard to, any earlier termination of the Credit Agreement). 

SECTION 8.2 Binding on Successors, Transferees and Assigns; Assignment. This Royalty Agreement shall remain in full force and
effect until the Term has concluded and shall be binding upon the Parties hereto and their respective successors, transferees and assigns; provided that Unilife may not assign or transfer any of its rights or obligations hereunder without the
prior written consent of ROS. 
 SECTION 8.3 Amendments, etc. No amendment to or waiver of any provision of this Royalty
Agreement, nor consent to any departure by a Party from its obligations under this Royalty Agreement, shall in any event be effective unless the same shall be in writing and signed by both Parties, and then such waiver or consent shall be effective
only in the specific instance and for the specific purpose for which given. 
 SECTION 8.4 Notices. All notices and other
communications provided for hereunder shall be given or made as set forth in Section 10.2 of the Credit Agreement. 
 SECTION 8.5
No Waiver; Remedies. No failure on the part of a Party to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or
further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by Law. 

SECTION 8.6 Section Captions. Section captions used in this Royalty Agreement are for convenience of reference only and shall not
affect the construction of this Royalty Agreement. 
 SECTION 8.7 Severability. Any provision of this Royalty Agreement which is
prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Royalty Agreement or
affecting the validity or enforceability of such provision in any other jurisdiction. 

  
 - 13 - 

 Exhibit 10.2 

 

 SECTION 8.8 Governing Law, Entire Agreement, etc. THIS ROYALTY AGREEMENT AND ANY
CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS ROYALTY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW
YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Royalty Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with
respect to the subject matter hereof and supersedes any prior agreements, written or oral, with respect hereto. 
 SECTION 8.9 Forum
Selection and Consent to Jurisdiction. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS ROYALTY AGREEMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF ROS OR
ANY GUARANTOR IN CONNECTION HEREWITH, SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK;
PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE OPTION OF ROS, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. UNILIFE IRREVOCABLY CONSENTS TO
THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION 10.2 OF THE CREDIT AGREEMENT. UNILIFE HEREBY EXPRESSLY AND IRREVOCABLY WAIVES,
TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN
INCONVENIENT FORUM. TO THE EXTENT THAT UNILIFE HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR
OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, UNILIFE HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THIS ROYALTY AGREEMENT. 

SECTION 8.10 Counterparts. This Royalty Agreement may be executed by the parties hereto in several counterparts, each of which
shall be an original and all of which shall constitute together but one and the same agreement. This Royalty Agreement shall become effective when counterparts hereof executed on behalf of Unilife and ROS shall have been received by ROS. Delivery of
an executed counterpart of a signature page to this Royalty Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Royalty Agreement. 

  
 - 14 - 

 Exhibit 10.2 

 

 SECTION 8.11 Waiver of Jury Trial. UNILIFE AND ROS HEREBY KNOWINGLY, VOLUNTARILY
AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS ROYALTY AGREEMENT, OR ANY COURSE OF CONDUCT,
COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF UNILIFE OR ROS IN CONNECTION HEREWITH. UNILIFE ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH
OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR ROS TO ENTER INTO THIS ROYALTY AGREEMENT, THE CREDIT AGREEMENT AND EACH OTHER LOAN DOCUMENT. 

SECTION 8.12 Relationship of the Parties. The status of a Party under this Royalty Agreement shall be that of an independent
contractor. Nothing contained in this Royalty Agreement shall be construed as creating a partnership, joint venture or agency relationship between Unilife or any of its Affiliates, on the one hand, and ROS or any of its Affiliates, on the other
hand. Except to the limited extent expressly provided in this Royalty Agreement, no Party hereto shall have the authority to bind, obligate or represent any other Party hereto. 

[Signature Page Follows] 

  
 - 15 - 

 Exhibit 10.2 

 

 IN WITNESS WHEREOF, the Parties have executed this Royalty Agreement on the day and year
first above written. 
  

			
	UNILIFE MEDICAL SOLUTIONS, INC.
		
	By:	 	 /s/ Alan Shortall

	Name:	 	Alan Shortall
	Title:	 	Chairman & CEO
	
	ROYALTY OPPORTUNITIES S.À R.L
	 By OrbiMed Advisors LLC,
 its
investment manager

		
	By:	 	 /s/ Sven Borho

	Name:	 	Sven Borho
	Title:	 	Managing Member

  
 Signature Page to
Royalty AgreementEX-10.3

 Exhibit 10.3 

PLEDGE AND SECURITY AGREEMENT 

This PLEDGE AND SECURITY AGREEMENT, dated as of March 12, 2014 (as amended, supplemented or otherwise modified from time to time, this
“Security Agreement”), is made by UNILIFE MEDICAL SOLUTIONS, INC., a Delaware corporation (the “Borrower”), UNILIFE CORPORATION, a Delaware corporation (“Holdings”), Unilife Cross Farm LLC, a
Delaware limited liability company (“Cross Farm”), UNILIFE MEDICAL SOLUTIONS PTY LIMITED, a company registered in South Australia with ACN 008 071 403 (“Solutions”) and UNITRACT SYRINGE PTY LTD, a company registered
in Western Australia with ACN 101 059 723 (“Syringe”; and together with the Borrower, Holdings, Cross Farm and Solutions, and any other entity that may become a party hereto as provided herein, each a “Grantor” and,
collectively, the “Grantors”) in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands exempted limited partnership (together with its successors, transferees and assignees, the “Lender”), for itself and as agent
for ROYALTY OPPORTUNITIES S.À R.L, a Luxembourg société à responsabilité limitée (together with its successors, transferees and assignees, “ROS”) and the other parties to which the Grantors
may owe any Obligations (together with the Lender and ROS, the “Secured Parties” and each, a “Secured Party”). 

W I T N E S S E T H : 

WHEREAS, pursuant to the Credit Agreement, dated as of the date hereof (as the same may be amended, supplemented or otherwise modified from
time to time, the “Credit Agreement”), by and between the Borrower and the Lender, the Lender has extended a Commitment to make Loans to the Borrower; and 

WHEREAS, as a condition precedent to the making of the Initial Loan under the Credit Agreement and entering into the other Loan Documents,
each Grantor is required to execute and deliver this Security Agreement; 
 NOW, THEREFORE, for good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Lender, as follows: 
 ARTICLE I 

DEFINITIONS 
 SECTION 1.1.
Certain Terms. The following terms (whether or not underscored) when used in this Security Agreement, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural
forms thereof): 
 “Borrower” is defined in the preamble. 

“Collateral” is defined in Section 2.1. 

“Collateral Accounts” is defined in Section 4.3(b). 

“Computer Hardware and Software Collateral” means (a) all of the Grantors’ computer and other electronic data
processing hardware, integrated computer systems, central processing 

  
 1 

 Exhibit 10.3 

 

 
units, memory units, display terminals, printers, features, computer elements, card readers, tape drives, hard and soft disk drives, cables, electrical supply hardware, generators, power
equalizers, accessories and all peripheral devices and other related computer hardware, including all operating system software, utilities and application programs in whatsoever form; (b) all software programs (including both source code,
object code and all related applications and data files) designed for use on the computers and electronic data processing hardware described in clause (a) above; (c) all firmware associated therewith; (d) all documentation
(including flow charts, logic diagrams, manuals, guides, specifications, training materials, charts and pseudo codes) with respect to such hardware, software and firmware described in the preceding clauses (a) through (c); and
(e) all rights with respect to all of the foregoing, including copyrights, licenses, options, warranties, service contracts, program services, test rights, maintenance rights, support rights, improvement rights, renewal rights and
indemnifications and any substitutions, replacements, improvements, error corrections, updates, additions or model conversions of any of the foregoing. 

“Control Agreement” means an authenticated record in form and substance reasonably satisfactory to the Lender, that provides
for the Lender to have “control” (as defined in the UCC) over certain Collateral. 
 “Copyright Collateral” means
all copyrights of the Grantors, whether statutory or common law, whether registered or unregistered and whether published or unpublished, now or hereafter in force throughout the world including all of the Grantors’ rights, titles and interests
in and to all copyrights registered in the United States Copyright Office or anywhere else in the world, including the copyrights referred to in Item A of Schedule V, and registrations and recordings thereof and all
applications for registration thereof, whether pending or in preparation, all copyright licenses, including each copyright license referred to in Item B of Schedule V, the right to sue for past, present and future
infringements of any of the foregoing, all rights corresponding thereto, all extensions and renewals of any thereof and all Proceeds of the foregoing, including licenses, royalties, income, payments, claims, damages and Proceeds of suit, which are
owned or licensed by the Grantors. 
 “Credit Agreement” is defined in the first recital. 

“Distributions” means all dividends paid on Capital Securities, liquidating dividends paid on Capital Securities, shares (or
other designations) of Capital Securities resulting from (or in connection with the exercise of) stock splits, reclassifications, warrants, options, non-cash dividends, mergers, consolidations, and all other
distributions (whether similar or dissimilar to the foregoing) on or with respect to any Capital Securities constituting Collateral. 

“Filing Statements” is defined in Section 3.7(b). 

“General Intangibles” means all “general intangibles” and all “payment intangibles”, each as defined in
the UCC, and shall include all interest rate or currency protection or hedging arrangements, all tax refunds, all licenses, permits, concessions and authorizations and all Intellectual Property Collateral (in each case, regardless of whether
characterized as general intangibles under the UCC). 

  
 2 

 Exhibit 10.3 

 

 “Grantor” and “Grantors” are defined in the
preamble. 
 “Hikma Collateral” has the meaning given such term in the Security Agreement, between Hikma
Pharmaceuticals LLC, the Borrower and Syringe, attached hereto as Exhibit D. 
 “Intellectual Property
Collateral” means, collectively, the Computer Hardware and Software Collateral, the Copyright Collateral, the Patent Collateral, the Trademark Collateral, the Trade Secrets Collateral, Product Agreements and Regulatory Authorizations. 

“Intercompany Note” means any promissory note evidencing loans made by any Grantor to any other Grantor. 

“Investment Property” means, collectively, (a) all “investment property” as such term is defined in
Section 9-102(a)(49) of the UCC and (b) whether or not constituting “investment property” as so defined, all Pledged Notes. 

“Lender” is defined in the preamble. 

“Patent Collateral” means: 

(a) all of the Grantors’ (i) inventions and discoveries, whether patentable or not, and (ii) letters patent and
applications for letters patent throughout the world, including all patent applications in preparation for filing and each patent and patent application referred to in Item A of Schedule III; 

(b) all reissues, divisions, continuations,
continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a); 

(c) all patent licenses, and other agreements providing any Grantor with the right to use any items of the type referred to in
clauses (a) and (b) above, including each patent license referred to in Item B of Schedule III; and 

(d) all Proceeds of, and rights associated with, the foregoing (including licenses, royalties income, payments, claims, damages
and Proceeds of infringement suits) and the right to sue third parties for past, present or future infringements of any patent or patent application and for breach or enforcement of any patent license. 

“Permitted Liens” means all Liens permitted by Section 8.3 of the Credit Agreement. 

“Pledged Notes” means all promissory notes listed on Item J of Schedule II (as such schedule may be amended or
supplemented from time to time), all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor. 

“ROS” is defined in the preamble. 

“Securities Act” is defined in Section 6.2(a). 

“Security Agreement” is defined in the preamble. 

  
 3 

 Exhibit 10.3 

 

 “Trade Secrets Collateral” means all of the Grantors’ common law and
statutory trade secrets and all other confidential, proprietary or useful information, and all know-how obtained by or used in or contemplated at any time for use in the business of any Grantor (all of the
foregoing being collectively called a “Trade Secret”), whether or not such Trade Secret has been reduced to a writing or other tangible form, including all documents and things embodying, incorporating or referring in any way to
such Trade Secret, all Trade Secret licenses, including each Trade Secret license referred to in Schedule VI, and including the right to sue for and to enjoin and to collect damages for the actual or threatened misappropriation of any
Trade Secret and for the breach or enforcement of any such Trade Secret license. 
 “Trademark Collateral” means: 

(a) (i) all of the Grantors’ trademarks, trade names, corporate names, company names, business names, fictitious business
names, trade styles, service marks, certification marks, collective marks, logos and other source or business identifiers, and all goodwill of the business associated therewith, now existing or hereafter adopted or acquired including those referred
to in Item A of Schedule IV, whether currently in use or not, all registrations and recordings thereof and all applications in connection therewith, whether pending or in preparation for filing, including registrations, recordings
and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America, or any State thereof or any other country or political subdivision thereof or otherwise, and all common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing (collectively referred to as the “Trademarks”); 

(b) all Trademark licenses for the grant by or to any Grantors of any right to use any Trademark, including each Trademark
license referred to in Item B of Schedule IV; and 
 (c) all of the goodwill of the business connected
with the use of, and symbolized by the items described in, clause (a), and to the extent applicable clause (b); 

(d) the right to sue third parties for past, present and future infringements of any Trademark Collateral described in
clause (a) and, to the extent applicable, clause (b); and 
 (e) all Proceeds of, and rights
associated with, the foregoing, including any claim by any Grantor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, or for any injury to the goodwill associated
with the use of any such Trademark or for breach or enforcement of any Trademark license and all rights corresponding thereto throughout the world. 

SECTION 1.2. Credit Agreement Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this
Security Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement. 

  
 4 

 SECTION 1.3. UCC Definitions. When used herein the terms “Account”,
“Certificate of Title”, “Certificated Securities”, “Chattel Paper”, “Commercial Tort Claim”, “Commodity Account”, “Commodity Contract”, “Deposit Account”, “Document”,
“Electronic Chattel Paper”, “Equipment”, “Goods”, “Instrument”, “Inventory”, “Letter-of-Credit Rights”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”,
“Securities Account”, “Security Entitlement”, “Supporting Obligations” and “Uncertificated Securities” have the meaning provided in Article 8 or Article 9, as applicable, of the UCC. “Letters of
Credit” has the meaning provided in Section 5-102 of the UCC. 
 SECTION 1.4. Interpretation. The provisions of
Section 1.5 of the Credit Agreement are incorporated in, and apply to, this Agreement as if set out in full with any necessary amendments. 

ARTICLE II 
 SECURITY INTEREST 

SECTION 2.1. Grant of Security Interest. Each Grantor hereby grants to the Lender, for its benefit, a continuing security interest in
all of such Grantor’s right, title and interest in and to the following property, whether now or hereafter existing, owned or acquired by such Grantor, and wherever located, (collectively, the “Collateral”): 

(a) Accounts; 

(b) Chattel Paper; 

(c) Commercial Tort Claims listed on Item I of Schedule II (as such schedule may be amended or supplemented from
time to time); 
 (d) Deposit Accounts; 

(e) Documents; 

(f) General Intangibles; 

(g) Goods (including Goods held on consignment with third parties); 

(h) Instruments; 

(i) Investment Property; 

(j) Letter-of-Credit Rights and Letters of Credit; 

(k) Supporting Obligations; 

(l) all books, records, writings, databases, information and other property relating to, used or useful in connection with,
evidencing, embodying, incorporating or referring to, any of the foregoing in this Section (collectively, “Collateral Records”); 

  
 5 

 Exhibit 10.3 

 

 (m) all Proceeds of the foregoing and, to the extent not otherwise included,
(A) all payments under insurance (whether or not the Lender is the loss payee thereof) in respect of Collateral and (B) all tort claims; and 

(n) all other property and rights of every kind and description and interests therein. 

Notwithstanding the foregoing, the term “Collateral” shall not include the following “Excluded Property”: 

(i) any General Intangibles or other rights arising under any contracts, instruments, licenses or other documents as to which
the grant of a security interest would (A) constitute a violation of a valid and enforceable restriction in favor of a third party on such grant, unless and until any required consents shall have been obtained, or (B) give any other party
to such contract, instrument, license or other document the right to terminate its obligations thereunder; 
 (ii) trademark
applications filed in the United States Patent and Trademark Office on the basis of such Grantor’s “intent to use” such trademark, unless and until acceptable evidence of use of the Trademark has been filed with the United States
Patent and Trademark Office pursuant to Section 1(c) or Section 1(d) of the Lanham Act (15 U.S.C. 1051, et seq.), to the extent that granting a Lien in such Trademark application prior to such filing would adversely affect the
enforceability or validity of such Trademark application; 
 (iii) any asset, the granting of a security interest in which
would be void or illegal under any applicable governmental law, rule or regulation, or pursuant thereto would result in, or permit the termination of, such asset; 

(iv) any asset subject to a Permitted Lien (other than Liens in favor of the Lender) securing obligations permitted under the
Credit Agreement to the extent that the grant of other Liens on such asset (A) would result in a breach or violation of, or constitute a default under, the agreement or instrument governing such Permitted Lien, (B) would result in the loss
of use of such asset or (C) would permit the holder of such Permitted Lien to terminate the Grantor’s use of such asset; 

(v) the accounts described in paragraphs (ii) and (iv) of the definition of Excluded Accounts; or 

(vi) any Hikma Collateral, until such time, with respect to any such Collateral, as such Collateral no longer secures any
obligations owing to Hikma Pharmaceuticals LLC; 
 provided, that the property described in paragraphs (i), (iii) and
(iv) above shall only be excluded from the term “Collateral” to the extent the conditions stated in such paragraphs are not rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC or any other applicable law
and the term “Excluded Property” shall not include any proceeds, products, substitutions or replacements of Excluded Property (unless such proceeds, products, substitutions or replacements would otherwise constitute Excluded Property).

  
 6 

 Exhibit 10.3 

 

 SECTION 2.2. Security for Obligations. This Security Agreement and the Collateral in
which the Lender is granted a security interest hereunder by the Grantors secure the payment and performance of all of the Obligations. 

SECTION 2.3. Grantors Remain Liable. Anything herein to the contrary notwithstanding: 

(a) the Grantors will remain liable under the contracts and agreements included in the Collateral to the extent set forth
therein, and will perform all of their duties and obligations under such contracts and agreements to the same extent as if this Security Agreement had not been executed; 

(b) the exercise by the Lender of any of its rights hereunder will not release any Grantor from any of its duties or
obligations under any such contracts or agreements included in the Collateral; and 
 (c) the Lender will not have any
obligation or liability under any contracts or agreements included in the Collateral by reason of this Security Agreement, nor will the Lender be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action
to collect or enforce any claim for payment assigned hereunder. 
 SECTION 2.4. Distributions on Capital Securities; Payments on Pledged
Notes. In the event that any (a) Distribution with respect to any Capital Securities or (b) payment with respect to any Pledged Notes, in each case pledged hereunder, is permitted to be paid (in accordance with Section 8.6 of the
Credit Agreement), such Distribution or payment may be paid directly to the applicable Grantor. If any Distribution or payment is made in contravention of Section 8.6 of the Credit Agreement, such Grantor shall hold the same segregated and in
trust for the Lender until paid to the Lender in accordance with Section 4.1.5. 
 SECTION 2.5. Security Interest Absolute,
Etc. This Security Agreement shall in all respects be a continuing, absolute, unconditional and irrevocable grant of security interest, and shall remain in full force and effect until the Termination Date. All rights of the Lender and the
security interests granted to the Lender hereunder, and all obligations of the Grantors hereunder, shall, to the fullest extent permitted by applicable law, in each case, be absolute, unconditional and irrevocable irrespective of: 

(a) any lack of validity, legality or enforceability of any Loan Document (other than this Security Agreement); 

(b) the failure of the Lender (i) to assert any claim or demand or to enforce any right or remedy against Holdings, the
Borrower or any of the Subsidiaries or any other Person (including any other Grantor) under the provisions of any Loan Document or otherwise, or (ii) to exercise any right or remedy against any other guarantor (including any other Grantor) of,
or Collateral securing, any Obligations; 

  
 7 

 Exhibit 10.3 

 

 (c) any change in the time, manner or place of payment of, or in any other
term of, all or any part of the Obligations, or any other extension, compromise or renewal of any Obligations; 
 (d) any
reduction, limitation, impairment or termination of any Obligations for any reason, including any claim of waiver, release, surrender, alteration or compromise, and shall not be subject to (and each Grantor hereby waives, until payment of all
Obligations, any right to or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality, nongenuineness, irregularity, compromise, unenforceability of, or any other event or occurrence
affecting, any Obligations or otherwise; 
 (e) any amendment to, rescission, waiver, or other modification of, or any
consent to or departure from, any of the terms of any Loan Document; 
 (f) any addition, exchange or release of any
Collateral or of any Person that is (or will become) a Grantor (including the Grantors hereunder), or any surrender or non-perfection of any Collateral, or any amendment to or waiver or release or addition to, or consent to or departure from, any
other guaranty held by the Lender securing any of the Obligations; or 
 (g) any other circumstance which might otherwise
constitute a defense available to, or a legal or equitable discharge of Holdings, the Borrower or any of the Subsidiaries, any surety or any guarantor. 

SECTION 2.6. Postponement of Subrogation. Each Grantor agrees that it will not exercise any rights against another Grantor which it may
acquire by way of rights of subrogation under any Loan Document to which it is a party until following the Termination Date. No Grantor shall seek or be entitled to seek any contribution or reimbursement from Holdings, the Borrower or any of the
Subsidiaries, in respect of any payment made under any Loan Document or otherwise, until following the Termination Date. Any amount paid to any Grantor on account of any such subrogation rights prior to the Termination Date shall be held in trust
for the benefit of the Lender and shall immediately be paid and turned over to the Lender in the exact form received by such Grantor (duly endorsed in favor of the Lender, if required), to be credited and applied against the Obligations, whether
matured or unmatured, in accordance with Section 6.1(b); provided that if such Grantor has made payment to the Lender of all or any part of the Obligations and the Termination Date has occurred, then at such Grantor’s
request, the Lender will, at the expense of such Grantor, execute and deliver to such Grantor appropriate documents (without recourse and without representation or warranty) necessary to evidence the transfer by subrogation to such Grantor of an
interest in the Obligations resulting from such payment. In furtherance of the foregoing, at all times prior to the Termination Date, such Grantor shall refrain from taking any action or commencing any proceeding against Holdings, the Borrower or
any of the Subsidiaries (or their successors or assigns, whether in connection with a bankruptcy proceeding or otherwise) to recover any amounts in respect of payments made under this Security Agreement to the Lender. 

  
 8 

 Exhibit 10.3 

 

 ARTICLE III 

REPRESENTATIONS AND WARRANTIES 

In order to induce the Lender to enter into the Credit Agreement and make the Loans thereunder, the Grantors represent and warrant to the
Lender as set forth below. 
 SECTION 3.1. As to Capital Securities of the Subsidiaries, Investment Property. 

(a) With respect to any U.S. Subsidiary of any Grantor that is 

(i) a corporation, business trust, joint stock company or similar Person, all Capital Securities issued by such Subsidiary
(including the Borrower) are duly authorized and validly issued, fully paid and non-assessable, and represented by a certificate or certificates; and 

(ii) a partnership or limited liability company, no Capital Securities issued by such Subsidiary (A) are dealt in or
traded on securities exchanges or in securities markets, (B) expressly provides that such Capital Securities is a security governed by Article 8 of the UCC or (C) is held in a Securities Account, except, with respect to this
clause (a)(ii), Capital Securities (x) for which the Lender is the registered owner or (y) with respect to which the issuer has agreed in an authenticated record with such Grantor and the Lender to comply with any instructions
of the Lender without the consent of such Grantor. 
 (b) Each Grantor has delivered all Certificated Securities constituting
Collateral held by such Grantor in a Subsidiary (including the Borrower) on the Closing Date (or the date such Grantor becomes a party to this Security Agreement, as applicable) to the Lender, together with duly executed undated blank stock powers,
or other equivalent instruments of transfer acceptable to the Lender. 
 (c) With respect to Uncertificated Securities
constituting Collateral owned by any Grantor in a Subsidiary (including the Borrower) on the Closing Date (or the date such Grantor becomes a party to this Security Agreement, as applicable), such Grantor has caused the issuer thereof either to
(i) register the Lender as the registered owner of such security or (ii) agree in an authenticated record with such Grantor and the Lender that such issuer will comply with instructions with respect to such security originated by the
Lender without further consent of such Grantor. 
 (d) The percentage of the issued and outstanding Capital Securities of
each Subsidiary (including the Borrower) pledged on the Closing Date by each Grantor hereunder is as set forth on Schedule I. All shares of such Capital Securities have been duly and validly issued and are fully paid and nonassessable.

 (e) Each of the Intercompany Notes constitutes the legal, valid and binding obligation of the obligor with respect
thereto, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general
equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing. 

  
 9 

 Exhibit 10.3 

 

 SECTION 3.2. Grantor Name, Location, Etc. In each case as of the date hereof: 

(a) (i) The jurisdiction in which each Grantor is located for purposes of Sections
9-301 and 9-307 of the UCC and (ii) the address of each Grantor’s executive office and principal place of business is set forth in Item A of
Schedule II. 
 (b) The Grantors do not have any trade names other than those set forth in Item C of
Schedule II hereto. 
 (c) During the twelve months preceding the date hereof (or preceding the date such Grantor
becomes a party to this Security Agreement, as applicable), no Grantor has been known by any legal name different from the one set forth on the signature page hereto, nor has such Grantor been the subject of any merger or other corporate
reorganization, except as set forth in Item D of Schedule II hereto. 
 (d) Each Grantor’s
federal taxpayer identification number (or foreign equivalent) is (and, during the twelve months preceding the date hereof, such Grantor has not had a federal taxpayer identification number (or equivalent) different from that) set forth in
Item E of Schedule II hereto. 
 (e) No Grantor is a party to any federal, state or local government
contract except as set forth in Item F of Schedule II hereto. 
 (f) No Grantor maintains any Deposit
Accounts, Securities Accounts or Commodity Accounts with any Person, in each case, except as set forth on Item G of Schedule II. 

(g) No Grantor is the beneficiary of any Letters of Credit, except as set forth on Item H of
Schedule II. 
 (h) No Grantor has Commercial Tort Claims except as set forth on Item I of
Schedule II. 
 (i) The name set forth on the signature page attached hereto is the true and correct legal name
(as defined in the UCC) of each Grantor. 
 SECTION 3.3. Ownership, No Liens, Etc. Each Grantor owns its Collateral free and clear of
any Lien, except for any security interest (a) created by this Security Agreement and (b) Permitted Liens. No effective UCC financing statement or other filing similar in effect covering all or any part of the Collateral is on file in any
recording office, except those filed in favor of the Lender relating to this Security Agreement, Permitted Liens or as to which a duly authorized termination statement relating to such UCC financing statement or other instrument has been delivered
to the Lender on the Closing Date. 

  
 10 

 Exhibit 10.3 

 

 SECTION 3.4. Possession of Inventory, Control, Etc. 

(a) Each Grantor has, and agrees that it will maintain, exclusive possession of its Documents, Instruments, Promissory Notes,
Goods, Equipment and Inventory, other than (i) Equipment and Inventory that is in transit in the ordinary course of business, (ii) Equipment and Inventory that in the ordinary course of business is in the possession or control of a
warehouseman, bailee agent or other Person (other than a Person controlled by or under common control with such Grantor) that has been notified of the security interest created in favor of the Lender pursuant to this Security Agreement and has
authenticated a record acknowledging that it holds possession of such Collateral for the Lender’s benefit and waives any Lien held by it against such Collateral, (iii) Inventory that is in the possession of a consignee in the ordinary
course of business, (iv) Instruments or Promissory Notes that have been delivered to the Lender pursuant to Section 3.5, and (v) Equipment and Inventory at any single location which does not meet the requirements of
sub-sections (i), (ii), (iii) or (iv) above, but the value of such Equipment and Inventory at such location is not in an aggregate amount of more than $100,000. In the case of Equipment or Inventory described in clause (ii)
above, no lessor or warehouseman of any premises or warehouse upon or in which such Equipment or Inventory is located has (w) issued any warehouse receipt or other receipt in the nature of a warehouse receipt in respect of any such Equipment or
Inventory, (x) issued any Document for any such Equipment or Inventory, or (y) received notification of the Lender’s interest (other than the security interest granted hereunder) in any such Equipment or Inventory or (z) any Lien
on any such Equipment or Inventory. All Collateral Records of the Grantors are maintained at or accessible from the locations set forth in Item A of Schedule II. 

(b) Each Grantor is the sole entitlement holder of its Deposit Accounts (other than the Excluded Accounts) and no other Person
(other than the Lender pursuant to this Security Agreement or any other Person with respect to Permitted Liens) has control or possession of, or any other interest in, any of its Deposit Accounts (other than the Excluded Accounts) or any other
securities or property credited thereto. 
 SECTION 3.5. Negotiable Documents, Instruments and Chattel Paper. Each Grantor has
delivered to the Lender possession of all originals of all Documents, Instruments, Promissory Notes, and tangible Chattel Paper (other than any Document, Instrument, Promissory Note or tangible Chattel Paper not exceeding $20,000 in principal
amount) owned or held by such Grantor on the Closing Date. 
 SECTION 3.6. Intellectual Property Collateral. Except as disclosed on
Schedules III through VI, with respect to any Intellectual Property Collateral: 
 (a) any Intellectual
Property Collateral owned by any Grantor is valid, subsisting, unexpired ahead of its natural expiration or term, and enforceable and has not been abandoned by the Grantor or adjudged invalid or unenforceable, in whole or in part; 

(b) such Grantor is the sole and exclusive owner of the entire and unencumbered right, title and interest in and to all
Intellectual Property Collateral owned by such Grantor and to the knowledge of such Grantor, no claim has been made that the use of such Intellectual Property Collateral by such Grantor does or may, conflict with, infringe, misappropriate, dilute,
misuse or otherwise violate in any material respect, any of the rights of any third party; 

  
 11 

 Exhibit 10.3 

 

 (c) such Grantor has made all necessary filings and recordations to protect
its interest in any Intellectual Property Collateral owned by such Grantor to the extent such filing or recordation is necessary for the conduct of the business substantially in the manner presently conducted, including recordations of all of its
interests in the Patent Collateral and Trademark Collateral in the United States Patent and Trademark Office (or foreign equivalent), and its claims to the Copyright Collateral in the United States Copyright Office (or foreign equivalent), and, to
the extent necessary, has used proper statutory notice in connection with its use of any material Patent, Trademark and Copyright in any of the Intellectual Property Collateral; 

(d) such Grantor has taken reasonable steps to safeguard its Trade Secrets and to its knowledge (A) none of the Trade
Secrets of such Grantor has been used, divulged, disclosed or appropriated for the benefit of any other Person other than such Grantor; (B) no employee, independent contractor or agent of such Grantor has misappropriated any Trade Secrets of
any other Person in the course of the performance of his or her duties as an employee, independent contractor or agent of such Grantor; and (C) no employee, independent contractor or agent of such Grantor is in default or breach of any material
term of any employment agreement, non-disclosure agreement, assignment of inventions agreement or similar agreement or contract relating in any material way to the protection, ownership, development, use or transfer of such Grantor’s
Intellectual Property Collateral; 
 (e) to such Grantor’s knowledge, no third party is infringing upon any Intellectual
Property owned or used by such Grantor in any material respect; 
 (f) no settlement or consents, covenants not to sue,
nonassertion assurances, or releases have been entered into by such Grantor or to which such Grantor is bound that adversely affects its rights to own or use any Intellectual Property; 

(g) such Grantor has not made a previous assignment, sale, transfer or agreement constituting a present or future assignment,
sale or transfer of any Intellectual Property for purposes of granting a security interest or as Collateral that has not been terminated or released except the security interest granted to Hikma Pharmaceuticals LLC in the Hikma Collateral; 

(h) such Grantor has executed and delivered to the Lender Intellectual Property Collateral security agreements for all
Copyrights, Patents and Trademarks owned by such Grantor, including all Copyrights, Patents and Trademarks on Schedule III through VI (as such schedules may be amended or supplemented from time to time by notice by such Grantor to the
Lender); 
 (i) such Grantor uses commercially reasonable standards of quality in the manufacture, distribution, and sale of
all products sold and in the provision of all services rendered under or in connection with all Trademarks and has taken commercially reasonable action necessary to insure that all licensees of the Trademarks owned by such Grantor use such adequate
standards of quality; 

  
 12 

 Exhibit 10.3 

 

 (j) the consummation of the transactions contemplated by the Credit Agreement
and this Security Agreement will not result in the termination or material impairment of any of the Intellectual Property Collateral; and 

(k) to such Grantor’s knowledge, such Grantor owns or is entitled to use by license, lease or other agreement, all
Patents, Trademarks, Trade Secrets, Copyrights, mask works, licenses, technology, know-how, processes and rights with respect to any of the foregoing as necessary to conduct the business and operations of such
Grantor substantially in the manner presently conducted. 
 SECTION 3.7. Validity, Etc. 

(a) This Security Agreement creates a valid security interest in the Collateral securing the payment of the Obligations to the
extent such security interest may be created pursuant to Article 9 of the UCC. 
 (b) As of the Closing Date, each Grantor
has filed or will cause to be filed all UCC-1 financing statements in the filing office for each Grantor’s jurisdiction of organization listed in Item A of Schedule II (collectively, the “Filing
Statements”) (or has delivered to the Lender the Filing Statements suitable for timely and proper filing in such offices) and has taken all other actions required by the Lender for the Lender to obtain control (either itself or through an
agent) of the Collateral as provided in Sections 9-104, 9-105, 9-106 and 9-107 of the UCC. 
 (c) Upon the filing of the
Filing Statements with the appropriate agencies therefor the security interests created under this Security Agreement shall constitute a perfected security interest in the Collateral described on such Filing Statements in favor of the Lender to the
extent that a security interest therein may be perfected by filing a financing statement pursuant to the relevant UCC, prior to all other Liens, except for Permitted Liens (in which case such security interest shall have such priority of right
contemplated by the Loan Documents and subject only to the Permitted Liens until the obligations secured by such Permitted Liens have been satisfied, except as expressly specified in the Loan Documents). 

SECTION 3.8. Authorization, Approval, Etc. Except as have been obtained or made and are in full force and effect, no authorization,
approval or other action by, and no notice to or filing with, any Governmental Authority or any other third party is required either 

(a) for the grant by the Grantors of the security interest granted hereby or for the execution, delivery and performance of
this Security Agreement by the Grantors; 
 (b) for the perfection or maintenance of the security interests hereunder
including the first priority nature of such security interest (except with respect to the Filing Statements or, with respect to Intellectual Property Collateral, the recordation of any agreements with the United States Patent and Trademark Office or
the United States 

  
 13 

 Exhibit 10.3 

 

 
Copyright Office or, with respect to foreign Intellectual Property Collateral, the taking of appropriate action under applicable foreign law and, with respect to after-acquired Intellectual
Property Collateral, any subsequent filings in United States intellectual property offices) or the exercise by the Lender of its rights and remedies hereunder; or 

(c) for the exercise by the Lender of the voting or other rights provided for in this Security Agreement, except (i) with
respect to any securities issued by a Subsidiary of the Grantors, as may be required in connection with a disposition of such securities by laws affecting the offering and sale of securities generally, the remedies in respect of the Collateral
pursuant to this Security Agreement and (ii) any “change of control” or similar filings required by state licensing agencies. 

SECTION 3.9. Best Interests. It is in the best interests, and for the commercial benefit, of each Grantor (other than the Borrower) to
execute this Security Agreement inasmuch as such Grantor will, as a result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans made to the Borrower by the Lender pursuant to the Credit Agreement, and
each Grantor agrees that the Lender is relying on this representation in agreeing to make such Loans pursuant to the Credit Agreement to the Borrower. 

ARTICLE IV 
 COVENANTS 

Each Grantor covenants and agrees that, until the Termination Date, such Grantor will perform, comply with and be bound by the obligations set
forth below. 
 SECTION 4.1. As to Investment Property, Etc. 

SECTION 4.1.1. Capital Securities of Subsidiaries. No Grantor will allow any of its Subsidiaries (including the Borrower): 

(a) that is a corporation, business trust, joint stock company or similar Person, to issue Uncertificated Securities; 

(b) that is a partnership or limited liability company, to (i) issue Capital Securities that are to be dealt in or traded
on securities exchanges or in securities markets, (ii) expressly provide in its Organic Documents that its Capital Securities are securities governed by Article 8 of the UCC, or (iii) place such Subsidiary’s Capital Securities in a
Securities Account; and 
 (c) to issue Capital Securities in addition to or in substitution for the Capital Securities
pledged hereunder, except to such Grantor (and such Capital Securities are immediately pledged and delivered to the Lender pursuant to the terms of this Security Agreement). 

  
 14 

 Exhibit 10.3 

 

 SECTION 4.1.2. Investment Property (other than Certificated Securities). 

(a) With respect to any Deposit Accounts, Securities Accounts, Commodity Accounts, Commodity Contracts or Security Entitlements
constituting Investment Property owned or held by any Grantor, such Grantor will cause (except for Excluded Accounts) the intermediary maintaining such Investment Property to execute a Control Agreement relating to such Investment Property pursuant
to which such intermediary agrees to comply with the Lender’s instructions with respect to such Investment Property without further consent by such Grantor. 

(b) With respect to any Uncertificated Securities (other than Uncertificated Securities credited to a Securities Account)
constituting Investment Property owned or held by any Grantor, such Grantor will cause the issuer of such securities to either (i) register the Lender as the registered owner thereof on the books and records of the issuer or (ii) execute a
Control Agreement relating to such Investment Property pursuant to which the issuer agrees to comply with the Lender’s instructions with respect to such Uncertificated Securities without further consent by such Grantor. Each party hereto that
is such an issuer of any Uncertificated Securities hereby agrees that such party will comply with instructions with respect to such security originated by the Lender. 

SECTION 4.1.3. Certificated Securities (Stock Powers). Each Grantor agrees that all Certificated Securities constituting Collateral,
including the Capital Securities delivered by such Grantor pursuant to this Security Agreement, will be accompanied by duly executed undated blank stock powers, or other equivalent instruments of transfer reasonably acceptable to the Lender. 

SECTION 4.1.4. Continuous Pledge. Each Grantor will (subject to the terms of the Credit Agreement) (a) deliver to the Lender all
Investment Property and all Payment Intangibles to the extent that such Investment Property or Payment Intangibles are evidenced by a Document, Instrument, Promissory Note or Chattel Paper (other than any Document, Instrument, Promissory Note or
Chattel Paper not exceeding $20,000 in the principal amount), and (b) at all times keep pledged to the Lender pursuant hereto, on a first-priority, perfected basis, security interest therein and in all
interest and principal with respect to such Payment Intangibles, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral. Each Grantor agrees that it will, promptly
following receipt thereof, deliver to the Lender possession of all originals of negotiable Documents, Instruments, Promissory Notes and Chattel Paper that it acquires following the Closing Date (other than any Document, Instrument, Promissory Note
or Chattel Paper not exceeding $20,000 in the principal amount). 
 SECTION 4.1.5. Voting Rights, Dividends, Etc. Each Grantor
agrees: 
 (a) upon receipt of notice of the occurrence and continuance of an Event of Default from the Lender and without
any request therefor by the Lender, so long as such Event of Default shall continue, to deliver (properly endorsed where required hereby or requested by the Lender) to the Lender all dividends and Distributions with respect to Investment Property,
all interest, principal, other cash payments on Payment Intangibles, and all Proceeds of the Collateral, in each case thereafter received by such Grantor, all of which shall be held by the Lender as additional Collateral, except for payments made in
accordance with Section 8.6 of the Credit Agreement; and 

  
 15 

 Exhibit 10.3 

 

 (b) immediately upon the occurrence and during the continuance of an Event of
Default and so long as the Lender has notified such Grantor of the Lender’s intention to exercise its voting power under this clause, 

(i) with respect to Collateral consisting of general partner interests or limited liability company interests, to promptly
modify its Organic Documents to admit the Lender as a general partner or member, as applicable; 
 (ii) that the Lender may
exercise (to the exclusion of such Grantor) the voting power and all other incidental rights of ownership with respect to any Investment Property constituting Collateral and such Grantor hereby grants the Lender an irrevocable proxy, exercisable
under such circumstances, to vote such Investment Property; and 
 (iii) to promptly deliver to the Lender such additional
proxies and other documents as may be necessary to allow the Lender to exercise such voting power. 
 All dividends, Distributions, interest, principal,
cash payments, Payment Intangibles and Proceeds that may at any time and from time to time be held by such Grantor, but which such Grantor is then obligated to deliver to the Lender, shall, until delivery to the Lender, be held by such Grantor
separate and apart from its other property in trust for the Lender. The Lender agrees that unless an Event of Default shall have occurred and be continuing and the Lender shall have given the notice referred to in clause (b), such
Grantor will have the exclusive voting power with respect to any Investment Property constituting Collateral and the Lender will, upon the written request of such Grantor, promptly deliver such proxies and other documents, if any, as shall be
reasonably requested by such Grantor which are necessary to allow such Grantor to exercise that voting power; provided that no vote shall be cast, or consent, waiver, or ratification given, or action taken by such Grantor that would impair
any such Collateral or be inconsistent with or violate any provision of any Loan Document. 
 SECTION 4.2. Change of Name, Etc. No
Grantor will change its name or place of incorporation or organization or federal taxpayer identification number except as otherwise permitted by the Credit Agreement. 

SECTION 4.3. As to Accounts. 

(a) Each Grantor shall have the right to collect all Accounts so long as no Event of Default shall have occurred and be
continuing. 
 (b) Upon (i) the occurrence and continuance of an Event of Default and (ii) the delivery of notice
by the Lender to each Grantor, all Proceeds of Collateral received by such Grantor shall be delivered in kind to the Lender for deposit in a Deposit Account of such Grantor maintained with the Lender (together with any other Deposit Accounts or
Security Accounts pursuant to which any portion of the Collateral is deposited with the 

  
 16 

 Exhibit 10.3 

 

 
Lender, the “Collateral Accounts”), and such Grantor shall not commingle any such Proceeds, and shall hold separate and apart from all other property, all such Proceeds in
express trust for the benefit of the Lender until delivery thereof is made to the Lender. 
 (c) Following the delivery of
notice pursuant to clause (b)(ii), the Lender shall have the right to apply any amount in the Collateral Account to the payment of any Obligations which are then due and payable. 

(d) With respect to each of the Collateral Accounts, it is hereby confirmed and agreed that (i) deposits in such
Collateral Account are subject to a security interest as contemplated hereby, (ii) such Collateral Account shall be under the control of the Lender and (iii) the Lender shall have the sole right of withdrawal over such Collateral Account.

 SECTION 4.4. As to Grantors’ Use of Collateral. 

(a) Subject to clause (b), each Grantor (i) may in the ordinary course of its business, at its own expense, sell, lease
or furnish under contracts of service any of the Inventory normally held by such Grantor for such purpose, and use and consume, in the ordinary course of its business, any raw materials, work in process or materials normally held by such Grantor for
such purpose, (ii) will, at its own expense, endeavor to collect, as and when due, all amounts due with respect to any of the Collateral, including the taking of such action with respect to such collection as the Lender may reasonably request
following the occurrence of an Event of Default or, in the absence of such request, as such Grantor may deem advisable, and (iii) may grant, in the ordinary course of business, to any party obligated on any of the Collateral, any rebate, refund or
allowance to which such party may be lawfully entitled, and may accept, in connection therewith, the return of Goods, the sale or lease of which shall have given rise to such Collateral. 

(b) At any time following the occurrence and during the continuance of an Event of Default, whether before or after the
maturity of any of the Obligations, the Lender may (i) revoke any or all of the rights of each Grantor set forth in clause (a), (ii) notify any parties obligated on any of the Collateral to make payment to the Lender of any
amounts due or to become due thereunder and (iii) enforce collection of any of the Collateral by suit or otherwise and surrender, release, or exchange all or any part thereof, or compromise or extend or renew for any period (whether or not
longer than the original period) any indebtedness thereunder or evidenced thereby. 
 (c) Upon the request of the Lender
following the occurrence and during the continuance of an Event of Default, each Grantor will, at its own expense, notify any parties obligated on any of the Collateral to make payment to the Lender of any amounts due or to become due thereunder.

 (d) At any time following the occurrence and during the continuation of an Event of Default, the Lender may endorse, in
the name of such Grantor, any item, howsoever received by the Lender, representing any payment on or other Proceeds of any of the Collateral. 

  
 17 

 Exhibit 10.3 

 

 SECTION 4.5. As to Intellectual Property Collateral. Each Grantor covenants and agrees
to comply with the following provisions as such provisions relate to any Intellectual Property Collateral material to the operations or business of such Grantor: 

(a) such Grantor will not (i) do or fail to perform any act whereby any of the Patent Collateral may lapse or become
abandoned or dedicated to the public or unenforceable, (ii) permit any of its licensees to (A) fail to continue to use any of the Trademark Collateral in order to maintain all of the Trademark Collateral in full force free from any claim
of abandonment for non-use, (B) fail to maintain the quality of products and services offered under all of the Trademark Collateral at a level substantially consistent with the quality of products and
services offered under such Trademark as of the date hereof, (C) fail to employ all of the Trademark Collateral registered with any federal or state or foreign authority with an appropriate notice of such registration, (D) adopt or use any
other Trademark which is confusingly similar or a colorable imitation of any of the Trademark Collateral, (E) use any of the Trademark Collateral registered with any federal, state or foreign authority except for the uses for which registration
or application for registration of all of the Trademark Collateral has been made or (F) do or permit any act or knowingly omit to do any act whereby any of the Trademark Collateral may become invalid or unenforceable, or (iii) do or permit
any act or knowingly omit to do any act whereby any of the Copyright Collateral or any of the Trade Secrets Collateral may lapse or become invalid or unenforceable or placed in the public domain except upon expiration of the end of an unrenewable
term of a registration thereof, unless, in the case of any of the foregoing requirements in clauses (i), (ii) and (iii), such Grantor reasonably and in good faith determines that either (x) the further prosecution or
maintenance of such Intellectual Property Collateral is not economically justified in relation to the economic value, or potential or expected economic value to such Grantor or any other Credit Obligor, (y) the loss of such Intellectual
Property Collateral would not be material to such Grantor or any other Credit Obligor or (z) the Grantor, in its reasonable judgment, determines that further prosecution of such Intellectual Property Collateral is unlikely to result in an
allowance of exclusive patent rights; 
 (b) such Grantor shall promptly notify the Lender if it knows, or has reason to
know, that any application or registration relating to any material item of the Intellectual Property Collateral may, in the Grantor’s reasonable commercial judgment, become abandoned or dedicated to the public or placed in the public domain or
invalid or unenforceable, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office
or any foreign counterpart thereof or any court) regarding such Grantor’s ownership of any of the Intellectual Property Collateral, its right to register the same or to keep and maintain and enforce the same; 

  
 18 

 Exhibit 10.3 

 

 (c) at the times and with such frequency set forth in Section 4.5(e)
below, each Grantor shall notify the Lender of the filing of an application for the registration of any Intellectual Property Collateral with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or
agency in any other country or any political subdivision thereof by such Grantor or any of its agents, employees, designees or licensees, and, upon request of the Lender (subject to the terms of the Credit Agreement), executes and delivers all
agreements, instruments and documents as the Lender may reasonably request to evidence the Lender’s security interest in such Intellectual Property Collateral; 

(d) such Grantor will take all reasonable and necessary steps, including in any proceeding before the United States Patent and
Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof (subject to the terms of the Credit Agreement), to maintain and pursue any material application (and to
obtain the relevant registration) filed with respect to, and to maintain any registration of, material Intellectual Property Collateral, including the filing of applications for renewal, affidavits of use, affidavits of incontestability and
opposition, interference and cancellation proceedings and the payment of fees and taxes (except to the extent that dedication, abandonment or invalidation is permitted under the foregoing clause (a) or (b) or such Grantor
reasonably and in good faith determines that the failure to take any such step would not have a material adverse effect on the interests of the Lender in such Intellectual Property Collateral); and 

(e) such Grantor will within 45 days after the end of each Fiscal Quarter execute and deliver to the Lender (as applicable) a
Patent Security Agreement, Trademark Security Agreement and/or Copyright Security Agreement, as the case may be, in the forms of Exhibit A, Exhibit B and Exhibit C hereto following its obtaining an interest in any
such Intellectual Property or such Grantor filing (or any of its agents, employees, designees or licensees filing on behalf of a Grantor) an application for the registration of any Intellectual Property Collateral in accordance with
Section 4.5(c) above, and shall execute and deliver to the Lender any other document reasonably required to evidence the Lender’s interest in any part of such item of Intellectual Property Collateral unless such Grantor shall determine in
good faith (with the consent of the Lender) that any Intellectual Property Collateral is of negligible economic value to such Grantor. 

SECTION 4.6. As to Letter-of-Credit Rights. 

(a) Each Grantor, by granting a security interest in its Letter-of-Credit Rights to the Lender, intends to (and hereby does)
collaterally assign to the Lender its rights (including its contingent rights ) to the Proceeds of all Letter-of-Credit Rights of which it is or hereafter becomes a beneficiary or assignee. 

(b) Upon the occurrence of an Event of Default, such Grantor will, promptly upon request by the Lender, (i) notify (and
such Grantor hereby authorizes the Lender to notify) the issuer and each nominated person with respect to each of the Letters of Credit that the Proceeds thereof have been assigned to the Lender hereunder and any payments due or to become due in
respect thereof are to be made directly to the Lender and (ii) arrange for the Lender to become the transferee beneficiary of such Letter of Credit. 

  
 19 

 Exhibit 10.3 

 

 SECTION 4.7. As to Commercial Tort Claims. Each Grantor covenants and agrees that,
until the payment in full of the Obligations and termination of all Commitments, with respect to any Commercial Tort Claim hereafter arising, it shall deliver to the Lender a supplement in form and substance reasonably satisfactory to the Lender,
together with all supplements to schedules thereto, identifying such new Commercial Tort Claim. 
 SECTION 4.8. Electronic Chattel Paper
and Transferable Records. If any Grantor at any time holds or acquires an interest in any electronic chattel paper or any “transferable record,” as that term is defined in Section 201 of the U.S. Federal Electronic Signatures in
Global and National Commerce Act, or in Section 16 of the U.S. Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, with a value in excess of $100,000, such Grantor shall promptly notify the Lender thereof and, at the
request of the Lender, shall take such action as the Lender may reasonably request to vest in the Lender control under Section 9-105 of the UCC of such electronic chattel paper or control under Section 201 of the Federal Electronic
Signatures in Global and National Commerce Act or, as the case may be, Section 16 of the Uniform Electronic Transactions Act, as so in effect in such jurisdiction, of such transferable record. The Lender agrees with such Grantor that the Lender
will arrange, pursuant to procedures satisfactory to the Lender and so long as such procedures will not result in the Lender’s loss of control, for the Grantor to make alterations to the electronic chattel paper or transferable record permitted
under Section 9-105 of the UCC or, as the case may be, Section 201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act or Section 16 of the U.S. Uniform Electronic Transactions Act for a party in control to
allow without loss of control, unless an Event of Default has occurred and is continuing or would occur after taking into account any action by such Grantor with respect to such electronic chattel paper or transferable record. 

SECTION 4.9. Further Assurances, Etc. Each Grantor agrees that, from time to time at its own expense, it will, subject to the terms of
this Security Agreement, promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary or that the Lender may reasonably request, in order to perfect, preserve and protect any security
interest granted or purported to be granted hereby or to enable the Lender to exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, such Grantor will 

(a) from time to time upon the request of the Lender, promptly deliver to the Lender such stock powers, instruments and similar
documents, reasonably satisfactory in form and substance to the Lender, with respect to such Collateral as the Lender may request and will, from time to time upon the request of the Lender, after the occurrence and during the continuance of any
Event of Default, promptly transfer any securities constituting Collateral into the name of any nominee designated by the Lender; if any Collateral shall be evidenced by an Instrument, negotiable Document, Promissory Note or tangible Chattel Paper,
deliver and pledge to the Lender hereunder such Instrument, negotiable Document, Promissory Note or tangible Chattel Paper (other than any Instrument, negotiable Document, Promissory Note or tangible Chattel Paper in principal amount less than
$20,000) duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance reasonably satisfactory to the Lender; 

  
 20 

 Exhibit 10.3 

 

 (b) file (and hereby authorizes the Lender to file) such Filing Statements or
continuation statements, or amendments thereto, and such other instruments or notices (including any assignment of claim form under or pursuant to the federal assignment of claims statute, 31 U.S.C. § 3726, any successor or amended version
thereof or any regulation promulgated under or pursuant to any version thereof), as may be necessary or that the Lender may reasonably request in order to perfect and preserve the security interests and other rights granted or purported to be
granted to the Lender hereby; 
 (c) at all times keep pledged to the Lender pursuant hereto, on a first-priority, perfected basis, at the request of the Lender, all Investment Property constituting Collateral, all dividends and Distributions with respect thereto, and all interest and principal with respect to
Promissory Notes, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral; 

(d) not take or omit to take any action the taking or the omission of which would result in any impairment or alteration of any
obligation of the maker of any Payment Intangible or other Instrument constituting Collateral, except as provided in Section 4.4; 

(e) not create any tangible Chattel Paper without placing a legend on such tangible Chattel Paper reasonably acceptable to the
Lender indicating that the Lender has a security interest in such Chattel Paper (provided that so long as no Event of Default is continuing, Chattel Paper and records relating to such Collateral for amounts in each case less than $20,000, need only
be marked upon Lender’s request); 
 (f) furnish to the Lender, from time to time at the Lender’s request,
statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral (including any real property locations where material Collateral Records or Collateral in excess of $100,000 in
aggregate are located) as the Lender may request, all in reasonable detail (provided however, for so long as no Event of Default has occurred, Lender may not require such additional statements and schedules more than once per fiscal quarter); and

 (g) do all things reasonably requested by the Lender in accordance with this Security Agreement (including dollar
thresholds herein) in order to enable the Lender to have and maintain control over the Collateral consisting of Investment Property, Deposit Accounts, Letter-of-Credit-Rights and Electronic Chattel Paper. 

With respect to the foregoing and the grant of the security interest hereunder, each Grantor hereby authorizes the Lender to file one or more
financing or continuation statements, and amendments thereto, relative to all or any part of the Collateral. Each Grantor agrees that a carbon, photographic or other reproduction of this Security Agreement or any UCC financing statement covering the
Collateral or any part thereof shall be sufficient as a UCC financing statement where permitted by law. Each Grantor hereby authorizes the Lender to file financing 

  
 21 

 Exhibit 10.3 

 

 
statements describing as the collateral covered thereby “all of the debtor’s personal property or assets” or words to that effect, notwithstanding that such wording may be broader
in scope than the Collateral described in this Security Agreement. Each Grantor also agrees to promptly notify the Lender of any change in the location of any office in which it maintains Collateral Records or any office or facility at which
Collateral is located (including the establishment of any such new office or facility). 
 ARTICLE V 

THE LENDER 
 SECTION 5.1.
Lender Appointed Attorney-in-Fact. Each Grantor hereby irrevocably appoints the Lender as its
attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor or otherwise, from time to time in the Lender’s
discretion, following the occurrence and during the continuance of an Event of Default, to take any action and to execute any instrument which the Lender may deem necessary or advisable to accomplish the purposes of this Security Agreement,
including: 
 (a) to ask, demand, collect, sue for, recover, compromise, receive and give acquittance and receipts for moneys
due and to become due under or in respect of any of the Collateral; 
 (b) to receive, endorse, and collect any drafts or
other Instruments, Documents and Chattel Paper, in connection with clause (a) above; and 
 (c) to file any
claims or take any action or institute any proceedings which the Lender may deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the Lender with respect to any of the Collateral. 

Each Grantor hereby acknowledges, consents and agrees that the power of attorney granted pursuant to this Section is irrevocable and coupled with an interest.

 SECTION 5.2. Lender May Perform. If any Grantor fails to perform any agreement contained herein, the Lender may itself perform, or
cause performance of, such agreement, that the Lender deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein to the extent provided for herein, and the expenses of the Lender
incurred in connection therewith shall be payable by such Grantor pursuant to Section 10.3 of the Credit Agreement. 
 SECTION 5.3.
Lender Has No Duty. The powers conferred on the Lender hereunder are solely to protect its interest in the Collateral and shall not impose any duty on it to exercise any such powers. Except for reasonable care of any Collateral in its
possession and the accounting for moneys actually received by it hereunder, the Lender shall have no duty as to any Collateral or responsibility for 

(a) ascertaining or taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relative
to any Investment Property, whether or not the Lender has or is deemed to have knowledge of such matters, or 
 (b) taking
any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral. 

  
 22 

 Exhibit 10.3 

 

 SECTION 5.4. Reasonable Care. The Lender is required to exercise reasonable care in
the custody and preservation of any of the Collateral in its possession; provided that the Lender shall be deemed to have exercised reasonable care in the custody and preservation of any of the Collateral, if it takes such action for that
purpose as each Grantor reasonably requests in writing at times other than upon the occurrence and during the continuance of any Event of Default, but failure of the Lender to comply with any such request at any time shall not in itself be deemed a
failure to exercise reasonable care. 
 SECTION 5.5. Lender as Agent for Other Secured Parties. 

(a) Each of the Lender and ROS hereby irrevocably appoints the Lender hereunder and under the other Loan Documents as its agent
and authorizes the Lender to take such actions on its behalf as collateral agent for all purposes hereunder and under the other Loan Documents pursuant to which any Grantor grants a Lien or other right in any collateral (including Collateral and any
“Collateral” howsoever described in any Australian Security Document) to secure the Obligations and for purposes of acquiring, holding and enforcing any and all Liens on any collateral (including Collateral and any “Collateral”
howsoever described in any Australian Security Document) granted by any Grantor to secure any of the Obligations, including execution of the other Loan Documents, and to exercise such powers as are delegated to the Lender by the terms of the Loan
Documents, together with such actions and powers as are reasonably incidental thereto. The provisions of this Section are solely for the benefit of the Lender and ROS, and no Grantor shall have rights as a third-party beneficiary of any of such
provisions. 
 (b) The Person serving as the collateral agent shall have the same rights and powers in its capacity as the
Lender under the Credit Agreement and may exercise the same as though it were not the collateral agent. The Lender shall not have any duties or obligations except those expressly set forth in the Loan Documents, and its duties thereunder shall be
administrative in nature. The Lender shall not be liable for any action taken or not taken by it with the consent or at the request of ROS or in the absence of its own gross negligence or willful misconduct as determined by a court of competent
jurisdiction by final and nonappealable judgment. The Lender may appoint any co-agents, sub-agents or attorneys-in-fact in connection with the foregoing. 

(c) The Lender shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request,
certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise
authenticated by the proper Person. The Lender also may rely upon any statement made to it orally (including by telephone) and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. The Lender
may consult with legal counsel, independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. If in accordance
with the terms of the 

  
 23 

 Exhibit 10.3 

 

 
applicable Loan Documents, any additional Person is assigned, granted or otherwise transferred all or any portion of the Obligations under the Loan Documents (each such new Person, an
“Additional Secured Party” and collectively, the “Additional Secured Parties”), such Additional Secured Party shall preserve all of its rights with respect to the security interests and Lien created pursuant to this
Agreement, so that the security created by hereunder shall be automatically transferred to the assignee, transferee or new creditor after novation. Notwithstanding the foregoing, each Additional Secured Party shall deliver a counterpart signature
page to this Agreement and accept and acknowledge its rights, duties and obligations as if it were a Secured Party to this Agreement as of the Closing Date (including the appointment of the Lender to act as its agent for the purposes of perfecting
and maintaining the security interest in the Collateral on its behalf). On and after the delivery of a counterpart signature page to this Agreement by an Additional Secured Party, all references in this Agreement or in the other Loan Documents to
the secured parties in reference to the Obligations shall mean, be and include a reference to such Additional Secured Party. 
 ARTICLE VI

 REMEDIES 
 SECTION 6.1.
Certain Remedies. If any Event of Default shall have occurred and be continuing: 
 (a) The Lender may exercise in
respect of the Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of the Lender on default under the UCC (whether or not the UCC applies to the affected Collateral) and
also may 
 (i) take possession of any Collateral not already in its possession without demand and without legal process;

 (ii) require each Grantor to, and each Grantor hereby agrees that it will, at its expense and upon request of the Lender
forthwith, assemble all or part of the Collateral as directed by the Lender and make it available to the Lender at a place to be designated by the Lender that is reasonably convenient to both parties, 

(iii) enter onto the property where any Collateral is located and take possession thereof without demand and without legal
process; and 
 (iv) without notice except as specified below, lease, license, sell or otherwise dispose of the Collateral
or any part thereof in one or more parcels at any public or private sale, at any of the Lender’s offices or elsewhere, for cash, on credit or for future delivery, and upon such other terms as the Lender may deem commercially reasonable. Each
Grantor agrees that, to the extent notice of sale shall be required by law, at least ten (10) days’ prior notice to such Grantor of the time and place of any public sale or the time after which any private sale is to be made shall
constitute reasonable notification. The Lender shall not be obligated 

  
 24 

 Exhibit 10.3 

 

 
to make any sale of Collateral regardless of notice of sale having been given. The Lender may adjourn any public or private sale from time to time by announcement at the time and place fixed
therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. 
 (b) All
cash Proceeds received by the Lender in respect of any sale of, collection from, or other realization upon, all or any part of the Collateral shall be applied by the Lender against all or any part of the Obligations as set forth in
Section 4.4(b) of the Credit Agreement. 
 (c) The Lender may: 

(i) transfer all or any part of the Collateral into the name of the Lender or its nominee, with or without disclosing that
such Collateral is subject to the Lien hereunder, 
 (ii) notify the parties obligated on any of the Collateral to make
payment to the Lender of any amount due or to become due thereunder, 
 (iii) withdraw, or cause or direct the withdrawal,
of all funds with respect to the Collateral Account; 
 (iv) enforce collection of any of the Collateral by suit or
otherwise, and surrender, release or exchange all or any part thereof, or compromise or extend or renew for any period (whether or not longer than the original period) any obligations of any nature of any party with respect thereto, 

(v) endorse any checks, drafts, or other writings in any Grantor’s name to allow collection of the Collateral, 

(vi) take control of any Proceeds of the Collateral, and 

(vii) execute (in the name, place and stead of any Grantor) endorsements, assignments, stock powers and other instruments of
conveyance or transfer with respect to all or any of the Collateral. 
 SECTION 6.2. Securities Laws. If the Lender shall determine
to exercise its right to sell all or any of the Collateral that are Capital Securities pursuant to Section 6.1(a)(iv), each Grantor agrees that, upon request of the Lender, such Grantor will, at its own expense: 

(a) execute and deliver, and cause (or, with respect to any issuer which is not a Subsidiary of such Grantor, use its best
efforts to cause) each issuer of the Collateral contemplated to be sold and the directors and officers thereof to execute and deliver, all such instruments and documents, and do or cause to be done all such other acts and things, as may be necessary
or, in the opinion of the Lender, advisable to register such Collateral under the provisions of the Securities Act of 1933, as from time to time amended (the “Securities Act”), and cause the registration statement relating thereto
to become effective and to remain effective for such period as prospectuses are required by 

  
 25 

 Exhibit 10.3 

 

 
law to be furnished, and to make all amendments and supplements thereto and to the related prospectus which, in the opinion of the Lender, are necessary or advisable, all in conformity with the
requirements of the Securities Act and the rules and regulations of the SEC applicable thereto; 
 (b) use its best efforts
to exempt the Collateral under the state securities or “Blue Sky” laws and to obtain all necessary governmental approvals for the sale of the Collateral, as requested by the Lender; 

(c) cause (or, with respect to any issuer that is not a Subsidiary of such Grantor, use its best efforts to cause) each such
issuer to make available to its security holders, as soon as practicable, an earnings statement that will satisfy the provisions of Section 11(a) of the Securities Act; and 

(d) do or cause to be done all such other acts and things as may be necessary to make such sale of the Collateral or any part
thereof valid and binding and in compliance with applicable law. 
 Each Grantor acknowledges the impossibility of ascertaining the amount of damages that
would be suffered by the Lender by reason of the failure by such Grantor to perform any of the covenants contained in this Section and consequently agrees, to the fullest extent permitted by applicable law, that, if such Grantor shall fail to
perform any of such covenants, it shall pay, as liquidated damages and not as a penalty, an amount equal to the value (as determined by the Lender) of such Collateral on the date the Lender shall demand compliance with this Section. 

SECTION 6.3. Compliance with Restrictions. Each Grantor agrees that in any sale of any of the Collateral whenever an Event of Default
shall have occurred and be continuing, the Lender is hereby authorized to comply with any limitation or restriction in connection with such sale as it may be advised by counsel is necessary in order to avoid any violation of applicable law
(including compliance with such procedures as may restrict the number of prospective bidders and purchasers, require that such prospective bidders and purchasers have certain qualifications, and restrict such prospective bidders and purchasers to
Persons who will represent and agree that they are purchasing for their own account for investment and not with a view to the distribution or resale of such Collateral), or in order to obtain any required approval of the sale or of the purchaser by
any Governmental Authority or official, and such Grantor further agrees that such compliance shall not result in such sale being considered or deemed not to have been made in a commercially reasonable manner, nor shall the Lender be liable nor
accountable to such Grantor for any discount allowed by the reason of the fact that such Collateral is sold in compliance with any such limitation or restriction. 

SECTION 6.4. Protection of Collateral. The Lender may from time to time, at its option, perform any act which any Grantor fails to
perform after being requested in writing so to perform (it being understood that no such request need be given after the occurrence and during the continuance of an Event of Default) and the Lender may from time to time take any other action which
the Lender deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein. 

  
 26 

 Exhibit 10.3 

 

 ARTICLE VII 

MISCELLANEOUS PROVISIONS 
 SECTION
7.1. Loan Document. This Security Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and
provisions thereof, including Article X thereof. 
 SECTION 7.2. Binding on Successors, Transferees and Assigns; Assignment. This
Security Agreement shall remain in full force and effect until the Termination Date has occurred, shall be binding upon the Grantors and their successors, transferees and assigns and shall inure to the benefit of and be enforceable by the Lender;
provided that no Grantor may assign any of its obligations hereunder without the prior consent of the Lender. 
 SECTION 7.3.
Amendments, Etc. No amendment or modification to or waiver of any provision of this Security Agreement, nor consent to any departure by any Grantor from its obligations under this Security Agreement, shall in any event be effective unless the
same shall be in writing and signed by the Lender and the Grantors and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given. 

SECTION 7.4. Notices. All notices and other communications provided for hereunder shall be delivered or made as provided in
Section 10.2 of the Credit Agreement. 
 SECTION 7.5. Release of Liens. Upon (a) the Disposition of Collateral in
accordance with the Credit Agreement or (b) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (i) such Collateral (in the case of clause (a)) or (ii) all
Collateral (in the case of clause (b)). Upon any such Disposition or termination, the Lender will, at the Grantors’ sole expense, deliver to the Grantors, without any representations, warranties or recourse of any kind whatsoever, all
Collateral held by the Lender hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request to evidence such termination. 

SECTION 7.6. Additional Grantors. Upon the execution and delivery by any other Person of a supplement in the form of Annex I
hereto, such Person shall become a “Grantor” hereunder with the same force and effect as if it were originally a party to this Security Agreement and named as a “Grantor” hereunder. The execution and delivery of such supplement
shall not require the consent of any other Grantor hereunder, and the rights and obligations of each Grantor hereunder shall remain in full force and effect notwithstanding the addition of any new Grantor as a party to this Security Agreement. 

SECTION 7.7. No Waiver, Remedies. In addition to, and not in limitation of Section 2.4, no failure on the part of the
Lender to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right.
The remedies herein provided are cumulative and not exclusive of any remedies provided by law. 

  
 27 

 Exhibit 10.3 

 

 SECTION 7.8. Severability. Any provision of this Security Agreement which is
prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Security Agreement or
affecting the validity or enforceability of such provision in any other jurisdiction. 
 SECTION 7.9. Governing Law, Entire Agreement,
Etc. THIS SECURITY AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Security Agreement, along with the other
Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto 

SECTION 7.10. Counterparts. This Security Agreement may be executed by the parties hereto in several counterparts, each of which shall
be an original and all of which shall constitute together but one and the same agreement. This Security Agreement shall become effective when counterparts hereof executed on behalf of all of the signatories hereto, shall have been received by the
Lender. Delivery of an executed counterpart of a signature page to this Security Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Security Agreement.

 SECTION 7.11. Australian Subsidiaries. Notwithstanding anything to the contrary herein, nothing herein shall apply to any
Collateral owned by an Australian Subsidiary and not located in the United States or any state or territory thereof (including the District of Columbia) or created pursuant to or governed by any United States federal law or the laws of state or
territory thereof (including the District of Columbia) (it being understood that all Intellectual Property (regardless of where registered), other than Intellectual Property registered in Australia, is deemed located in the United States for
purposes of this paragraph), which is in the subject of the General Security Deed executed by Holdings and the Australian Subsidiaries in favor of Lender and not this Agreement. 

[Signature Page Follows] 

  
 28 

 Exhibit 10.3 

 

 IN WITNESS WHEREOF, each of the parties hereto has caused this Security Agreement to be duly
executed and delivered by its Authorized Officer as of the date first above written. 
 EXECUTED as a deed by each Australian Subsidiary.

  

													
	UNILIFE MEDICAL SOLUTIONS, INC.	 	UNILIFE CORPORATION
					
	By:	 	 /s/ Alan Shortall
	 		 	By:	 	 /s/ Alan Shortall

		 	Name:	 	Alan Shortall	 		 		 	Name:	 	Alan Shortall
		 	Title:	 	Chairman and CEO	 		 		 	Title:	 	Chairman and CEO
					
		 		 		 		 	UNILIFE CROSS FARM LLC
						
		 		 		 		 	By:	 	 /s/ Alan Shortall

		 		 		 		 		 	Name:	 	Alan Shortall
		 		 		 		 		 	Title:	 	Chairman and CEO

  

									
	Executed by Unilife Medical Solutions Pty Limited in accordance with Section 127 of the Corporations Act 2001	 		 		 		 	
					
	 /s/ Alan Shortall
	 	f	 		 	 /s/ Ramin Mojdehbakhsh
	 	f
	Signature of director	 		 		 	Signature of director/company secretary	 	
		 		 		 	(Please delete as applicable)	 	
					
	 Alan Shortall
	 		 		 	 Ramin Mojdehbakhsh
	 	
	Name of director (print)	 		 		 	Name of director/company secretary (print)	 	
					
	Executed by Unitract Syringe Pty Ltd in accordance with Section 127 of the Corporations Act 2001	 		 		 		 	
					
	 /s/ Alan Shortall
	 	f	 		 	 /s/ Ramin Mojdehbakhsh
	 	f
	Signature of director	 		 		 	Signature of director/company secretary	 	
		 		 		 	(Please delete as applicable)	 	
					
	 Alan Shortall
	 		 		 	 Ramin Mojdehbakhsh
	 	
	Name of director (print)	 		 		 	Name of director/company secretary (print)	 	

  
 Signature Page to
Security Agreement 

 Exhibit 10.3 

 

 
					
	 ROS ACQUISITION OFFSHORE LP,
 as the
Lender, for itself and as agent

	By OrbiMed Advisors LLC,
	its investment manager
		
	By:	 	 /s/ Sven Borho

		 	Name:	 	Sven Borho
		 	Title:	 	Managing Member
	
	ROYALTY OPPORTUNITIES S.À R.L, as Secured Party
		
	By	 	OrbiMed Advisors LLC,
	its investment manager
		
	By:	 	 /s/ Sven Borho

		 	Name:	 	Sven Borho
		 	Title:	 	Managing Member

  
 Signature Page to
Security Agreement 

 Exhibit 10.3 

 

 SCHEDULE I 

to Security Agreement 
  

			
	 Name of Grantor:
	  	 Interest:

	Unilife Corporation	  	100% of the membership interests in Unilife Cross Farm, LLC
	Unilife Corporation	  	315,706,616 ordinary shares of Unilife Medical Solutions Pty Limited
	Unilife Medical Solutions Pty Limited	  	44,750,000 ordinary shares of Unitract Syringe Pty Ltd.
	Unilife Medical Solutions Pty Limited	  	15,000 common shares of Unilife Medical Solutions, Inc.

 Exhibit 10.3 

 

 SCHEDULE II 

to Security Agreement 
  

	I.	Item A. Location of each Grantor. 

  

					
	 Name of Grantor:
	  	 Location for purposes of UCC:
	  	 Chief Executive Office

and Principal Place of

Business

			
	 Unilife Medical Solutions, Inc.
	  	Delaware	  	 250 Cross Farm Lane
 York, PA
17406

			
	 Unilife Corporation
	  	Delaware	  	 250 Cross Farm Lane
 York, PA
17406

			
	 Unilife Cross Farm LLC
	  	Delaware	  	 250 Cross Farm Lane
 York, PA
17406

			
	 Unilife Medical Solutions Pty Ltd.
	  	Washington, DC	  	 250 Cross Farm Lane
 York, PA
17406
  
 1 Chifley Square, Level 1

Sydney, NSW, Australia

			
	 Unitract Syringe Pty Ltd.
	  	Washington, DC	  	 250 Cross Farm Lane
 York, PA 17406

 
 1 Chifley Square, Level 1

Sydney, NSW, Australia

  

	II.	Item B. Filing locations last five years. 

 Same as above 

 

	III.	Item C. Trade names. 

  

			
	 Name of Grantor:
	  	 Trade Names:

	 None.
	  	

  

	IV.	Item D. Merger or other corporate reorganization. 

 None 

 Exhibit 10.3 

 

	V.	Item E. Grantor’s federal taxpayer ID numbers. 

  

			
	 Name of Grantor:
	  	 Taxpayer ID numbers:

	Unilife Medical Solutions, Inc.	  	11-2679944
	Unilife Corporation	  	27-1049354
	Unilife Cross Farm LLC	  	80-0503994
	Unilife Medical Solutions PTY LTD	  	N/A
	Unitract Syringe Pty Ltd.	  	N/A

  

	VI.	Item F. Government Contracts. 

 None. 

 

	VII.	Item G. Deposit Accounts, Securities Accounts and Commodities Accounts. 

 See attached Exhibit II(G) for
deposit accounts 
  

			
	 Name of Grantor:
	  	 Description of Deposit Accounts, Securities Accounts and
Commodities Accounts:

		  	
		  	
		  	

  

	VIII.	Item H. Letter of Credit Rights. 

 None. 

 

	IX.	Item I. Commercial Tort Claims. 

 None 

 

	X.	Item J. Pledged Notes. 

 None. 

 Exhibit 10.3 

 

 SCHEDULE III 

to Security Agreement 
  

	XI.	Item A. Patents 

 See attached Exhibit III 

 

	XII.	Item B. Patent Licenses 

 None 

 Exhibit 10.3 

 

 Exhibit III 

UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 

 

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	RETRACTABLE SYRINGE	 	Australia	 	PATENT 731159	 	22.09.1998	 		 	GRANTED 19.01.2001	 	 Patent Valid to 22 September

2018

							
		 	USA	 	PATENT 6,083,199	 	22.09.1998	 		 	GRANTED 04.07.2000	 	 Patent Valid to 22 September

2018

							
	SINGLE USE SYRINGE	 	International Patent Application	 	PCT/AU01/000458	 	20.04.2001	 	 WO 01/80930
 (01.11.2001)
	 	Expired	 	
							
		 	Australia	 	PATENT 2001252019	 	20.04.2001	 	AU200152019	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	Brazil	 	PATENT PI 0110366-0	 	20.04.2001	 	BR200110366	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	Canada	 	PATENT 2,406,567	 	20.04.2001	 	CA2406567	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	China	 	PATENT ZL 01808697.7	 	20.04.2001	 	CN1429122A-CN1236827	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	Europe (Designated UK, Ireland, Germany, Sweden, Denmark, Liechtenstein, Switzerland, Cyprus, Turkey, Netherlands, Greece, Spain, Portugal, Monaco, Italy, Belgium, Luxembourg, France, Austria & Finland)	 	01925194.1	 		 	EP1276530A	 	Pending	 	
							
		 	India	 	PATENT 239341	 	20.04.2001	 		 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	Indonesia	 	WO 02002 02614	 	20.04.2001	 	035.615A 20.03.2003	 	Pending	 	
							
		 	Hong Kong	 	03105302.9	 	20.04.2001	 		 	Pending	 	
							
		 	Japan	 	PATENT 4891512	 	20.04.2001	 	JP2003530974	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	Mexico	 	PATENT 282164	 	20.04.2001	 	MX2002PA0104 88A	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	New Zealand	 	PATENT 522533	 	20.04.2001	 	NZ522533A	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	Norway	 	20025092	 	20.04.2001	 	NO200205092	 	Pending	 	
							
		 	Russia    	 	PATENT 2270033	 	20.04.2001	 	RU2002131643	 	GRANTED	 	Patent Valid to 20 April 2021

  
 -1- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Singapore	 	PATENT 92936	 	20.04.2001	 		 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	South Africa	 	PATENT 2002/9574	 	20.04.2002	 	ZA200209574	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	South Korea	 	PATENT 0772083	 	20.04.2001	 	KR772083	 	GRANTED	 	Patent Valid to 20 April 2021
							
		 	USA	 	PATENT 7,500,967	 	20.04.2001	 	 US2003-0158525

Pub 21-08-03
	 	GRANTED 3/10/2009	 	Patent Valid to 15 July 2022 (Extended by 451 days)
							
	SYRINGE SPRING RETAINER	 	International Patent Application	 	PCT/AU 2004/000354	 	20.03.2004	 	 WO 2004/082747
 (30.09.2004)
	 	Expired	 	
							
		 	Australia	 	2003901301	 	20.03.2003	 		 	Expired	 	
							
		 	Australia	 	2003905080	 	18.09.2003	 		 	Expired	 	
							
		 	Australia	 	PATENT 2004222676	 	19.03.2004	 	AU2004222676	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Canada	 	PATENT 2,518,360	 	19.03.2004	 	CA2518360	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	China	 	PATENT ZL 200480007595.8	 	19.03.2004	 	CN1761497-CN100479876	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Hong Kong	 	PATENT HK1090859	 	19.03.2004	 	HK1090859	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Europe	 	PATENT 1608421	 	19.03.2004	 	EP1608421	 	GRANTED	 	Patent Valid to 19 March 2023
							
		 	Austria	 	PATENT E611814	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Belgium    	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024

  
 -2- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Denmark	 	PATENT DK/EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Finland	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	France	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Germany	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Great Britain	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Greece	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Ireland	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Italy	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Luxembourg	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Monaco	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Netherlands	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Portugal	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Spain	 	ES PATENT 2424947	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Sweden	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Switzerland/ Liechtenstein	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Turkey	 	EP PATENT 1608421	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Europe	 	13156459.3	 	19.03.2004	 	2596824	 	Pending	 	
							
		 	India	 	PATENT 228410	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Indonesia	 	PATENT ID P 0024840	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Japan    	 	PATENT 4652326	 	19.03.2004	 	JP2006520219-JP04652326	 	GRANTED	 	Patent Valid to 19 March 2024

  
 -3- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Mexico	 	PATENT 257268	 	19.03.2004	 	MX2005PA0099 32	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	New Zealand	 	PATENT 542635	 	19.03.2004	 	NZ542635	 	GRANTED	 	Patent Valid to 19 March 2025
							
		 	Singapore	 	PATENT 115034	 	19.03.2004	 		 	GRANTED	 	Patent Valid to 19 March 2023
							
		 	South Africa	 	PATENT 2005-08400	 	19.03.2004	 	ZA200508400	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	USA	 	PATENT 8,021,333	 	19.03.2004	 	US-2006-0235354 Pub 19-10-06	 	GRANTED 9/20/2011	 	Patent Valid to 23 Feb 2028 (Extended by 1,436 Days)
							
		 	Malaysia	 	PATENT MY-141268-A	 	19.03.2004	 	MY141268	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Taiwan	 	PATENT 253944	 	19.03.2004	 	TWI253944	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Thailand	 	089525	 	18.03.2004	 		 	Pending	 	
							
		 	Peru	 	PATENT 4890	 	19.03.2004	 	PE20050098	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Chile	 	581-2004	 	19.03.2004	 	CL5812004	 	Pending	 	
							
		 	Argentina	 	PATENT AR043668	 	19.03.2004	 	AR43668	 	GRANTED	 	Patent Valid to 19 March 2024
							
		 	Venezuela	 	0407-2004	 	20.03.2004	 		 	Pending	 	
							
	RETRACTABLE SYRINGE WITH PLUNDER DISABLING SYSTEM	 	Australian Provisional Patent Application	 	2004900362	 	28.01.2004	 		 	Expired	 	
							
		 	Australian Provisional Patent Application	 	2004906116	 	22.10.2004	 		 	Expired	 	
							
		 	US Provisional Patent Application	 	US 60/638,623	 	22.12.2004	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2005/000107	 	28.01.2005	 	 WO 2005/072801
 (11.08.2005)
	 	Expired	 	
							
		 	Australia	 	PATENT 2005209014	 	28.01.2005	 	AU2005209014	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Canada    	 	PATENT 2,554,196	 	28.01.2005	 	CA2554196	 	GRANTED	 	Patent Valid to 28 January 2025

  
 -4- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	China	 	PATENT 731869	 	28.01.2005	 	CN1929887A	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Europe	 	PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Austria	 	PATENT E562657	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Belgium	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Denmark	 	PATENT DK/EP 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Finland	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	France	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Germany	 	PATENT 602005034821.2	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Great Britain	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Greece	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Ireland	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Italy	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Luxembourg	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Monaco    	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025

  
 -5- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Netherlands	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Portugal	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Spain	 	EP PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Sweden	 	PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Switzerland	 	PATENT 1708772	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Turkey	 	PATENT TR 2012 10731T4	 	28.01.2005	 	EP1708772	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	USA	 	PATENT 8,002,745	 	28.01.2005	 	US20080255513	 	GRANTED 8/23/2011	 	Patent Valid to 4 Dec 2027(675 day
							
		 	Malaysia	 	PATENT MY-147055-A	 	28.01.2005	 		 	Pending	 	
							
		 	Taiwan	 	PATENT 1290840	 	28.01.2005	 	TWI290840	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Thailand	 	097311	 	28.01.2005	 		 	Pending	 	
							
	IMPROVED CONTROLLED RETRACTION SYRINGE	 	Australian Provisional Patent Application	 	2005902392	 	12.05.2005	 		 	Expired	 	
							
		 	Amended filing for Provisional Patent	 	2005904256	 	08.08.2005	 		 	Expired	 	
							
		 	US Provisional Patent Application	 	US 60/732,777	 	02.11.2005	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2006/000618	 	12.05.2006	 	 WO2006/119570
 (16-11-2006)
	 	Expired	 	
							
		 	Australia	 	PATENT 2006246309	 	11.05.2006	 	AU2006246309	 	GRANTED	 	Patent Valid to 11 May 2026
							
		 	Canada    	 	2607836	 	11.05.2006	 	CA2607836	 	Pending	 	

  
 -6- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	China	 	PATENT ZL200680016383.5	 	11.05.2007	 	CN101203258	 	GRANTED	 	Patent Valid to 11 May 2026
							
		 	Europe	 	06721494.0	 	11.05.2006	 	 EP1879635
 (23-01-2008)
	 	Pending	 	
							
		 	India	 	8880/DELNP/2007	 	11.05.2007	 		 	Pending	 	
							
		 	Indonesia	 	PATENT ID P0026343	 	11.05.2006	 	 048.1949 A
 (02-05-2008)
	 	GRANTED	 	Patent Valid to 11 May 2026
							
		 	South Africa	 	PATENT 2007/09607	 	11.05.2006	 	ZA200709607	 	GRANTED	 	Patent Valid to 11 May 2026
							
		 	USA	 	PATENT 8,114,050	 	11.05.2007	 	20090221962	 	GRANTED 2/14/2012	 	Patent Valid to 11 May 2026
							
		 	Malaysia	 	PATENT MY-145011-A	 	11.05.2006	 		 	GRANTED	 	Patent Valid to 11 May 2026
							
		 	Taiwan	 	PATENT 1315206	 	09.05.2006	 		 	GRANTED	 	Patent Valid to 11 May 2026
							
		 	Thailand	 	PATENT 0601002136	 		 		 	GRANTED	 	Patent Valid to 9 May 2026
							
	CLINICAL SYRINGE	 	US Provisional Patent Application	 	US 61/260,253	 	11.11.2009	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2010/001504	 	11.11.2010	 	WO2011/057334	 	Expired	 	
							
		 	Australia	 	PATENT 2010317659	 	11.11.2010	 	2010317659	 	GRANTED	 	Patent Valid to 11 November 2030
							
		 	Canada	 	2780168	 	11.11.2010	 	2780168	 	Pending	 	
							
		 	China	 	201080050897.9	 	11.11.2010	 	 CN 102695533
 (26-09-2012)
	 	Pending	 	
							
		 	Hong Kong	 		 	11.11.2010	 		 	Pending	 	
							
		 	Europe	 	10829351.5	 	11.11.2010	 	2498843	 	Pending	 	
							
		 	India	 	1381/KOLNP/2012	 	11.11.2010	 		 	Pending	 	
							
		 	Japan	 	2012-538141	 	11.11.2010	 	2013-510596	 	Pending	 	
							
		 	New Zealand	 	PATENT 600455	 	11.11.2010	 		 	GRANTED	 	Patent Valid to 11 November 2030
							
		 	South Africa	 	PATENT 2012/04048	 	11.11.2010	 		 	GRANTED	 	Patent Valid to 11 November 2030
							
		 	USA    	 	13/508690	 	11.11.2010	 	 2013/0060202
 (07.03.13)
	 	Pending	 	

  
 -7- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	ONE USE SYRINGE WITH RATCHET ON PLUNGER AND PAWL ON BODY	 	Australian Provisional Patent Application	 	2004900363	 	28.01.2004	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2005/000106	 	28.01.2005	 	 WO 2005/072797
 (11.08.2005)
	 	Expired	 	
							
		 	Australia	 	PATENT 2005209013	 	28.01.2005	 	AU2005209013	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Canada	 	PATENT 2554427	 	28.01.2005	 	CA2554427	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	China	 	PATENT 584670	 	28.01.2005	 	CN1933863-CN100574824	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Europe (Designated Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania,
Slovenia, Slovakia, Spain, Sweden, Switzerland/ Liechtenstein, Turkey, United Kingdom)	 	05700137.2	 	28.01.2005	 	EP1708770	 	Pending	 	
							
		 	USA	 	PATENT 8,052,654	 	28.01.2005	 	US20080208143	 	GRANTED 11/8/2011	 	Patent Valid to 28 January 2025
							
		 	Malaysia	 	PATENT MY-138413-A	 	28.01.2005	 		 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Taiwan	 	PATENT 1282743	 	28.01.2005	 	TWI282743	 	GRANTED	 	Patent Valid to 28 January 2025
							
		 	Thailand	 	097310	 	28.01.2005	 		 	Pending	 	
							
	SYRINGE NEEDLE SHEATH	 	Australian Provisional Patent Application	 	2004903915	 	16.07.2004	 		 	Expired	 	
							
		 	US Provisional Patent Application	 	60/638,504	 	23.12.2004	 	Not yet published	 	Expired	 	

  
 -8- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Amendment Filing for Auto Needle Sheath	 	2005902526	 	18.05.2005	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2005/001054	 	18.07.2005	 	 WO2006/007642
 (26.01.2006)
	 	Expired	 	
							
		 	Australia	 	PATENT 2005263180	 	18.07.2005	 	AU2005263180	 	GRANTED	 	Patent Valid to 17 July 2025
							
		 	China	 	PATENT ZL 200580024023.5	 	18.07.2005	 	CN101052430A	 	GRANTED	 	Patent Valid to 18 July 2025
							
		 	Europe (Designated Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania,
Slovenia, Slovakia, Spain, Sweden, Switzerland/ Liechtenstein, Turkey, United Kingdom)	 	05760724.4	 	18.07.2005	 	 EP1791583
 (06.06.2007)
	 	Pending	 	
							
		 	India	 	806/DELNP/2007	 	18.07.2005	 		 		 	
							
		 	Indonesia	 	PATENT IDP0033050 B	 	18.07.2005	 	 047.1981
 (10.05.2007)
	 	GRANTED	 	Patent Valid to 18 July 2025
							
		 	South Africa	 	PATENT 2007/00639	 	18.07.2005	 	ZA200700639	 	GRANTED	 	Patent Valid to 18 July 2025
							
		 	USA	 	PATENT 7,935,087	 	18.07.2005	 	US-2008-0097337-A1	 	GRANTED	 	Patent Valid to 18 July 2025
							
		 	USA	 	PATENT 8,617,122	 	18.07.2005	 	 US-2011-0190699-A1
 (04.08.2011)
	 	GRANTED 12/31/2013 035	 	Patent Valid to 18 July 2025
							
	CONTROLLED RETRACTABLE SYRINGE AND PLUNGER THEREOF	 	Australian Provisional Patent Application	 	2005901893	 	15.04.2005	 		 	Expired	 	
							
		 	Australian Provisional Patent Application	 	2005906768	 	02.12.2005	 		 	Expired	 	
							
		 	International Patent Application    	 	PCT/AU2006/000516	 	18.04.2006	 	 WO2006/108243
 (19.10.2006)
	 	Expired	 	

  
 -9- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Australia	 	PATENT 2006235224	 	18.04.2006	 	AU2006235224	 	GRANTED	 	Patent Valid to 18 April 2026
							
		 	Australia	 	PATENT 2010210012	 	18.04.2006	 	AU2010210012	 	GRANTED	 	Patent Valid to 18 April 2026
							
		 	Canada	 	2604322	 	18.04.2006	 	CA2604322	 	Pending	 	
							
		 	China	 	PATENT 200680019140.7	 	18.04.2006	 	 CN101203256A
 (18-06-2008)
	 	GRANTED	 	Patent Valid to 18 April 2026
							
		 	Europe (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania,
Slovenia, Slovakia, Spain, Sweden, Switzerland/Liechtenstein, Turkey, United Kingdom.)	 	06721397.5	 	18.04.2006	 	 EP1868669
 (26.12.2007)
	 	Pending	 	
							
		 	India	 	4637/CHENP/2007	 	18.04.2007	 		 	Pending	 	
							
		 	Indonesia	 	PATENT IDP0024625	 	18.04.2006	 		 	GRANTED	 	Patent Valid to 18 April 2026
							
		 	Japan	 	PATENT 5436852	 	18.04.2006	 	 JP2008 535589
 (04-09-2008)
	 	GRANTED	 	Patent Valid to 18 April 2026
							
		 	Japan	 	2012-150616	 	18.04.2006	 	 2012-210458
 (01.11.2012)
	 	Pending	 	
							
		 	South Africa	 	PATENT 2007/08653	 	18.04.2006	 	ZA200708653	 	GRANTED	 	Patent Valid to 18 April 2026
							
		 	USA	 	PATENT 8,167,837	 	18.04.2006	 	US20090093759	 	GRANTED 5/1/2012	 	Patent Valid to 11 May 2026* -Term. Disci. To 8,114,050
							
	PREFILLED RETRACTABLE SYRINGE, PLUNGER AND NEEDLE ASSEMBLY	 	International Patent Application	 	PCT/AU 2008/000971	 	02.07.2008	 	 WO2009/003234
 Al (08.01.2009)
	 	Expired	 	
							
		 	Australia    	 	PATENT 2008271920	 	02.07.2008	 	AU2008271920	 	GRANTED	 	Patent Valid to 2 July 2028

  
 -10- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Australia	 	PATENT 2011250720	 	02.07.2008	 		 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	Brazil	 	PI0812986-0	 		 		 	Pending	 	
							
		 	Canada	 	PATENT 2,692,968	 	30.12.2009	 		 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	China	 	PATENT 200880021389.0	 	02.07.2008	 	 CN 101730558
 (09-06-2010)
	 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	China	 	201310043623.2	 	02.07.2008	 	CN103182115A	 		 	
							
		 	Europe	 	08757038.8	 	02.07.2008	 	EP2162173	 	Pending	 	
							
		 	Hong Kong	 	PATENT 10110473.3	 	01.07.2008	 	1143770A(14.01.2010)	 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	India	 	7710/CHENP/2009	 	30.12.2009	 		 	Pending	 	
							
		 	Indonesia	 	W00200903539	 	02.07.2008	 	 050.0844 A
 (01.04.2010)
	 	Pending	 	
							
		 	Indonesia	 	WO0201205165	 	02.07.2008	 		 	Pending	 	
							
		 	Israel	 	202736	 	02.07.2008	 	IL202736	 	Pending	 	
							
		 	Japan	 	PATENT 5192543	 	02.07.2008	 	 JP2010-531679
 (30.09.2010)
	 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	Japan	 	2012-139803	 	02.07.2008	 	2012-176315	 	Pending	 	
							
		 	Malaysia	 	PI 20095599	 	02.07.2008	 		 	Pending	 	
							
		 	Malaysia	 	PI 2012222672	 	02.07.2008	 		 	Pending	 	
							
		 	Mexico	 	PATENT 300441	 	02.07.2008	 		 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	Mexico	 	MX/a/2012/004434	 	02.07.2008	 		 	Pending	 	
							
		 	New Zealand	 	PATENT 582012	 	02.07.2008	 	NZ582012A	 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	New Zealand	 	PATENT 595031	 	06.09.2011	 		 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	Russian Federation	 	PATENT 2450834	 	02.07.2008	 	RU 2010103265	 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	Singapore	 	PATENT 157665	 	02.07.2008	 		 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	Singapore	 	PATENT 181342	 	02.07.2008	 		 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	South Africa	 	PATENT 2009/09165	 	01.07.2008	 		 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	South Africa    	 	PATENT 2011/01518	 	02.07.2008	 		 	GRANTED	 	Patent Valid to 2 July 2028

  
 -11- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	South Korea	 	PATENT 10-1230434	 	02.07.2008	 	 KR2010047223
 (07-05-2010)
	 	GRANTED	 	Patent Valid to 2 July 2028
							
		 	USA	 	PATENT 8,361,035	 	02.07.2008	 	 US20110015572-Al
 (20.01.2011)
	 	GRANTED 1/29/2013	 	Patent Valid to 2 July 2028
							
		 	USA	 	13/688386	 	02.07.2008	 	US2013338602	 	Pending	 	
							
		 	Thailand	 	0801003413	 	02.07.2008	 	106106 (24-02-2011)	 	Pending	 	
							
		 	Taiwan	 	PATENT 97124808	 	01.07.2008	 	415646	 	GRANTED	 	Patent Valid to 2 July 2028
							
	RETRACTABLE SYRINGE WITH IMPROVED DELIVERY EFFICIENCY AND LOCKING SYSTEM	 	US Provisional Patent Application	 	61/289,259	 	22.12.2009	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2010/001677	 	10.12.2010	 	WO2011/075760 Al (30.06.2011)	 	Expired	 	
							
		 	Australia	 	2010336003	 	10.12.2010	 	2010336003	 	Pending	 	
							
		 	Brazil	 	1120120155202	 	10.12.2010	 		 	Pending	 	
							
		 	Canada	 	2784437	 	10.12.2010	 	2784437	 	Pending	 	
							
		 	China	 	201080058498.7	 	10.12.2010	 	CN 102791312 A	 	Pending	 	
							
		 	Hong Kong	 	13102672.6	 	10.12.2010	 	1175723A (12.07.2013)	 	Pending	 	
							
		 	Europe	 	10838400.9	 	10.12.2010	 	2515976	 	Pending	 	
							
		 	India	 	1564/KOLNP/2012	 	10.12.2010	 		 	Pending	 	
							
		 	Indonesia	 	WO0201202900	 	10.12.2010	 	2013/00240(28.02.2013)	 	Pending	 	
							
		 	Israel	 	220366	 	10.12.2010	 		 	Pending	 	
							
		 	Japan	 	2012-545010	 	10.12.2010	 	2013-514844 (02.05.2013)	 	Pending	 	
							
		 	Mexico	 	MX/a/2012/007116	 	10.12.2010	 	2012/007116	 	Pending	 	
							
		 	New Zealand	 	601140	 	10.12.2010	 		 	Pending	 	
							
		 	Singapore	 	201204578-7	 	10.12.2010	 	181849	 	Pending	 	
							
		 	South Africa    	 	PATENT 2012/04653	 	10.12.2010	 		 	GRANTED	 	Patent Valid to 10 December 2030

  
 -12- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	South Korea	 	10-2012-7019228	 	10.12.2010	 	 10-2012-0120250
 (01.11.2012)
	 	Pending	 	
							
		 	USA	 	13/516,692	 	10.12.2010	 	US2013079716	 	Pending	 	
							
		 	Taiwan	 		 	10.12.2010	 		 	Pending	 	
							
		 	Thailand	 	1201003024	 	10.12.2010	 		 	Pending	 	
							
	VACCINATION SYRINGE	 	US Provisional Patent Application	 	61/260,252	 	11.11.2009	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2010/001505	 	11.11.2010	 	WO2011/057335 Al (19.05.2011)	 	Expired	 	
							
		 	Australia	 	PATENT 2010317660	 	11.11.2010	 		 	GRANTED	 	Patent Valid to 11 November 2030
							
		 	Australia	 	2014200807	 	11.11.2010	 		 	Pending	 	
							
		 	Brazil	 	1120120112074	 	11.11.2010	 		 	Pending	 	
							
		 	Canada	 	2779731	 	11.11.2010	 	2779731	 	Pending	 	
							
		 	China	 	201080050871.4	 	11.11.2010	 	CN 102725014 A (10-10-2012)	 	Pending	 	
							
		 	Hong Kong	 		 	11.11.2010	 		 	Pending	 	
							
		 	Europe	 	10829352.3	 	11.11.2010	 	2498844	 	Pending	 	
							
		 	India	 	1382/KOLNP/2012	 	11.11.2010	 		 	Pending	 	
							
		 	Japan	 	2012-538142	 	11.11.2010	 	2013-510597	 	Pending	 	
							
		 	Mexico	 	MX/a/2012/005454	 	11.11.2010	 	2012/005454	 	Pending	 	
							
		 	New Zealand	 	600456	 	11.11.2010	 		 	Pending	 	
							
		 	Singapore	 	201203230-6	 	11.11.2010	 	180014	 	Pending	 	
							
		 	South Africa	 	PATENT 2012/04050	 	11.11.2010	 		 	GRANTED	 	Patent Valid to 11 November 2030
							
		 	USA	 	13/508,944	 	11.11.2010	 	 2013/0060191
 (07.03.13)
	 	Pending	 	
							
		 	Taiwan	 	99138840	 	11.11.2010	 	201125610	 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/863,113	 	07.08.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/934,963	 	03.02.2014	 		 	Pending	 	

  
 -13- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	SYRINGE BARREL ADAPTER AND NEEDLE ASSEMBLY	 	US Provisional Patent Application	 	61/331,197	 	14.05.2010	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2011/000515	 	04.05.2011	 	 WO2011/137488
 (10.11.2011)
	 	Expired	 	
							
		 	Australia	 	2011250654	 	04.05.2011	 	2011250654	 	Pending	 	
							
		 	Brazil	 	1120120280384	 	04.05.2011	 		 	Pending	 	
							
		 	Canada	 	2797207	 	04.05.2011	 	2797207	 	Pending	 	
							
		 	China	 	201180022073.5	 	04.05.2011	 	CN 102869398 A (09.01.2013)	 	Pending	 	
							
		 	Hong Kong	 	13106386.4	 	04.05.2011	 	 1179192A
 (27.10.2013)
	 	Pending	 	
							
		 	Europe	 	11777028.9	 	04.05.2011	 	2571552	 	Pending	 	
							
		 	India	 	3516/KOLNP/2012	 	04.05.2011	 		 	Pending	 	
							
		 	Israel	 	222478	 	04.05.2011	 	222478	 	Pending	 	
							
		 	Japan	 	2013-508329	 	04.05.2011	 	2013525038	 	Pending	 	
							
		 	Mexico	 	MX/a/2012/012363	 	04.05.2011	 	2012/012363	 	Pending	 	
							
		 	New Zealand	 	603794	 	04.05.2011	 	603794	 	Pending	 	
							
		 	South Africa	 	PATENT 2012/08659	 	04.05.2011	 		 	GRANTED	 	Patent Valid to 04 May 2031
							
		 	South Korea	 	10-2012-7031606	 	04.05.2011	 	 10-2013-0066628
 (20.06.2013)
	 	Pending	 	
							
		 	USA	 	13/695,599	 	04.05.2011	 	2013/0102973(25.04.2013)	 	Pending	 	
							
		 	Taiwan	 	100115608	 	04.05.2011	 	201141451	 	Pending	 	
							
	IMPROVED SYRINGE BARREL ADAPTER, NEEDLE ASSEMBLY AND PLUNGER THEREFOR	 	US Provisional Patent Application	 	61/557,792	 	09.11.2011	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2012/001376	 	09.11.2012	 	 WO 2013/067588
 (16.05.2013)
	 	Pending-National Stage	 	
							
		 	Taiwan	 	101141881	 	09.11.2012	 	201330895	 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/863,098	 	07.08.2013	 		 	Pending	 	

  
 -14- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	redacted	 	US Provisional Patent Application	 	61/898,077	 	31.10.2013	 		 	Pending	 	
							
	SYRINGE ADAPTER	 	Australian Provisional Patent Application	 	2009902776	 	17.06.2009	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2010/000743	 	16.06.2010	 	WO 2010/144957 Al (23.12.2010)	 	Expired	 	
							
		 	Australia	 	PATENT 2010262752	 	16.06.2010	 	2010262752	 	GRANTED	 	Patent Valid to 16 June 2030
							
		 	Canada	 	2762847	 	16.06.2010	 	2762847	 	Pending	 	
							
		 	China	 	201080025669.6	 	16.06.2010	 	CN 102802701 A	 	Pending	 	
							
		 	Europe	 	10788502.2	 	16.06.2010	 	 2442853
 (25.04.2012)
	 	Pending	 	
							
		 	India	 	4836/KOLNP/2011	 	16.06.2010	 		 	Pending	 	
							
		 	Japan	 	2012-515285	 	16.06.2010	 	 2012-529932
 (29.11.2012)
	 	Pending	 	
							
		 	New Zealand	 	PATENT 596905	 	16.06.2010	 		 	GRANTED	 	Patent Valid to 16 June 2030
							
		 	South Africa	 	PATENT 2011/08674	 	16.06.2010	 		 	GRANTED	 	Patent Valid to 16 June 2030
							
		 	USA	 	13/378,030	 	16.06.2010	 	US2012130317	 	Pending	 	
							
	VIAL ADAPTERS	 	US Provisional Patent Application	 	61/738,151	 	17.12.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/073283	 	05.12.2013	 		 	Pending-National Stage	 	
							
		 	Taiwan	 	102146554	 	17.12.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/935,081	 	03.02.2014	 		 	Pending	 	
							
	DUAL-CHAMBER MIXING DEVICE FOR A SYRINGE	 	US Provisional Patent Application	 	US 61/515,554	 	05.08.2011	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2012/000925	 	03.08.2012	 	WO201320170	 	Expired	 	
							
		 	USA	 	13/566,079	 	03.08.2012	 	US2013035664	 	Pending	 	
							
		 	Australia	 	2012292953	 	03.08.2012	 		 	Pending	 	
							
		 	Canada	 		 	03.08.2012	 		 	Pending	 	
							
		 	China    	 		 	03.08.2012	 		 	Pending	 	

  
 -15- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Europe	 		 	03.08.2012	 		 	Pending	 	
							
		 	India	 	75/KOLNP/2014	 	03.08.2012	 		 	Pending	 	
							
		 	Japan	 		 	03.08.2012	 		 	Pending	 	
							
		 	Brazil	 	1120140028028	 	03.08.2012	 		 	Pending	 	
							
		 	Israel	 	230485	 	03.08.2012	 		 	Pending	 	
							
		 	Taiwan	 	101128060	 	03.08.2012	 		 	Pending	 	
							
	AUTOMATIC RECONSTITUTION FOR DUAL CHAMBER SYRINGE	 	US Provisional Patent Application	 	US 61/530,765	 	02.09.2011	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/AU2012/001029	 	31.08.2011	 	WO 2013/029113	 	Expired	 	
							
		 	USA	 	13/599,013	 	30.08.2011	 	US2013060232	 	Pending	 	
							
		 	Australia	 	2012304198	 	30.08.2011	 		 	Pending	 	
							
		 	Canada	 		 	30.08.2011	 		 	Pending	 	
							
		 	China	 		 	30.08.2011	 		 	Pending	 	
							
		 	Europe	 		 	30.08.2011	 		 	Pending	 	
							
		 	India	 	243/KOLNP/2014	 	30.08.2011	 		 	Pending	 	
							
		 	Japan	 		 	30.08.2011	 		 	Pending	 	
							
		 	Brazil	 		 	30.08.2011	 		 	Pending	 	
							
		 	Israel	 	230785	 	30.08.2011	 		 	Pending	 	
							
		 	Taiwan	 	101131792	 	31.08.2012	 	201315498	 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	US 61/875,386	 	09.09.2013	 		 	Pending	 	
							
	COMBINATION PLUNGER FOR DUAL CHAMBER MIXING SYRINGE	 	US Provisional Patent Application	 	US 61/731,972	 	30.11.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/070494	 	18.12.2013	 		 	Pending-National Stage	 	
							
		 	Taiwan	 	102143401	 	28.11.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	US 61/831,017	 	04.06.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/933,502	 	30.01.2014	 		 	Pending	 	

  
 -16- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	redacted	 	US Provisional Patent Application	 	61/941,235	 	18.02.2014	 		 	Pending	 	
							
	INSERTION MECHANISM FOR A DRUG DELIVERY PUMP	 	US Provisional Patent Application	 	US 61/530,774	 	02.09.2011	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2012/53174	 	30.08.2011	 	WO201333421	 	Pending-National Stage	 	
							
		 	USA	 	US 13/599,727	 	30.08.2011	 	US2013060233	 	Pending	 	
							
		 	Australia	 	2012301834	 	30.08.2011	 		 	Pending	 	
							
		 	Canada	 		 	30.08.2011	 		 	Pending	 	
							
		 	China	 		 	30.08.2011	 		 	Pending	 	
							
		 	Europe	 	12759316.8	 	30.08.2011	 		 	Pending	 	
							
		 	India	 		 	30.08.2011	 		 	Pending	 	
							
		 	Japan	 		 	30.08.2011	 		 	Pending	 	
							
		 	Brazil	 		 	30.08.2011	 		 	Pending	 	
							
		 	Israel	 		 	30.08.2011	 		 	Pending	 	
							
		 	Mexico	 		 	30.08.2011	 		 	Pending	 	
							
		 	Taiwan	 	101131744	 	31.08.2011	 	201315497	 	Pending	 	
							
	CONTROLLED DELIVERY FROM SYRINGE OR RESERVOIR	 	US Provisional Patent Application	 	US 61/530,779	 	02.09.2011	 		 	Expired	 	
							
		 	US Provisional Patent Application	 	US 61/694,534	 	29.08.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/057259	 	29.08.2013	 		 	Pending-National Stage	 	
							
	DRIVE MECHANISM FOR DRUG DELIVERY PUMPS WITH INTEGRATED STATUS INDICATION	 	US Provisional Patent Application	 	US 61/530,788	 	02.09.2011	 		 	Expired	 	
							
		 	International Patent Application    	 	PCT/US2012/53241	 	30.08.2011	 	WO2013033467	 	Pending-National Stage	 	

  
 -17- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	USA	 	13/600,114	 	30.08.2011	 	US2013060196	 	Pending	 	
							
		 	USA-DESIGN	 	29/453,258	 	26.04.2013	 		 	Pending	 	
							
		 	Australia	 	2012301784	 	30.08.2011	 		 	Pending	 	
							
		 	Canada	 		 	30.08.2011	 		 	Pending	 	
							
		 	China	 		 	30.08.2011	 		 	Pending	 	
							
		 	Europe	 	12759575.9	 	30.08.2011	 		 	Pending	 	
							
		 	India	 		 	30.08.2011	 		 	Pending	 	
							
		 	Japan	 		 	30.08.2011	 		 	Pending	 	
							
		 	Brazil	 		 	30.08.2011	 		 	Pending	 	
							
		 	Israel	 		 	30.08.2011	 		 	Pending	 	
							
		 	Mexico	 		 	30.08.2011	 		 	Pending	 	
							
		 	Taiwan	 	101131742	 	31.08.2011	 	201315503	 	Pending	 	
							
	STERILE FLUID PATHWAY CONNECTION TO DRUG CONTAINERS FOR DRUG DELIVERY PUMPS STERILE FLUID PATHWAY CONNECTION TO DRUG CONTAINERS FOR DRUG DELIVERY PUMPS	 	US Provisional Patent Application	 	US 61/534,059	 	13.09.2011	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2012/054861	 	12.09.2012	 	WO2013040032	 	Pending-National Stage	 	
							
		 	USA	 	13/612,203	 	12.09.2012	 	US2013066274	 	Pending	 	
							
		 	Australia	 	2012308764	 	12.09.2012	 		 	Pending	 	
							
		 	Canada	 		 	12.09.2012	 		 	Pending	 	
							
		 	China	 		 	12.09.2012	 		 	Pending	 	
							
		 	Europe	 		 	12.09.2012	 		 	Pending	 	
							
		 	India	 		 	12.09.2012	 		 	Pending	 	
							
		 	Japan	 		 	12.09.2012	 		 	Pending	 	
							
		 	Brazil	 		 	12.09.2012	 		 	Pending	 	
							
		 	Israel    	 		 	12.09.2012	 		 	Pending	 	

  
 -18- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	Mexico	 		 	12.09.2012	 		 	Pending	 	
							
		 	Taiwan	 	101133433	 	13.09.2012	 		 	Pending	 	
							
	CONTROLLED DELIVERY DRIVE MECHANISMS FOR DRUG DELIVERY PUMPS	 	US Provisional Patent Application	 	61/748,667	 	03.01.2013	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/057367	 	29.08.2013	 		 	Pending-National Stage	 	
							
	FILL FINISH ADAPTERS FOR STERILE FLUID PATHWAY ASSEMBLIES	 	US Provisional Patent Application	 	US 61/609,745	 	12.03.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/030624	 	12.03.2013	 	WO2013138392	 	Pending-National Stage	 	
							
		 	USA	 	13/798,037	 	12.03.2013	 	US2013237916	 	Pending	 	
							
	CONFIGURABLE RESTRICTION PLATES FOR MICROFLUIDIC PATHWAYS AND DRUG DELIVERY PUMPS UTILIZING THE SAME	 	US Provisional Patent Application	 	61/756,556	 	25.01.2013	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2014/013019	 	24.01.2014	 		 	Pending-National Stage	 	
							
	VENTED FLUID PATHWAY SYSTEMS AND DRUG DELIVERY DEVICES UTILIZING THE SAME	 	US Provisional Patent Application	 	US 61/670,203	 	11.07.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/050075	 	11.07.2013	 	WO2014/011879	 	Pending-National Stage	 	
							
	VARIABLE RATE CONTROLLED DELIVERY DRIVE MECHANISMS FOR DRUG DELIVERY PUMPS    	 	US Provisional Patent Application	 	US 61/731,744	 	30.11.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/057327	 	29.08.2013	 		 	Pending-National Stage	 	

  
 -19- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	INTEGRATED SLIDING SEAL FLUID PATHWAY CONNECTION AND DRUG CONTAINERS FOR DRUG DELIVERY PUMPS	 	US Provisional Patent Application	 	61/756,638	 	25.01.2013	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/030478	 	12.03.2013	 	WO2014011879	 	Pending-National Stage	 	
							
		 	USA	 	13/796,156	 	12.03.2013	 		 	Pending	 	
							
		 	USA-DESIGN	 	29/455,724	 	12.03.2013	 		 	Pending	 	
							
	NESTED SPRING DRIVE MECHANISMS FOR DRUG DELIVERY PUMPS	 	US Provisional Patent Application	 	61/756,667	 	25.01.2013	 		 	Expired	 	
							
		 	US Provisional Patent Application	 	61/912,642	 	06.12.2013	 		 	Pending	 	
							
		 	International Patent Application	 	PCT/US2014/013005	 	24.01.2014	 		 	Pending-National Stage	 	
							
		 	USA	 	14/163,690	 	24.01.2014	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/869,192	 	23.08.2013	 		 	Pending	 	
							
	INJECTABLE DRUG DELIVERY ARRANGEMENT WITH CONTROLLED DELIVERY CANNULA POSITION RELATIVE TO POINT OF DELIVERY	 	US Provisional Patent Application	 	US 61/515,547	 	05.08.2011	 		 	Expired	 	
							
		 	International Patent Application    	 	PCT/US2012/049575	 	03.08.2012	 	WO201322772	 	Expired	 	

  
 -20- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
		 	USA	 	13/566,626	 	03.08.2012	 	US2013035662	 	Pending	 	
							
		 	Australia	 	2012294614	 	03.08.2012	 	2012294614	 	Pending	 	
							
		 	Canada	 		 	03.08.2012	 		 	Pending	 	
							
		 	China	 		 	03.08.2012	 		 	Pending	 	
							
		 	Europe	 		 	03.08.2012	 		 	Pending	 	
							
		 	India	 		 	03.08.2012	 		 	Pending	 	
							
		 	Japan	 		 	03.08.2012	 		 	Pending	 	
							
	ACCURATE DOSE DELIVERY SYRINGE	 	US Provisional Patent Application	 	US 61/568,509	 	08.12.2011	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2012/068210	 		 	WO2013086167	 	Pending-National Stage	 	
							
		 	USA	 	13/707,201	 	12/6/2012	 	US2013150803	 	Pending	 	
							
		 	Taiwan	 	101146033	 	12/7/2012	 	201330889	 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/911,823	 	04.12.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/929,224	 	20.01.2014	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/929,228	 	20.01.2014	 		 	Pending	 	
							
	DEVICE FOR TARGETED DELIVERY OF A THERAPEUTIC IMPLANT	 	US Provisional Patent Application	 	US 61/677,186	 	30.07.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/027529	 	23.02.2013	 	WO2013126853	 	Pending-National Stage	 	
							
		 	USA	 	13/775,155	 	23.02.2013	 	US2013237910	 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/828,973	 	30.05.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/839,254	 	25.07.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/846,940	 	16.07.2013	 		 	Pending	 	

  
 -21- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	redacted	 	US Provisional Patent Application	 	61/847,154	 	17.07.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/877,723	 	13.09.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/941,862	 	19.02.2014	 		 	Pending	 	
							
	redacted	 	US Provisional Application	 	61/949,674	 	07.03.2014	 		 	Pending	 	
							
	AUTO-INJECTOR FOR RETRACTABLE PREFILLED SYRINGE	 	US Provisional Patent Application	 	US 61/526,995	 	24.08.2011	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2012/052129	 	23.08.2012	 	WO/2013/02890 6	 	Expired	 	
							
		 	USA	 	13/593,293	 	23.08.2012	 	 2013-0060231
 (07.03.2013)
	 	Pending	 	
							
		 	Australia	 	2012298793	 	23.08.2012	 		 	Pending	 	
							
		 	Canada	 		 	23.08.2012	 		 	Pending	 	
							
		 	China	 		 	23.08.2012	 		 	Pending	 	
							
		 	Europe	 		 	23.08.2012	 		 	Pending	 	
							
		 	India	 		 	23.08.2012	 		 	Pending	 	
							
		 	Japan	 		 	23.08.2012	 		 	Pending	 	
							
		 	Brazil	 	11 2014 004103-2	 	23.08.2012	 		 	Pending	 	
							
		 	Israel	 		 	23.08.2012	 		 	Pending	 	
							
		 	Taiwan	 	101130775	 	24.08.2012	 	201125609	 	Pending	 	
							
	PLUNGER SUB-ASSEMBLIES AND AUTO-INJECTORS HAVING LOW RETRACTION ACTIVATION FORCE	 	US Provisional Patent Application	 	US 61/595,539	 	06.02.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/024819	 	06.02.2013	 	WO2013119591	 	Pending-National Stage	 	

  
 -22- 

 Exhibit 10.3 

Exhibit III 
 UNILIFE
CORPORATION (held by UNITRACT SYRINGE PTY LTD) -10 MARCH 2014 
  

													
	 Title of Patent
	 	 Country
	 	 Patent Number or

Serial Number
	 	 Filing

Date
	 	 Pre-Grant

Publication

Number
	 	 Status
	 	 Anticipated

Expiration

Date

							
	redacted	 	US Provisional Patent Application	 	61/943,603	 	24.02.2014	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	US 61/817,981	 	01.05.2013	 		 	Pending	 	
							
	DRIVE CONTROL MECHANISMS AND AUTOMATIC INJECTORS FOR INJECTABLE SYRINGES	 	US Provisional Patent Application	 	US 61/683,499	 	15.08.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2013/049314	 	03.07.2013	 		 	Pending	 	
							
		 	USA	 	13/934,958	 	03.07.2013	 	US2014012229	 	Pending	 	
							
		 	USA-DESIGN	 	29/459,890	 	03.07.2013	 		 	Pending	 	
							
		 	Taiwan	 	102124140	 	03.07.2013	 		 	Pending	 	
							
	RETRACTABLE NEEDLE SAFETY SYRINGES	 	US Provisional Patent Application	 	US 61/667,010	 	02.07.2012	 		 	Expired	 	
							
		 	International Patent Application	 	PCT/US2012/067793	 	04.12.2012	 	WO2013126118	 	Pending-National Stage	 	
							
		 	USA	 	US 13/693,915	 	04.12.2012	 	US2013226084	 	Pending	 	
							
		 	Taiwan	 	101145949	 	06.12.2012	 	201336540	 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/777,362	 	12.03.2013	 		 	Pending	 	
							
	redacted	 	US Provisional Patent Application	 	61/806,219	 	28.03.2013	 		 	Pending	 	

  
 -23- 

 Exhibit 10.3 

 

 SCHEDULE IV 

to Security Agreement 
  

	XIII.	Item A. Trademarks 

 See Attached Exhibit IV 

 

	XIV.	Item B. Trademark Licenses 

 None 

 Exhibit 10.3 

 

 EXHIBIT IV 

TRADEMARKS AND SERVICE MARKS 

UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

	XV.	Registrations and Pending Applications 

  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	DEPOT-JECT	  	United States	  	85/732,440	  		  	Published	  	Unitract Syringe Pty Ltd.
						
	EZMIX	  	United States	  	85/905,664	  	4472583	  	Registered	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	Australia	  		  	1523279	  	Registered	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	Canada	  	1594545	  		  	Advertised	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	India	  	2408943	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	Int’l Registration - Madrid Protocol Only COUNTRIES: European Community (statement of grant of protection), France (refusal period has expired), Japan (statement of grant of protection following a provisional refusal; limited
goods listing), Spain (statement of grant of protection), United Kingdom (statement of grant of protection)	  		  	1132932	  	Registered	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	Malaysia	  	2012015998	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	Singapore	  	T1216520I	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	Taiwan	  	101051705	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	FLEX-THERAPY	  	United States	  	85/714,424
(WIPO Basic
Application)	  		  	Allowed -Statement of Use on file	  	Unitract Syringe Pty Ltd.
						
	MICRO-JECT	  	United States	  	85/936,543	  		  	Allowed -Statement of Use to be filed	  	Unitract Syringe Pty Ltd.
						
	OCU-JECT	  	United States	  	85/732,489	  		  	Allowed -Statement of Use to be filed	  	Unitract Syringe Pty Ltd.

  
 -1- 

 Exhibit 10.3 

EXHIBIT IV 
 TRADEMARKS
AND SERVICE MARKS 
 UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	OCU-MIX	  	United States	  	85/936,550	  		  	Allowed -Statement of Use to be filed	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	Australia	  		  	1523280	  	Registered	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	Canada	  	1594546	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	India	  	2408947	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	 Int’l Registration - Madrid Protocol Only

COUNTRIES: France (refusal period has expired), Japan (statement of grant of protection following a provisional refusal; limited goods listing), Spain
(statement of grant of protection)
	  	1132933	  		  	Registered	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	Malaysia	  	2012015999	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	Singapore	  	T1216521G	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	Taiwan	  	101051702	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	PRECISION-THERAPY	  	United States	  	85/714,442
(WIPO Basic
Application)	  		  	Allowed -Statement of Use on file	  	Unitract Syringe Pty Ltd.
						
	RITA	  	 Int’l Registration - Madrid Protocol Only

COUNTRIES: Austria (statement of grant of protection), European Community (statement of grant of protection), France (refusal period has expired), Germany
(statement of grant of protection), Italy (statement of grant of protection), Portugal (statement of grant of protection), Spain (statement of grant of protection), Switzerland (refusal period has expired), United Kingdom (statement of grant of
protection)
	  		  	1134679	  	Registered	  	Unitract Syringe Pty Ltd.

  
 -2- 

 Exhibit 10.3 

EXHIBIT IV 
 TRADEMARKS
AND SERVICE MARKS 
 UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	RITA	  	Singapore	  	T1217334A	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	RITA	  	United States	  	85/737,821
(WIPO
Basic
Application)	  	4467511	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	Australia	  	1323553
(WIPO
Basic
Application)	  	1323553	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	Canada	  	1453791	  		  	Allowed	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	India	  	1868929	  		  	Published	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	 Int’l Registration - Madrid Protocol Only

COUNTRIES: China (statement of grant of protection), European Community (statement of grant of protection), France (statement of grant of protection),
Germany (refusal period has expired), Italy (refusal period has expired), Japan (statement of grant of protection), Portugal (refusal period has expired), Spain (statement of grant of protection), Switzerland (statement of grant of protection),
United Kingdom (statement of grant of protection), United States (registration; limited goods listing)
	  		  	1028438	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	Malaysia	  	09017653	  	09017653	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	Singapore	  		  	T1002301F	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	Taiwan	  	98044614	  	1414108	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL	  	United States	  	79/078,763	  	3913242 /
IR
1028438	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL ASSURE	  	United States	  	85/908,281	  		  	Allowed -Statement of Use to be filed	  	Unitract Syringe Pty Ltd.

  
 -3- 

 Exhibit 10.3 

EXHIBIT IV 
 TRADEMARKS
AND SERVICE MARKS 
 UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	UNIFILL FINESSE	  	Australia	  		  	1557449	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL FINESSE	  	France	  	13/3985673	  	13/3985673	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL FINESSE	  	Germany	  	30 2013 019
064.5/10	  	30 2013
019 064	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL FINESSE	  	 Int’l Registration - Madrid Protocol Only

COUNTRIES: China (statement of grant of protection), European Community (examination completed, but opposition still possible), Italy (refusal period has
expired), Japan (statement of grant of protection), Spain (statement of grant of protection), Switzerland (refusal period has expired)
	  		  	1158706	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL FINESSE	  	Singapore	  	T1308015J	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	UNIFILL FINESSE	  	United Kingdom	  		  	3000974	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNIFILL FINESSE	  	United States	  	85/849,023
(WIPO
Basic
Application)	  		  	Allowed - Statement of Use to be filed	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Australia	  	1323554
(WIPO
Basic
Application)	  	1323554	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Australia	  		  	1533919	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Canada	  	1453790	  		  	Published (Opposition pending- resolution reached by not yet entered)	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Canada	  	1,603,742	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	India	  	1868928	  	1042798	  	Registered	  	Unitract Syringe Pty Ltd.

  
 -4- 

 Exhibit 10.3 

EXHIBIT IV 
 TRADEMARKS
AND SERVICE MARKS 
 UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	UNILIFE	  	India	  	2428802	  		  	Pending	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	 Int’l Registration - Madrid Protocol Only

COUNTRIES: European Community (statement of grant of protection following a provisional refusal), France (statement of grant of protection), Germany
(refusal period has expired), Italy (refusal period has expired), Japan (statement of grant of protection), Spain (statement of grant of protection), Switzerland (refusal period has expired), United Kingdom (statement of grant of protection), United
States (registration)
	  		  	1021229	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	 Int’l Registration - Madrid Protocol Only

COUNTRIES: European Community (statement of grant of protection), France (statement of grant of protection), Germany (statement of grant of protection),
Italy (statement of grant of protection), Japan (statement of grant of protection), Spain (statement of grant of protection), Switzerland (subsequent designation), United Kingdom (statement of grant of protection)
	  		  	1141884	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Malaysia	  	09017652	  	09017652	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Malaysia	  	2012019033	  		  	Published	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Singapore	  		  	T1300168D	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Singapore	  		  	T0914729G	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	Taiwan	  	98044613	  	01429368	  	Registered	  	Unitract Syringe Pty Ltd.

  
 -5- 

 Exhibit 10.3 

EXHIBIT IV 
 TRADEMARKS
AND SERVICE MARKS 
 UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	UNILIFE	  	Taiwan	  	101063509	  	1593695	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	United States	  	79/075,972	  	3807347 /
IR 1021229	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE	  	United States	  	85/769,873
(WIPO
Basic
Application)	  	4,410,026	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	Australia	  	1323552
(WIPO
Basic
Application)	  	1323552	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	Australia	  		  	1533919	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	Canada	  	1453789	  	TMA819140	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	India	  	1868930	  	1014728	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	 Int’l Registration - Madrid Protocol Only

COUNTRIES: European Community (statement of grant of protection), France (statement of grant of protection), Germany (refusal period has expired), Italy
(refusal period has expired), Japan (statement of grant of protection), Portugal (refusal period has expired), Spain (statement of grant of protection), Switzerland (refusal period has expired), United Kingdom (statement of grant of protection),
United States (registration)
	  		  	1021228	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	Malaysia	  	09017651	  	09017651	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	Singapore	  		  	T0914866H	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	Taiwan	  	98044612	  	1414107	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNILIFE Logo	  	United States	  	79/075,971	  	3807346 /
IR 1021228	  	Registered	  	Unitract Syringe Pty Ltd.

  
 -6- 

 Exhibit 10.3 

EXHIBIT IV 
 TRADEMARKS
AND SERVICE MARKS 
 UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	UNITRACT	  	Australia	  	872446	  	872446
(WIPO Basic
Application)	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	Brazil	  	826075908	  	826075908	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	Canada	  	1185587	  	TMA744061	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	India	  	1234887	  	467600	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	Indonesia	  	D002003-
25162-
25369	  	1DM0000314
73	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	 Int’l Registration - Madrid Protocol only

COUNTRIES: Austria (refusal period has expired), Benelux (Belgium/Netherlands/L uxembourg) (refusal period has expired), China (refusal period has expired),
Denmark (refusal period has expired), Finland (refusal period has expired), France (refusal period has expired), Germany (refusal period has expired), Greece (refusal period has expired), Ireland (statement of grant of protection), Italy (refusal
period has expired), Japan (statement of grant of protection), Liechtenstein (refusal period has expired); Monaco (refusal period has expired), Norway (statement of grant of protection), Portugal (refusal period has expired), Russian Federation
(refusal period has expired), Spain (statement of grant of protection), Sweden (refusal period has expired), Switzerland (refusal period has expired), Turkey (statement of grant of protection), United Kingdom (statement of grant of
protection)
	  		  	807476	  	Registered	  	Unitract Syringe Pty Ltd.

  
 -7- 

 Exhibit 10.3 

EXHIBIT IV 
 TRADEMARKS
AND SERVICE MARKS 
 UNILIFE CORPORATION (held by UNITRACT SYRINGE PTY LTD) 

March 11, 2014 
  

											
	 Mark
	  	 Country
	  	Application
Number	  	Registration
Number	  	 Status
	  	 Owner

						
	UNITRACT	  	Mexico	  	632074	  	820917	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	New Zealand	  	683685	  	683685	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	Singapore	  		  	T0312845	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	South Africa	  	2003/15870	  	2003/15870	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT	  	United States	  	78/211,056	  	2,821,246	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT Logo (Reverse Italic)	  	Australia	  	963430	  	963430	  	Registered	  	Unitract Syringe Pty Ltd.
						
	UNITRACT SAFE SYRINGE	  	Australia	  	1026295	  	1026295	  	Registered	  	Unitract Syringe Pty Ltd.

  

	XVI.	Common Law Marks 

 AUTOMIX 

OCURATE 
 LISA 

INJECTING INNOVATION 
 READYTOGO

 FLEXWEAR 
 OCU-MIX 

AUTOMIX PRESTO 
 EZMIX PRODIGY

 EZMIX ENGAGE 
 EZMIX GENESIS

 UNIFILL NEXUS 
 UNIFILL
ALLURE 
 UNIFILL SELECT 

  
 -8- 

 Exhibit 10.3 

 

 SCHEDULE V 

to Security Agreement 
  

	XVII.	Item A. Copyrights/Mask Works 

 None 

 

	XVIII.	Item B. Copyright/Mask Work Licenses 

 None 

 Exhibit 10.3 

 

 SCHEDULE VI 

to Security Agreement 
 (b) Trade
Secret or Know-How Licenses 
 Standard Operating Procedures (SOPs) 

Unpatentable know-how, including documented know-how related to manufacturing and automation processes 

 Exhibit 10.3 

 

 EXHIBIT A 

to Security Agreement 
 PATENT
SECURITY AGREEMENT 
 This PATENT SECURITY AGREEMENT, dated as of
                 , 20     (this “Agreement”), is made by [NAME OF GRANTOR], a
                     (the “Grantor”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands exempted limited partnership, for
itself and as agent for the other parties to which the Grantor may owe any Obligations (together with its Affiliates, successors, transferees and assignees, the “Lender”). 

W I T N E S S E T H: 

WHEREAS, pursuant to a Credit Agreement, dated as of [            ], 2014 (as
amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and between Unilife Medical Solutions, Inc., a Delaware corporation (the “Borrower”) and the Lender, the Lender has extended
a Commitment to make the Loans to the Borrower; 
 WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have
executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of [            ], 2014 (as amended, supplemented or otherwise modified from time to time, the
“Security Agreement”); 
 WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of
the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the
benefit of the Lender, as follows: 
 SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires,
terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement. 

SECTION 2. Grant of Security Interest. The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all
of the Grantor’s right, title and interest in and to the following property, whether now or hereafter existing or acquired by the Grantor (the “Patent Collateral”): 

(a) all of its letters patent and applications for letters patent throughout the world, including each patent and patent
application referred to in Item A of Schedule I attached hereto; 

  
 -1- 

 Exhibit 10.3 

 

 (b) all reissues, divisions, continuations, continuations-in-part,
extensions, renewals and reexaminations of any of the items described in clause (a); 
 (c) all patent licenses and
other agreements providing the Grantor with the right to use any items of the type referred to in clauses (a) and (b) above, including each patent license referred to in Item B of Schedule I attached hereto; and 

(d) all Proceeds of, and rights associated with, the foregoing (including licenses, royalties income, payments, claims, damages
and Proceeds of infringement suits) and the right to sue third parties for past, present or future infringements of any patent or patent application and for breach or enforcement of any patent license. 

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of registering the
security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the
Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms. 

SECTION 4. Release of Liens. Upon (i) the Disposition of Patent Collateral in accordance with the Credit Agreement or
(ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Patent Collateral (in the case of clause (i)) or (B) all Patent Collateral (in the case
of clause (ii)). Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Patent Collateral held by
the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination. 

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with
respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if
fully set forth herein. 
 SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and
shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof. 

SECTION 7. Effective. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received
by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf’ or “tiff’) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement. 

[Signature Page Follows] 

  
 -2- 

 Exhibit 10.3 

 

 IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and
delivered by its Authorized Officer as of the date first above written. 
  

			
	[NAME OF GRANTOR]
		
	By:	 	  

		 	Name:
		 	Title:

 Signature Page to Patent Security Agreement 

 Exhibit 10.3 

 

 SCHEDULE I 

to Patent Security Agreement 
  

	XIX.	Item A. Patents 

 Issued Patents 

 

									
	 Country
	 	 Patent No.
	 	 Issue Date
	 	 Inventor(s)
	 	 Title

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

 (c) Pending Patent Applications 

 

									
	 Country
	 	 Serial No.
	 	 Filing Date
	 	 Inventor(s)
	 	 Title

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

 (d) Patent Applications in Preparation 

 

									
	 Country
	 	 Serial No.
	 	 Expected

Filing Date
	 	 Inventor(s)
	 	 Title

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  

	XX.	Item B. Patent Licenses 

  

											
	 Country or

Territory
	 	 Licensor
	 	 Licensee
	 	 Effective

Date
	 	 Expiration

Date
	 	 Subject

Matter

		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	

 Exhibit 10.3 

 

 EXHIBIT B 

to Security Agreement 
 TRADEMARK
SECURITY AGREEMENT 
 This TRADEMARK SECURITY AGREEMENT, dated as of
                 , 20     (this “Agreement”), is made by [NAME OF GRANTOR], a
             (the “Grantor”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands exempted limited partnership, for itself and as agent for the other parties to which
the Grantor may owe any Obligations (together with its Affiliates, successors, transferees and assignees, the “Lender”). 

W I T N E S S E T H: 

WHEREAS, pursuant to a Credit Agreement, dated as of [            ], 2014 (as
amended, supplemented, or otherwise modified from time to time, the “Credit Agreement”), by and between Unilife Medical Solutions, Inc., a Delaware corporation (the “Borrower”) and the Lender, the Lender has
extended a Commitment to make the Loans to the Borrower; 
 WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates
have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of [            ], 2014 (as amended, supplemented, or otherwise modified from time to time, the
“Security Agreement”); 
 WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of
the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Trademark Collateral (as defined below) to secure all of the Obligations; and 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the
benefit of each Lender, as follows: 
 SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires,
terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement. 

SECTION 2. Grant of Security Interest. The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all
of Grantor’s right, title and interest in and to the following property, whether now or hereafter existing or acquired by the Grantor (the “Trademark Collateral”): 

(a) (i) all of its trademarks, trade names, corporate names, company names, business names, fictitious business names, trade
styles, service marks, certification marks, collective marks, logos and other source or business identifiers, and all goodwill of the business associated therewith, including those referred to in Item A of Schedule I hereto, whether
currently in use or not, all registrations and recordings thereof and all 

 Exhibit 10.3 

 

 
applications in connection therewith, whether pending or filed, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of
the United States of America or any State thereof, and all common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing (collectively referred to as the
“Trademarks”); 
 (b) all Trademark licenses for the grant by or to the Grantor of any right to use any
Trademark, including each Trademark license referred to in Item B of Schedule I hereto; 
 (c) all of the
goodwill of the business connected with the use of, and symbolized by the items described in, clause (a), and to the extent applicable, clause (b); 

(d) the right to sue third parties for past, present and future infringements of any Trademark Collateral described in
clause (a) and, to the extent applicable, clause (b); and 
 (e) all Proceeds of, and rights associated
with, the foregoing, including any claim by the Grantor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, or for any injury to the goodwill associated with the
use of any such Trademark or for breach or enforcement of any Trademark license and all rights corresponding thereto throughout the world. 

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of registering the
security interest of the Lender in the Trademark Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the
Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms. 

SECTION 4. Release of Liens. Upon (i) the Disposition of Trademark Collateral in accordance with the Credit Agreement or
(ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Trademark Collateral (in the case of clause (i)) or (B) all Trademark Collateral (in the
case of clause (ii)). Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Trademark Collateral
held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination. 

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with
respect to the security interest in the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as
if fully set forth herein. 

 Exhibit 10.3 

 

 SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the
Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof. 

SECTION 7. Effective. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received
by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf’ or “tiff’) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement. 

[Signature Page Follows] 

 Exhibit 10.3 

 

 IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and
delivered by Authorized Officer as of the date first above written. 
  

			
	[NAME OF GRANTOR]
		
	By:	 	  

		 	Name:
		 	Title:

 Signature Page to Trademark Security Agreement 

 Exhibit 10.3 

 

 SCHEDULE I 

to Trademark Security Agreement 
  

	Item A.	Trademarks 

 (e) Registered Trademarks 

 

							
	 Country
	 	 Trademark
	 	 Registration No.
	 	 Registration Date

		 		 		 	
		 		 		 	
		 		 		 	

 (f) Pending Trademark Applications 

 

							
	 Country
	 	 Trademark
	 	 Serial No.
	 	 Filing Date

		 		 		 	
		 		 		 	
		 		 		 	

 (g) Trademark Applications in Preparation 

 

									
	 Country
	 	 Trademark
	 	 Docket No.
	 	 Expected

Filing Date
	 	 Products/Services

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  

	Item B.	Trademark Licenses 

  

											
	 Country or

Territory
	 	 Trademark
	 	 Licensor
	 	 Licensee
	 	 Effective

Date
	 	 Expiration

Date

		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	

 Exhibit 10.3 

 

 EXHIBIT C 

to Security Agreement 
 COPYRIGHT
SECURITY AGREEMENT 
 This COPYRIGHT SECURITY AGREEMENT, dated as of
                 , 20     (this “Agreement”), is made by [NAME OF GRANTOR], a
                                          (the
“Grantor”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands exempted limited partnership, for itself and as agent for the other parties to which the Grantor may owe any Obligations (together with its Affiliates,
successors, transferees and assignees, the “Lender”). 
 W I T N E S S
E T H: 
 WHEREAS, pursuant to a Credit Agreement, dated as of
[            ], 2014 (as amended, supplemented, or otherwise modified from time to time, the “Credit Agreement”), among by and between Unilife Medical Solutions, Inc., a
Delaware corporation (the “Borrower”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower; 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement
in favor of the Lender, dated as of [            ], 2014 (as amended, supplemented, or otherwise modified from time to time, the “Security Agreement”); 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of the Security Agreement, the Grantor is
required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Copyright Collateral (as defined below) to secure all of the Obligations; and 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the
benefit of the Lender, as follows: 
 SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires,
terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement. 

SECTION 2. Grant of Security Interest. The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all
of the Grantor’s right, title and interest in and to the following (the “Copyright Collateral”), whether now or hereafter existing or acquired by the Grantor: all copyrights of the Grantor, whether statutory or common law,
whether registered or unregistered and whether published or unpublished, now or hereafter in force throughout the world including all of the Grantor’s right, title and interest in and to all copyrights registered in the United States Copyright
Office or anywhere else in the world including the copyrights referred to in Item A of Schedule I hereto, and registrations and recordings thereof and all applications for registration thereof, whether pending or in preparation, all
copyright licenses, including each copyright license referred to in Item B of Schedule I hereto, the right to sue for 

  
 -1- 

 Exhibit 10.3 

 

 
past, present and future infringements of any of the foregoing, all rights corresponding thereto, all extensions and renewals of any thereof and all Proceeds of the foregoing, including licenses,
royalties, income, payments, claims, damages and Proceeds of suit. 
 SECTION 3. Security Agreement. This Agreement has been executed
and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Copyright Collateral with the United States Copyright Office. The security interest granted hereby has been granted in furtherance of, and not in
limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its
terms. 
 SECTION 4. Release of Liens. Upon (i) the Disposition of Copyright Collateral in accordance with the Credit Agreement
or (ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Copyright Collateral (in the case of clause (i)) or (B) all Copyright Collateral (in
the case of clause (ii)). Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Copyright
Collateral held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination. 

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with
respect to the security interest in the Copyright Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as
if fully set forth herein. 
 SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement
and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof. 

SECTION 7. Effective. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received
by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf’ or “tiff’) or telecopy shall be effective as delivery or a manually executed counterpart of this Agreement. 

[Signature Page Follows] 

  
 -2- 

 Exhibit 10.3 

 

 IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and
delivered by its Authorized Officer as of the date first above written. 
  

			
	[NAME OF GRANTOR]
		
	By:	 	  

		 	Name:
		 	Title:

  
 -1- 

 Exhibit 10.3 

 

 SCHEDULE I 

to Copyright Security Agreement 
  

	Item A.	Copyright/Mask Works 

 (h) Registered Copyrights/Mask Works 

 

									
	 Country
	 	 Registration No.
	 	 Registration Date
	 	 Author(s)
	 	 Title

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

 (i) Copyright/Mask Work Pending Registration Applications 

 

									
	 Country
	 	 Serial No.
	 	 Filing Date
	 	 Author(s)
	 	 Title

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

 (j) Copyright/Mask Works Applications in Preparation 

 

									
	 Country
	 	 Docket No.
	 	 Expected

Filing Date
	 	 Author(s)
	 	 Title

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  

	Item B.	Copyright/Mask Work Licenses 

  

											
	 Country or

Territory
	 	 Trademark
	 	 Licensor
	 	 Licensee
	 	 Effective

Date
	 	 Expiration

Date

		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	

  
 -1- 

 Exhibit 10.3 

 

 ANNEX I 

to Security Agreement 
 SUPPLEMENT
TO 
 PLEDGE AND SECURITY AGREEMENT 

This SUPPLEMENT, dated as of                  ,
20     (this “Supplement”), is to the Pledge and Security Agreement, dated as of [            ], 2014 (as amended, supplemented, amended and restated or
otherwise modified from time to time, the “Security Agreement”), among the Grantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of the Security Agreement) from time to time
party thereto, in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands exempted limited partnership, for itself and as agent for the other parties to which the undersigned may owe any Obligations (together with its Affiliates, successors,
transferees and assignees, the “Lender”). 
 W I T N E S S E
T H: 
 WHEREAS, pursuant to a Credit Agreement, dated as of
[            ], 2014 (as amended, supplemented, or otherwise modified from time to time, the “Credit Agreement”), by and between Unilife Medical Solutions, Inc., a Delaware
corporation (the “Borrower”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower; 

WHEREAS, pursuant to the provisions of Section 7.6 of the Security Agreement, each of the undersigned is becoming a Grantor under the
Security Agreement; and 
 WHEREAS, each of the undersigned desires to become a “Grantor” under the Security Agreement in order to
induce the Lender to continue to extend Loans under the Credit Agreement; 
 NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, each of the undersigned agrees, for the benefit of the Lender, as follows. 

SECTION 1. Party to Security Agreement, Etc. In accordance with the terms of the Security Agreement, by its signature below, each of
the undersigned hereby irrevocably agrees to become a Grantor under the Security Agreement with the same force and effect as if it were an original signatory thereto and each of the undersigned hereby (a) agrees to be bound by and comply with
all of the terms and provisions of the Security Agreement applicable to it as a Grantor and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct as of the date hereof,
unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct as of such earlier date. In furtherance of the foregoing, each reference to a “Grantor” and/or
“Grantors” in the Security Agreement shall be deemed to include each of the undersigned. 
 SECTION 2. Schedules. Each of
the undersigned Grantors hereby authorizes the Lender to add the information set forth on the Schedules to this Supplement to the correlative Schedules attached to the Security Agreement. 

  
 -1- 

 Exhibit 10.3 

 

 SECTION 3. Representations. Each of the undersigned Grantors hereby represents and
warrants that this Supplement has been duly authorized, executed and delivered by it and that this Supplement and the Security Agreement constitute its legal, valid and binding obligation, enforceable against it in accordance with its terms. 

SECTION 4. Full Force of Security Agreement. Except as expressly supplemented hereby, the Security Agreement shall remain in full force
and effect in accordance with its terms. 
 SECTION 5. Severability. Wherever possible each provision of this Supplement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Supplement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or
invalidity, without invalidating the remainder of such provision or the remaining provisions of this Supplement or the Security Agreement. 

SECTION 6. Governing Law, Entire Agreement, Etc. THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN
CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR
SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Supplement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter
thereof and supersedes any prior agreements, written or oral, with respect thereto. 
 SECTION 7. Effective. This Supplement shall
become effective when a counterpart hereof executed by the Grantor shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Supplement by email (e.g. “pdf’ or “tiff’) or telecopy
shall be effective as delivery of a manually executed counterpart of this Supplement. 
 [Signature Page Follows] 

  
 -2- 

 Exhibit 10.3 

 

 IN WITNESS WHEREOF, each of the parties hereto has caused this Supplement to be duly executed
and delivered by its Authorized Officer as of the date first above written. 
  

			
	[NAME OF ADDITIONAL SUBSIDIARY]
		
	By:	 	  

		 	Name:
		 	Title:
	
	[NAME OF ADDITIONAL SUBSIDIARY]
		
	By:	 	  

		 	Name:
		 	Title:

  
 -1- 

 Exhibit 10.3 

 

 SCHEDULES 

  
 -1- 

 Exhibit 10.3 

 

 EXHIBIT D 

to Security Agreement 
 Hikma
Security Agreement 
 [see attached] 

 Exhibit 10.3 

 

 SECURITY AGREEMENT 

THIS SECURITY AGREEMENT (this “Agreement”‘) is made as of December 18, 2013, by UNILIFE MEDICAL SOLUTIONS, INC., a
Delaware corporation (“Unilife”), and UNITRACT SYRINGE PTY LTD., a Western Australia company (“Unitract”; Unilife and Unitract are sometimes hereinafter referred to individually as a “Debtor” and
collectively as the “Debtors”), in favor of HIKMA PHARMACEUTICALS LLC, a company registered in Jordan (“Secured Party”). 

WHEREAS, pursuant to that certain Binding License, Development and Supply Agreement, dated as of November 18, 2013, as the same may be
amended, restated, modified or supplemented and in effect from time to time in accordance with the terms thereof (the “BLDS Agreement”), by and between Secured Party and Unilife, Unilife and Secured Party agreed, among other things,
to the terms and conditions upon which Unilife will develop and exclusively supply customized Devices to be filled with Secured Party’s drugs and sold worldwide by Secured Party as drug-device combination products (the “Combination
Products”); and 
 WHEREAS, as a condition to the Secured Party agreeing to enter into the BLDS Agreement, Unilife has agreed to
execute, and to cause Unitract to execute, this Agreement in favor of Secured Party to grant liens on and security interests in all of Debtors’ Collateral to secure the Secured Obligations, in each case subject to the terms and conditions of
this Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and Agreements set forth herein, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Debtors hereby agree as follows; 
 Definitions. 

Defined Terms. As used in this Agreement, the following capitalized terms have the corresponding meanings specified below: 

“Agreement” means this Security Agreement, as the same may be amended, restated, modified or supplemented and in effect from
time to time in accordance with the terms hereof. 
 “Collateral” has the meaning assigned to that term in 0. 

“Device IPR” means all Intellectual Property relating to the Devices (including, without limitation, the Patents listed in
Schedule 0), any know-how associated with the design, construction or manufacture of the Devices, and all improvements, changes, and customization to the Devices. 

“Devices” means all “Devices” as defined in the BLDS Agreement, namely the following three types of Devices:
(1) a lmL-Long prefillable syringe with 0.5” needle and integrated needle retraction safety mechanism, sold by Debtor under the trade name Unifill®; (2) a 2mL prefillable syringe with a luer connection for intra-venous delivery,
without needle retraction, sold by Debtor under the trade name Unifill NexusTM; and (3) a 2mL prefillable syringe with a luer connection for subcutaneous, intra-muscular, or intra-venous delivery, with needle retraction,

 Exhibit 10.3 

 

 
sold by Debtor under (he trade name Unifill NexusTM Select or Unifill AllureTM. For the sake of clarity, the parties understand and agree that Unifill NexusTM Select and Unifill
AllureTM are names for the same devices. 
 “Equipment IPR” means all Equipment dedicated to or used in the manufacture
of the Devices, including the Equipment specified on Schedule 0, but excluding the equipment used for the manufacture of the Unifill. 

“Event of Default” means any of the following events: 

termination of the BLDS Agreement by Unilife without cause; or 

Unilife shall fail to pay any amount owing to Secured Party under the BLDS Agreement (subject to the relevant cure period set forth in the
BLDS Agreement) as and when due; or 
 the occurrence of a material breach of the BLDS Agreement by Unilife (subject to the relevant cure
period set forth in the BLDS Agreement); or 
 either Debtor shall materially breach any term, covenant, representation or other provision
of this Agreement; or 
 any of the Collateral shall be attached or levied upon or seized in any legal adjudication. 

if Unilife is adjudicated bankrupt or insolvent or files a petition seeking relief from its creditors under the bankruptcy or insolvency laws
of any governing jurisdiction. 
 “Lien” means any mortgage, deed of trust, grant, pledge, security interest, assignment to
a third party, encumbrance, judgment, lien, claim or charge of any kind, whether perfected or unperfected, avoidable or unavoidable, including, without limitation, any conditional sale or other title retention agreement, any lease in the nature
thereof, the agreement to any provision for a confession of judgment, cognovit, consent to decree or similar remedy. 
 “Release
Milestones” means that Debtors shall have satisfied and filled when requested all of Secured Party’s purchase orders for Devices for two (2) consecutive years from the later of (1) Debtor’s first shipment of Devices to
Hikma in response to a duly issued purchase order, or (2) Debtor’s curing of any Event of Default under the BLDS Agreement. 

“Secured Obligations” means, collectively, (a) all obligations of Unilife under the BLDS Agreement, including, without
limitation, all obligations of Unilife’s obligation to refund to Secured Party all milestone / development fees, (b) all obligations of either Debtor arising hereunder, and (c) all of Secured Party’s costs and expenses (including
without limitation reasonable attorney’s fees and costs) in connection with this Agreement or any other document or instrument, in each case whether for principals premium, interest, fees, or costs and expenses and including interest arising in
any bankruptcy or insolvency proceeding. 

  
 -3- 

 Exhibit 10.3 

 

 “UCC” or “Uniform Commercial Code” means the Uniform
Commercial Code as in effect in the State of New York, unless the context requires application of the Uniform Commercial Code as in effect in another state, in which case such term means the Uniform Commercial Code as in effect in such slate. 

“Unilife Approvals” has the meaning given to such term in the BLDS Agreement and shall include all clearances, approvals,
permissions, and authorizations secured by either Debtor for the manufacture, distribution, import, marketing or sale of the Devices as part of the Combination Products in the United States, as well as any other jurisdiction. 

Other Definition Provisions. References to “Sections” or “Schedules” shall be to Sections or Schedules of this
Agreement unless otherwise specifically provided. For purposes hereof, “including” is not limiting and “or” is not exclusive. All capitalized terms defined in the UCC and not otherwise defined herein shall have the respective
meanings provided for by the UCC. Any of the terms defined in Schedule 0 may, unless the context otherwise requires, be used in the singular or the plural depending on the reference. All references to statutes and related regulations
shall include any amendments of same and any successor statutes and regulations. 
 Grant of Security Interests. To secure the payment and
performance of the Secured Obligations, each Debtor hereby grants to Secured Party a lien on, security interest in and right of set-off against any and all right, title and interest in and to all of the following property and interests in property
of such Debtor, whether now owned or hereafter created, acquired or arising (all being collectively referred to herein as the “Collateral”): 

Unilife Approvals; 
 the license
rights to the Device IPR, specifically, upon an Event of Default, a royalty-free, irrevocable, worldwide license (and entitlement to sublicense and/or assign such license at Secured Party’s absolute discretion) to use the Device IPR, on the
basis of exclusivity maintained prior to such Event of Default, to: (i) manufacture and fill the Devices with the Hikma Drugs of the BLDS Agreement, and (ii) sell the Combination Products, in each case, for the remainder of the term of the
BLDS Agreement; 
 Equipment IPR; 

Inventory of Devices and components for the manufacture of Devices for orders received from Secured Party, including, without limitation,
finished goods and unfinished components; and 
 all books and records, in whatever form or medium, that at any time evidence or contain
information relating to the Collateral or helpful in the collection thereof or realization thereon; 
 all Accessions and additions to, and
substitutions and replacements of, any and all of the foregoing; and 

  
 -4- 

 Exhibit 10.3 

 

 all Proceeds and products of the foregoing, and all insurance pertaining to the foregoing and
proceeds thereof. 
 Representations and Warranties. Each Debtor represents and warrants, at the time of this Agreement, to Secured Party as follows:

 Binding Obligation; Perfection, This Agreement constitutes a valid and binding obligation of such Debtor, enforceable against it
in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, or similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles. Secured Party has a valid and
perfected first priority security interest in the Collateral, securing the payment of the Secured Obligations, and such security interests are entitled to all of the rights, priorities and benefits afforded by the UCC or other applicable law as
enacted in any relevant jurisdiction which relates to perfected security interests. 
 Organizational Information. Schedule 0
sets forth (i) the full, correct and current name of such Debtor, as its appears in such Debtor’s organizational documents, (ii) any names of such Debtor other than such Debtor’s current name, used during the five (5) year
period preceding the date hereof, (iii) such Debtor’s type of organization, (iv) such Debtor’s jurisdiction of organization, and (v) such Debtor’s organizational identification number. 

Collateral Locations. Schedule 0 sets forth all addresses at which any Collateral is located, indicating for each whether
such location is owned or leased by each Debtor, or owned or operated by a third-party such as a warehouseman, consignee or processor. Schedule 0 indicates which of the foregoing addresses serves as each Debtor’s chief executive office.

 No Existing Liens. The Debtors own the Collateral, and will own all after-acquired Collateral, free and clear of any Lien. No
effective financing statement or other form of Lien notice covering all or any part of the Collateral is on file in any recording office. 

Governmental Authorizations; Consents. No authorization, approval or other action by, and no notice to or filing with, any governmental
authority or consent of any other Person is required for (i) the grant by Debtors of the security interests granted hereby or for the execution, delivery or performance of this Agreement by either Debtor; or (ii) the exercise by Secured
Party of its rights and remedies hereunder (except as may have been accomplished by or at the direction of either Debtor or Secured Party). Except for the filing of UCC financing statements with the Secretary of State of Delaware, in the case of
Unilife, and with the Recorder of Deeds of the District of Columbia, in the case of Unitract, and appropriate filings with the United Stated Patent and Trademark Office, no authorization, approval or other action by, and no notice to or filing with,
any governmental authority or consent of any other Person is required for the perfection of the security interests granted hereby. The Parties will, concurrent with the execution of this Agreement, execute a separate Patent Security Agreement
attached hereto as Schedule 0 which is suitable for recordation with the United Slated Patent and Trademark Office. 

  
 -5- 

 Exhibit 10.3 

 

 Intellectual Property. 

Schedule 3.6 lists all Collateral consisting of intellectual property (“Intellectual Property”) registered in the name of
each Debtor with the U.S. Patent and Trademark Office and U.S. Copyright Office or any similar office of any other jurisdiction. 
 At the
time of this Agreement, all Collateral consisting of Intellectual Property is valid, subsisting, unexpired and enforceable, has not been abandoned and does not knowingly infringe the intellectual property rights of any other person. 

At the time of this Agreement, no holding, decision or judgment has been rendered by any governmental authority which would limit, cancel or
question the validity of, or either Debtor’s rights in, any Collateral consisting of Intellectual Property. 
 At the time of this
Agreement, no action or proceeding is pending, or, to the knowledge of either Debtor, threatened, seeking to limit, cancel or question the validity of any Collateral consisting of Intellectual Property or either such Debtor’s ownership interest
therein. 
 Accurate Information. All information heretofore and herein supplied to Secured Party by or on behalf of either Debtor
with respect to the Collateral is accurate and complete in all material respects. 
 Survival of Representations and Warranties. All
representations and warranties of Debtors contained in this Agreement shall survive the execution and delivery of this Agreement. 
 Covenants and
Further Assurances. 
 Name or Entity Changes. Neither Debtor shall change its name, type of organization or jurisdiction of
organization, unless such Debtor has given Secured Party not less than twenty (20) days prior written notice thereof. 

Intellectual Property. 

Neither Debtor (either itself or through licensees) will do any act, or omit to do any act, whereby any patent that is included in the
Collateral will become forfeited, abandoned or dedicated to the public, other than the expiration of any such patent at the end of its term. 

Neither Debtor (either itself or through licensees) will do any act that knowingly uses any Intellectual Property to infringe the intellectual
property rights of any other person. 
 Debtors will notify Secured Party of the status of any application or registration relating to any
Intellectual Property that is included in the Collateral on an annual basis (or within thirty 30 days of a written request by Secured Party) and will notify Secured Party of any adverse determination or development (including, without limitation,
the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country) regarding cither Debtor’s ownership
of, or the validity of, any such Intellectual Property or either Debtor’s right to register the same or to own and maintain the same. 

  
 -6- 

 Exhibit 10.3 

 

 Whenever either Debtor, either by itself or through any agent, employee, licensee or
designee, shall file an application for the registration of any Intellectual Property included in the Collateral with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other
country or any political subdivision thereof, such Debtor will report such filing to Secured Party on an annual basis (or within thirty 30 days of a written request by Secured Party). Upon request of Secured Party, such Debtor shall execute and
deliver, and have recorded, any and all agreements, instruments, documents, and papers as Secured Party may request to evidence the Secured Party’s security interest in any Intellectual Property and the goodwill and general intangibles of such
Debtor relating thereto or represented thereby. 
 Each Debtor will take all reasonable and necessary steps, including, without limitation,
in any proceeding before the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof, to maintain and pursue each application (and to
obtain the relevant registration) and to maintain each registration of the Intellectual Property included in the Collateral, including, without limitation, filing of applications for renewal, affidavits of use and affidavits of incontestability, in
each case if determined by such Debtor in its business judgment to be appropriate and likely to achieve a favorable outcome. 
 In the event
that any Intellectual Property included in the Collateral is infringed, misappropriated or diluted by a third party, Debtors shall (i) take such actions as Debtors shall reasonably deem appropriate under the circumstances to protect such
Intellectual Property and (ii) promptly notify the Secured Party after it learns thereof and, if reasonably deemed by Debtors to be appropriate under the circumstances, sue for appropriate relief, which may include injunctive relief and
damages. 
 Bailees. No Collateral shall at any time be in the possession or control of any warehouse, consignee, bailee or any of
either Debtor’s agents or processors without prior written notice to Secured Party and the receipt by Secured Party, if Secured Party has so requested, of warehouse receipts or bailee lien waivers (as applicable) reasonably satisfactory to
Secured Party prior to the commencement of such possession or control. Debtors shall, upon the reasonable request of Secured Party, notify any such warehouse, consignee, bailee, agent or processor of the Secured Party’s security interests in
the Collateral, shall instruct such person to hold all such Collateral for Secured Party’s account subject to Secured Party’s instructions and shall obtain an acknowledgement from such person that such person holds the Collateral for
Secured Party’s benefit. Secured Party agrees with Debtors that it shall not give any such instructions unless an Event of Default has occurred and is continuing. 

General Intangibles. Debtors shall use their best efforts to obtain any consents, waivers or Agreements necessary to enable Secured
Party to exercise remedies hereunder with respect to any of either Debtor’s rights under any General Intangibles, including, without limitation, the Unilife Approvals. 

Taxes and Claims. Debtors shall pay when due all property and other taxes, assessments and governmental charges imposed upon, and all
claims against, the Collateral (including claims for labor, materials and supplies); provided that no such tax, assessment or charge need be paid to the extent the same is being contested in good faith and the same may be contested without risk of
loss or forfeiture or material impairment of the Collateral or the use thereof. 

  
 -7- 

 Exhibit 10.3 

 

 Collateral Generally. 

Each Debtor hereby authorizes Secured Party to file one or more financing or continuation statements, and amendments thereto (or similar
documents required by any laws of any applicable jurisdiction), relating to all or any part of the Collateral without the signature of either Debtor (to the extent such signature is required under the laws of any applicable jurisdiction), which
financing statements may describe the Collateral as “all assets” or “all personal property” or words of like import. 

Debtors will furnish to Secured Party, from time to time upon request, statements and schedules further identifying, updating, and describing
the Collateral and such other information, reports and evidence concerning the Collateral as Secured Party may reasonably request, all in reasonable detail. 

Debtors shall not use or permit any Collateral to be used unlawfully or in material violation of any provision of applicable law, or any
policy of insurance covering any of the Collateral. 
 Subject to the next sentence, Debtors shall keep the Collateral (other than
Collateral in the possession of Secured Party) at the locations maintained by Debtors and set forth on Schedule 0. Debtors shall give Secured Party not less than twenty (20) days prior written notice of any change in its chief executive
office and principal place of business or of any new location of business or any new location for any of the Collateral. With respect to any new location, Debtors shall execute and deliver such instruments, documents and notices and take such
actions as may be necessary or desirable, or that Secured Party may reasonably request, to create, perfect and protect its security interest. 

Debtors shall keep full and accurate books and records relating to the Collateral. 

Except as otherwise permitted herein, Debtors shall not (i) sell, assign to a third party (by operation of law or otherwise) or otherwise
dispose of, or grant any option with respect to, any of the Collateral, except that Debtors may sell Inventory to buyers in the ordinary course of their business; or (ii) create or suffer to exist any Lien upon or with respect to any of the
Collateral to secure indebtedness of Debtors, or either of them, or any other Person except for the security interests arising under this Agreement. 

Beyond the safe custody thereof, Debtors agree that Secured Party shall have no duties concerning the custody and preservation of any
Collateral in its possession (or in the possession of any agent or bailee) or with respect to any income thereon or the preservation of rights against prior parties or any other rights pertaining thereto. Secured Party shall be deemed to have
exercised reasonable care in the custody and preservation of the Collateral in its possession if the Collateral is accorded treatment substantially equal to that which it accords its own property. Secured Party shall not be liable or responsible for
any loss or damage to any of the Collateral, or for any diminution in the value thereof, by reason of the act or omission of any warehouseman, carrier, forwarding agency, consignee or other agent or bailee selected by Secured Party in good faith.

  
 -8- 

 Exhibit 10.3 

 

 Debtors shall not take any action that will impair the rights of Secured Party in the
Collateral. Debtors shall at all times maintain insurance with respect to the Collateral reasonably satisfactory to the Secured Party. Debtors assume all liability and responsibility in connection with the Collateral acquired by either of them, and
the liability of Debtors to pay the Secured Obligations shall in no way be affected or diminished by reason of the fact that such Collateral may be lost, stolen, damaged, or for any reason whatsoever unavailable to either Debtor. 

Debtors Remain Liable. Anything herein to the contrary notwithstanding: (i) Debtors shall remain liable under the contracts and
agreements included in the Collateral to the extent set forth therein and shall perform all of its duties and obligations thereunder to the same extent as if this Agreement had not been executed; (ii) the exercise by Secured Party of any of the
rights hereunder shall not release either Debtor from any of its duties or obligations under the contracts and agreements included in the Collateral; (iii) Secured Party shall not have any obligation or liability under the contracts and
agreements included in the Collateral by reason of this Agreement, nor shall Secured Party be obligated to perform any of the obligations or duties of either Debtor thereunder or to take any action to collect or enforce any claim for payment
assigned hereunder; and (iv) Secured Party shall not have any liability in contract or tort for either Debtor’s acts or omissions. 

Other Documents and Actions. Debtors shall, from time to time, at their expense, promptly execute and deliver all further instruments,
documents and notices and take all further action that may be necessary or desirable, or that Secured Party may request, in order to create, perfect and protect any Security Interests, or to enable Secured Party to exercise and enforce its rights
and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, Debtors shall: (i) at any reasonable time, upon commercially reasonable prior written notice to Debtors by Secured Party, exhibit the
Collateral to allow inspection of the Collateral by Secured Party or persons designated by Secured Party and to examine and make copies of the records of Debtors related thereto, and to discuss the Collateral and the records of Debtors with respect
thereto with, and to be advised as to the same by, Debtors’ officers and employees and, after the occurrence and during the continuance of an Event of Default, with any other person which is or may be obligated with respect to any Collateral;
and (ii) upon Secured Party’s request, appear in and defend any action or proceeding that may affect either Debtor’s title to or Secured Party’s security interest in the Collateral. 

Remedial Provisions. 
 Following the
occurrence of an Event of Default, the Secured Party shall have any and all rights and remedies available at law or in equity, including, without limitation, all rights and remedies of a secured party under the UCC. 

Following the occurrence of an Event of Default, Secured Party or its attorneys shall have the right, without notice or demand or legal
process (unless the same shall be required by applicable law), personally, or by an agent, (i) to enter upon, occupy and use any premises owned or leased by either Debtor or where the Collateral is located (or is believed to be located)

  
 -9- 

 Exhibit 10.3 

 

 
until the Secured Obligations are paid in full and satisfied without any obligation to pay rent to either Debtor, to manufacture syringes and other products, to assume Debtor’s rights under
the Equipment IPR, and to render the Collateral useable or saleable and to remove the Collateral or any part thereof to the premises of Secured Party for such time as Secured Party may desire in order to effectively collect or liquidate the
Collateral and use in connection with such removal any and all services, supplies and other facilities of Debtors; and (ii) to take possession of Debtor’s books and records related to the Collateral, to obtain access to Debtors’ data
processing equipment, computer hardware and software relating to the Collateral and to use all of the foregoing and the information contained therein in any manner reasonably appropriate. 

If any Event of Default shall have occurred and be continuing, Secured Party may, exercise in respect of the Collateral, in addition to all
other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of Secured Party on default under the UCC (whether or not the UCC applies to the affected Collateral) and also may: (i) require Debtors to,
and each Debtor hereby agrees that it will, at its expense and upon request of Secured Party forthwith, assemble all or part of the Collateral as directed by Secured Party and make it available to Secured Party at any place or places designated by
Secured Party which is reasonably convenient to Secured Party in which event Debtors shall at their own expense (A) forthwith cause the same to be moved to the place or places so designated by Secured Party, (B) store and keep any
Collateral so delivered to Secured Party at such place or places pending further action by Secured Party, and (C) while Collateral shall be so stored and kept, provide such guards and maintenance services as shall be necessary to protect the
same and to preserve and maintain the Collateral In good condition; and (ii) without notice except as specified below, sell, lease, license or otherwise dispose of the Collateral or any part thereof by one or more contracts, in one or more
parcels at public or private sale, and without the necessity of gathering at the place of sale of the property to be sold, at any of Secured Party’s offices or elsewhere, at such time or times, for cash, on credit or for future delivery, and at
such price or prices and upon such other terms as Secured Party may deem commercially reasonable. Secured Party shall have no obligation to marshal any Collateral in favor of cither Debtor or any other Person. 

Debtors agree that, to the extent notice of sale shall be required by law, a reasonable authenticated notification of disposition shall be a
notification given at least ten (10) days prior to any such sale. At any sale of the Collateral, if permitted by law, Secured Party may bid (which bid may be, in whole or in part, in the form of cancellation of indebtedness) for the purchase,
lease, license or other disposition of the Collateral or any portion thereof for the account of Secured Party. Secured Party shall not be obligated to make any sale of Collateral regardless of notice of sale having been given. Secured Party may
disclaim any warranties that might arise in connection with the sale, lease, license or other disposition of the Collateral and have no obligation to provide any warranties at such time. Secured Party may adjourn any public or private sale from time
to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. To the extent permitted by law, each Debtor hereby specifically waives all rights of
redemption, stay or appraisal, which it has or may have under any law now existing or hereafter enacted. 
 If an Event of Default has
occurred, each Debtor hereby irrevocably authorizes and empowers Secured Party, to assert, either directly or on behalf of Debtor, any claims such Debtor 

  
 -10- 

 Exhibit 10.3 

 

 
may have, from time to time, against any other party to any of the Agreements to which such Debtor is a party or to otherwise exercise any right or remedy of such Debtor under any such Agreements
(including, without limitation, the right to enforce directly against any party to any such Agreement all of such Debtor’s rights thereunder, to make all demands and give all notices and to make all requests required or permitted to be made by
such Debtor thereunder). 
 If an Event of Default has occurred, the proceeds of any collection, enforcement, sale or other disposition of,
or other realization upon, all or any part of the Collateral shall be applied as determined by the Secured Party in its reasonable discretion. 

Debtors acknowledge and agree that a material breach by either or both of them of any of the covenants contained in 0, 0 and 0 hereof
will cause irreparable injury to Secured Party and that Secured Party has no adequate remedy at law in respect of such breaches and therefore agrees, without limiting the right of Secured Party to seek and obtain specific performance of other
obligations of Debtors contained in this Agreement, that the covenants of Debtors contained in such Sections shall be specifically enforceable against Debtors. 

No failure or delay on the part of Secured Party in the exercise of any power, right or privilege hereunder shall impair such power, right or
privilege or be construed to be a waiver of any default or acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or any other right, power or privilege. All
rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available. 

Attorney-in-Fact. Each Debtor hereby irrevocably appoints Secured Party, its nominee, and any other Person whom Secured Party may designate, as such
Debtor’s attorney-in-fact for the purposes of carrying out the terms of this Agreement, with full power after the occurrence and during the continuance of any Event of Default to sign such Debtor’s name on verifications of Collateral; to
sign such Debtor’s name on any invoice or bill of lading relating to any Collateral, on claims to enforce collection of any Collateral, on schedules and assignments of Collateral, on notices of assignment and on public records; and to do all
things reasonably necessary to carry out the terms and provisions of this Agreement. Each Debtor hereby ratifies and approves all acts of any such attorney and agrees that neither Secured Party nor any such attorney will be liable for any acts or
omissions nor for any error of judgment or mistake of fact or law other than, and to the extent of, such person’s gross negligence or willful misconduct. The foregoing powers of attorney, being coupled with an interest, are irrevocable until
the Secured Obligations have been fully paid and satisfied and the security interests granted hereunder shall have terminated in accordance with the terms hereof. 

Expenses. Debtors, jointly and severally, hereby agree to promptly pay all fees, costs and expenses (including reasonable attorneys’ fees and
expenses) incurred in connection with (i) protecting, storing, warehousing, appraising, insuring, handling, maintaining and shipping the Collateral, (ii) maintaining and enforcing Secured Party’s Liens and (iii) collecting,
enforcing, retaking, holding, preparing for disposition, processing and disposing of the Collateral. 
 If Debtors fail to promptly pay any
portion of the above costs, fees and expenses when due or to perform any other obligation of Debtors under this Agreement, Secured Party may, at 

  
 -11- 

 Exhibit 10.3 

 

 
its option, but shall not be required to, pay or perform the same and charge Debtors for all fees, costs and expenses incurred therefor, and Debtors, jointly and severally, agree to reimburse
Secured Party therefor on demand. All sums so paid or incurred by Secured Party for any of the foregoing, any and all other sums for which Debtors may become liable hereunder and all fees, costs and expenses (including reasonable attorneys’
fees, legal expenses and court costs) incurred by Secured Party in enforcing or protecting the Security Interests or any of its lights or remedies under this Agreement shall be payable on demand, shall constitute Secured Obligations, and shall be
secured by the Collateral. 
 Termination. This Agreement shall terminate and be of no further force or effect at the earliest of: (i) Debtor
meets all the Release Milestones; or (ii) the Secured Obligations shall be paid and performed in full. Upon such termination of the Secured Obligations, Secured Party shall promptly deliver to Debtors any Collateral at the time subject to this
Agreement and then in Secured Party’s possession or control and all instruments of assignment executed in connection therewith, free and clear of the Liens hereof, and in any and all forms reasonably necessary for Debtors to record the release
thereof (collectively, the “Release”) and, except as otherwise provided herein, all of Debtors’ obligations hereunder shall at such time terminate. 

Reinstatement. In the event any payment of, or any application of any amount, asset or property to, any of the Secured Obligations, or any part
thereof, made at any time (including, without limitation, made prior to any applicable proceeding under the United States Bankruptcy Code or other insolvency law) is rescinded or must otherwise be restored or returned by Secured Party at any time
after such payment or application as a result of the United States Bankruptcy Code or other insolvency law, including (without limitation) the application of such law in any proceeding involving either Debtor or any other person, whether by order of
any court, by any settlement approved by any court, or otherwise, then the Secured Obligations and Secured Party’s Liens in the Collateral and the other terms and provisions of this Agreement shall be reinstated, all as though such payment or
application had never been made. Notwithstanding anything to the contrary in this Agreement, the Secured Obligations shall not be deemed to have been fully paid and satisfied so long as any applicable preference period available under the United
States Bankruptcy Code or other insolvency law has not expired with respect to any such payment or application or any part thereof, irrespective of whether all monetary obligations then outstanding have been paid or satisfied. 

Notices. All notices, requests and other communications hereunder must be in writing and shall be deemed to have been duly given only if delivered
personally or by facsimile transmission or e-mailed with evidence of receipt to the Parties at the following addresses or facsimile numbers: 

If to the Secured Party, to: 

Hikma Pharmaceuticals PLC 
 Attn:
General Counsel 
 13 Hanover Square 

London W1S 11IW, England 
 Fax:+44
(0)20 7399 2761 

  
 -12- 

 Exhibit 10.3 

 

 If to Debtors, to: 

Unilife Medicals Solutions, Inc. 

Attn: General Counsel 
 250 Cross
Farm Lane 
 York, Pennsylvania 17406, U.S.A. 

Fax: +00 (717) 384-3402 

Email: legal@unilife.com 
 Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns except that neither Debtor may assign its rights or obligations hereunder without the written consent of
Secured Party. No sales of participations, other sales, assignments, transfers or other dispositions of any Agreement governing or instrument evidencing the Secured Obligations or any portion thereof or interest therein shall in any manner impair
the Lien granted to Secured Party hereunder. 
 Changes in Writing. No amendment, modification, termination or waiver of any provision of this
Agreement shall be effective unless the same shall be in writing signed by Secured Party. 
 Governing Law. This Agreement, all acts and transactions
hereunder and the rights and obligations of the parties hereto shall be governed, construed and interpreted according to the internal laws of the State of New York, without regard to conflicts of laws principles that would apply the laws of a
jurisdiction other than the State of New York to this Agreement. 
 WAIVER OF JURY TRIAL. EACH OF THE DEBTORS AND SECURED PARTY HEREBY WAIVES THE
RIGHT TO A JURY TRIAL IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATED TO THIS Agreement. 
 JURISDICTION AND VENUE. EACH
DEBTOR IRREVOCABLY CONSENTS THAT ANY LEGAL ACTION OR PROCEEDING AGAINST IT UNDER ARISING OUT OF OR IN ANY MANNER RELATING TO THIS AGREEMENT MAY BE BROUGHT IN ANY COURT OF THE STATE OF NEW YORK OR ANY UNITED STATES DISTRICT COURT LOCATED IN THE
BOROUGH OF MANHATTAN, STATE OF NEW YORK. EACH DEBTOR, BY ITS EXECUTION AND DELIVERY OF THIS AGREEMENT, EXPRESSLY AND IRREVOCABLY CONSENTS AND SUBMITS TO THE PERSONAL JURISDICTION OF ANY OF SUCH COURTS IN ANY SUCH ACTION OR PROCEEDING. EACH DEBTOR
FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF ANY COMPLAINT, SUMMONS, NOTICE OR OTHER PROCESS RELATING TO SUCH ACTION OR PROCEEDING BY DELIVERY THEREOF IN THE MANNER PROVIDED IN 0 OF THIS AGREEMENT. EACH DEBTOR HEREBY EXPRESSLY AND IRREVOCABLY
WAIVES ANY CLAIM OR DEFENSE IN ANY SUCH ACTION OR PROCEEDING BASED ON ANY ALLEGED LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON CONVEN1ENS OR ANY SIMILAR BASIS. NEITHER DEBTOR SHALL BE ENTITLED IN ANY SUCH ACTION OR PROCEEDING TO ASSERT
ANY DEFENSE GIVEN OR ALLOWED UNDER THE LAWS OF ANY STATE OTHER THAN THE STATE OF NEW YORK, UNLESS SUCH DEFENSE IS ALSO GIVEN OR ALLOWED BY THE LAWS OF THE STATE OF NEW YORK. NOTHING IN THIS PARAGRAPH SHALL AFFECT OR

  
 -13- 

 Exhibit 10.3 

 

 
IMPAIR IN ANY MANNER OR TO ANY EXTENT THE RIGHT OF THE SECURED PARTY TO COMMENCE LEGAL PROCEEDINGS OR OTHERWISE PROCEED AGAINST DEBTORS, OR EITHER OF THEM, IN ANY JURISDICTION OR TO SERVE PROCESS
IN ANY MANNER PERMITTED BY LAW. 
 Rights and Remedies Cumulative. All rights and remedies of any party hereto are cumulative of each other and of
every other right or remedy such party may otherwise have at law or in equity, and the exercise of one or more rights or remedies shall not prejudice or impair the concurrent or subsequent exercise of other rights or remedies. 

Further Assurances. Upon the reasonable request of Secured Party, each Debtor shall take any and all actions, including, without limitation, the
execution of certificates, documents or instruments, necessary or appropriate to give effect to the transactions described herein or contemplated by this Agreement. 

Counterparts; Integration. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if
the signatures thereto and hereto were upon the same instrument. This Agreement constitutes the entire Agreement and understanding among the parties hereto and supersede any and all prior Agreements and understandings, oral or written, relating to
the subject matter hereof. 
 Headings. Headings and captions used in this Agreement are included for convenience of reference and shall not be given
any substantive effect. 
 [Signature Page Follows] 

  
 -14- 

 Exhibit 10.3 

 

 IN WITNESS WHEREOF, each of the undersigned has executed this Security Agreement as of the
date first written above. 
  

					
	DEBTORS:
	
	UNILIFE MEDICAL SOLUTIONS, INC.
		
	By:	 	  

		 	Name:	 	J. Christopher Naftzger
		 	Title:	 	Vice President, General Counsel, Corporate Secretary & CCO
	
	UNITRACT SYRINGE PTY LTD.
		
	By:	 	  

		 	Name:	 	Alan D. Shortall
		 	Title:	 	Director & CEO
	
	SECURED PARTY:
	
	HIKMA PHARMACEUTICALS LLC
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	

 Exhibit 10.3 

 

 Schedules to Security Agreement 

Schedule 1.1 
 Equipment

 Manufacturing line for the Unifill NexusTM and Unifill AllureTM Barrel Sub-Assembly, inclusive of assembly
operations, washing and siliconization, and packaging of the barrels into nested tubs; 
 Manufacturing line for the Needle
Sub-Assembly of the Unifill AllureTM, inclusive of sealing operations; 
 Mold and press for manufacturing the Needle
Over-Mold which is a component of the Needle Sub-Assembly of the Unifill AllureTM; 
 Assembly line for the Unifill
AllureTM Plunger Sub-Assembly (Plunger Rod); 
 Molds for manufacturing the release ring, barrel tip, plunger rod, tub
and tray for Unifill Nexus as well as molds for manufacturing the needle cap, needle retainer, needle hub, and plunger sub-assembly components for Unifill AllureTM; 

Molds for manufacturing the needle seal, plunger seal and tip cap for Unifill Nexus and Unifill AllureTM. 

Any additional manufacturing equipment and assets acquired by Unilife to meet Hikma’s future demand for the Devices, or purchased using monies furnished
by Hikma under the BLDS Agreement, or otherwise authorized for purchase by the Joint Steering Committee under the BLDS Agreement. 

 Exhibit 10.3 

 

 Schedule 3.2 

Legal Name; Prior Names; Organizational Type and Jurisdiction 

Legal Name: Unilife Medical Solutions, Inc. 
 Prior Names:
Integrated BioSciences, Inc. 
 Type of Organization: Corporation 

Jurisdiction of Organization: Delaware 
 Organizational ID:
3613755 
 Legal Name: Unitract Syringe Pty Ltd 
 Prior Names:
N/A 
 Type of Organization: Proprietary Company 

Jurisdiction of Organization: Western Australia, Australia 

Organizational ID: 101 059 723 

 Exhibit 10.3 

 

 Schedule 3.3 

Collateral Locations, Chief Executive Office 

250 Cross Farm Lane, York, Pennsylvania 17406, U.S.A. 
 150
South Warner Road, King of Prussia, Pennsylvania 19406, U.S.A. 

 Exhibit 10.3 

 

 Schedule 3.6 

Specified Patents 
  

					
	 Patent Type
	 	 Patent Number
	 	 Inventor/Applicant

	U.S. Patent	 	PATENT 6,083,199	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 7,500,967	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,021,333	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,002,745	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,114,050	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,052,654	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 7,935,087	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,167,837	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,361,035	 	Unitract Syringe Pty. Ltd
	International Patent Application	 	PCT/AU2010/001677	 	Unitract Syringe Pty. Ltd
	International Patent Application	 	PCT/AU2010/001505	 	Unitract Syringe Pty. Ltd
	U.S. Provisional Patent Application	 	61/863,113	 	Unitract Syringe Pty. Ltd
	International Patent Application	 	PCT/AU2011/000515	 	Unitract Syringe Pty. Ltd
	International Patent Application	 	PCT/AU2012/001376	 	Unitract Syringe Pty. Ltd
	U.S. Provisional Patent Application	 	61/863,098	 	Unitract Syringe Pty. Ltd

 Exhibit 10.3 

 

 Schedule 3.7 

NOTICE OF PATENT LICENSE AND SECURITY AGREEMENT 

THIS NOTICE OF PATENT LICENSE AND SECURITY AGREEMENT (“NOTICE”) is given on this
             day of December, 2013, by and among UNILIFE MEDICAL SOLUTIONS, INC., a company incorporated under the laws of the State of Delaware (“UMSI”), having a
principal place of business at 250 Cross Farm Lane, York, Pennsylvania 17406, U.S.A, UNITRACT SYRINGE PTY LTD, a limited propriety company under the laws of Australia, having a registered address at Level 0, 0 Chifley Square, Sydney 2000, New South
Wales, Australia (“Unitract”, and collectively with UMSI, “Grantor”) and HIKMA PHARMACEUTICALS LLC, a company registered in Jordan with the company registration number [475] whose registered office is at Bayader Wadi El
Seer, Industrial Area, Saleem Bin Al-Hareth St, Building No. 21, P.O. Box 182400, Amman, 11118, Jordan (“Secured Party”). 

RECITALS: 
 A. Grantor is the
owner, assignee, licensor, and/or licensee of the U.S. and PCX International patents and patent applications listed on the attached Schedule A (collectively the “Patents”). 

B. Pursuant to the terms and conditions of the Security Agreement between Grantor and Secured Party dated the
             day of December, 2013 (the “Security Agreement”) and the Binding License, Development and Supply Agreement between the Parties dated the 18” day of
November, 2013, as such agreement may be amended from time to time (the “BLDS Agreement”), Grantor has granted Secured Party a security interest in certain collateral to secure Grantor’s obligations under the BLDS Agreement.

 C. Pursuant to the terms and conditions of the BLDS Agreement, Grantor has granted Secured Party a security interest in certain rights to
license the Patents. 
 D. Grantor and Secured Party by this instrument seek to confirm and make a record of the grant of the security
interest in the license rights to the Patents. 
 [Remainder of the page intentionally left blank] 

 Exhibit 10.3 

 

 IN WITNESS WHEREOF, the parties have caused this NOTICE to be duly executed by its duly
authorized officers as of the date written above. 
  

					
	GRANTORS:
	
	UNILIFE MEDICAL SOLUTIONS, INC.
		
	By:	 	  

		 	Name:	 	J. Christopher Naftzger
		 	Title:	 	Vice President, General Counsel, Corporate Secretary & CCO
	
	UNITRACT SYRINGE PTY LTD.
		
	By:	 	  

		 	Name:	 	Alan D. Shortall
		 	Title:	 	Director & CEO
	
	SECURED PARTY:
	
	HIKMA PHARMACEUTICALS LLC
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	

 Exhibit 10.3 

 

 Schedule A 
  

					
	 Patent Type
	 	 Patent Number
	 	 Assignee

	U.S. Patent	 	PATENT 6,083,199	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 7,500,967	 	Unitract Syringe Ply. Ltd
	U.S. Patent	 	PATENT 8,021,333	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,002,745	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,114,050	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,052,654	 	Unitract Syringe Ply. Ltd
	U.S. Patent	 	PATENT 7,935,087	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,167,837	 	Unitract Syringe Pty. Ltd
	U.S. Patent	 	PATENT 8,361,035	 	Unitract Syringe Pty. Ltd
	International Patent Application	 	PCT/AU2010/001677	 	Unitract Syringe Ply. Ltd
	International Patent Application	 	PCT/AU2010/001505	 	Unitract Syringe Pty. Ltd
	U.S. Provisional Patent Application	 	61/863,113	 	Unitract Syringe Pty. Ltd
	International Patent Application	 	PCT/AU2011/000515	 	Unitract Syringe Pty. Ltd
	International Patent Application	 	PCT/AU2012/001376	 	Unitract Syringe Pty. Ltd
	U.S. Provisional Patent Application	 	61/863,098	 	Unitract Syringe Pty. Ltd

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]